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ABSTRACT 
Hepatic stem cells are found in the liver at all stages of development, including adult, and 
have the potential to give rise to daughter cells of biliary, hepatocytic and pancreatic lineages. 
Hepatic stem cells contribute significantly to liver regeneration, but may be associated with 
development of primary liver cancer, and are being investigated as a cellular therapy for liver 
failure. 
   
This thesis describes the development of methods for the immunohistochemical quantification 
of hepatic stem cell activation, allowing assessment of the association between hepatic stem 
cell activation in needle biopsy tissue and subsequent development of HCC in a 
retrospectively identified cohort of cirrhotic patients. A murine dietary model of NASH and 
HCC was developed and characterised in detail demonstrating progressive hepatic stem cell 
activation with increasing injury severity. We then went on to describe and prospectively 
isolate a resident population of stromal stem/progenitor cells in adult, uninjured mouse liver 
with the potential to give rise to both myofibroblasts, and under selective conditions, 
epithelial stem/progenitor cells. Finally, we demonstrated the isolation of hepatic stem cells 
from explanted cirrhotic liver and normal common bile duct and assessed their utility as a 
source of hepatic stem cells for cellular or regenerative therapy. 
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CHAPTER 1 
GENERAL INTRODUCTION 
!
!
!1
1.1 OVERVIEW 
Liver disease prevalence and death rates are rising with the unmet clinical need for 
improved prevention, detection and treatment. The prevalence of liver disease is 
increasing, driven by the concomitant increase in the prevalence of chronic metabolic disease, 
predominantly alcoholic liver disease (ALD) and non-alcoholic fatty liver disease, and 
infectious disease, predominantly hepatitis C virus (HCV) and hepatic B virus (HBV). Other 
causes of liver disease, including biliary, autoimmune, and genetic disorders, have largely 
constant, but considerable, incidence rates. Clinical management of liver disease largely 
focusses on removing the cause of liver injury and preventing liver scarring and progression 
to end stage liver disease. The liver has considerable regenerative capacity and functional 
reserve and may withstand ongoing injury for years. Chronic liver diseases are progressive 
and, if untreated, ultimately lead to impairment of liver function below physiological demand 
resulting in liver failure. Currently there are no artificial devices that can be used to augment 
or replace lost liver function analogous to approaches used in kidney (dialysis), heart or lung 
failure. Consequently the only treatment for end stage liver disease is orthotopic liver 
transplantation involving high risk and relying on organ donation. Thus there is a great unmet 
need for clinical therapies with utility in slowing or preventing disease progression, avoiding 
liver transplantation and reducing deaths as a result of liver disease.  
!
Hepatic stem cells are present in adult liver, are activated in all liver diseases and 
contribute to liver regeneration. The recent definitive identification of adult hepatic stem 
cells, and development of techniques for their isolation, culture and differentiation into 
mature, functional cells of the liver, has altered our understanding of liver tissue homeostasis, 
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disease and regeneration. The isolation of human hepatic stem cells from foetal and adult liver 
without significant disease has been well demonstrated1 and has allowed detailed 
characterisation of the proliferative capacity and differential potential of hepatic stem cells2, 3. 
Human hepatic stem cells can be maintained in culture for weeks and retain the potential to 
differentiate into mature hepatic parenchymal populations, hepatocytes and cholangiocytes 
with function comparable to cells derived from induced pluripotent4, or embryonic5, 6, stem 
cells. Consequently, there is considerable interest in the use of in vitro cultured human hepatic 
stem cells a cellular therapy for chronic liver disease or in devices providing short-term liver 
function, or a bridge to transplantation, in cases of acute liver failure. 
Research using in vitro cultured human hepatic stem cells has greatly increased our 
understanding of the maturation lineage of hepatic stem cells allowing the expression and 
morphological profiles of cell types at each stage of differentiation to be defined3. This has 
allowed more accurate assessment of hepatic stem cell activation in clinical disease and 
experimental animal models. These studies have demonstrated the proliferation and 
differentiation of hepatic stem cells towards mature, functional cell types occurs in response 
to all causes of liver injury and disease7-9. The liver has substantial regenerative capacity in 
non-pathological settings, with much of the regenerative capacity thought to be contributed by 
the ability of mature hepatocytes to proliferate and restore lost tissue and function. However, 
hepatic stem cells provide a second regenerative mechanism allowing complete regeneration 
of the liver even in cases where the proliferative capacity of mature hepatocytes is completely 
lost due to chronic disease or experimentally in animal models. Ongoing work is defining the 
relative contribution, and clinical significance, of hepatic stem cell-mediated regeneration. 
!
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1.2. LIVER ANATOMY 
1.2.1. General anatomy of the liver and hepatic plate. The liver is the largest glandular 
organ in the human body and has functions in: glucose and lipid metabolism; immunity; 
protein production; the filtering of waste products and toxins; the storage of nutrients; and the 
production of bile. The liver is supplied with blood from both the hepatic artery and the 
hepatic portal vein, which drains directly from the gut, and drained by the central veins and 
ultimately the inferior vena cava. Hepatocytes produce bile which is collected and transported 
through the hepatic plate by the biliary canaliculi (Fig 1.1A). Hepatic arteries, portal veins 
and bile ducts are found in close proximity throughout the liver in portal tracts and are 
commonly referred to as the portal triad (Fig 1.1B). The regions of the parenchyma between 
portal tracts and central veins are exposed to a gradient of gradually decreasing supply of 
oxygen and nutrients highest in portal regions and lowest at central veins. By convention, the 
regions of the lobule are termed peri-portal, mid-zonal, and centri-lobular to reflect their 
location in relation to the the portal tract and central veins (Fig 1.1B, annotated in italics). 
Bile ducts are observed as lumen, generally smaller than adjacent hepatic arteries (Fig 1.1B, 
arrowheads) and portal veins, and are constituted by columnar epithelial cells termed biliary 
epithelial cells (BEC) or cholangiocytes (Fig 1.1B, arrows). The parenchyma predominantly 
comprises hepatocytes, the cells responsible for the majority of functions performed by the 
liver. Stromal and mononuclear cells are also found throughout the hepatic lobule with greater 
numbers observed in disease states.  
!
!
!
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1.2.2. Micro-anatomy of the biliary tree. The most proximal branches of the biliary tree, 
termed the Canals of Hering10, are lined by both cholangiocytes and hepatocytes and connect 
directly to the hepatocyte cannicular system that extends throughout the lobule and collects 
bile produced and secreted by hepatocytes. Bile is principally composed of water, bile salts, 
mucus, pigments and lipids but also contains many fragments of molecules released by 
hepatocytes during their normal function or during cellular injury and death in response to 
liver insult or disease. Bile flows through the hepatic plate into the Canals of Hering in peri-
portal regions before entering into increasing large branches of the biliary tree. The Canals of 
Hering drain into the hepatic ductules, channels formed entirely by cholangiocytes. 
‘Intralobular ductules’ are often observed as isolated strings of cholangiocytes in liver 
sections and are contiguous with the ‘intraportal ductules’ within the portal tract which flow 
into the terminal ductules adjoining the bile ducts of the portal triad. These continue into the 
progressively larger and more distal structures of the biliary tree: the interlobular bile ducts, 
septal ducts, segmental ducts, right or left bile ducts and ultimately the common hepatic bile 
duct. Larger branches of the biliary are lined by peri-biliary glands that function in secreting 
mucus facilitating the transport of bile. Peri-biliary glands have recently been shown to 
harbour high proportions of epithelial stem cells with the potential to differentiate into 
functional hepatocytes, cholangiocytes and pancreatic beta cells in vitro11-13. Thus, the entire 
biliary epithelium, from the Canals of Hering through to the common bile duct, contains 
potent biliary tree/hepatic stem cells. The function and contribution of these cells, particular 
the newly identified cells of the peri-biliary glands, to tissue homeostasis and regeneration has 
yet to be fully elucidated. 
!
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Figure 1.1. Anatomy of the adult liver. A, Gross anatomy of the adult liver including hepatic 
veins (blue), hepatic portal veins (purple), hepatic arteries (red) and bile ducts and gallbladder 
(green). Enlarged image shows finer branches of the biliary tree including the intra-portal, 
intra-lobular ducts and Canals of Hering. Panel A from review10. B, Representative image 
(100x magnification) of cytokeratin 19 immunohistochemistry of normal adult liver 
demonstrating cytoplasmic staining of biliary epithelium (arrows). Hepatic arteries 
(arrowheads), portal veins (P) and hepatic veins (H) are also annotated along with peri-portal, 
mid-zonal and centri-lobular regions of the liver parenchyma (italics) 
A.
B.
Peri-portal
Centri-lobular
Mid-zonal
H
H
P
P
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1.2.3. Cell types present in adult liver. 
Hepatocytes 
Hepatocytes are the main functional epithelial cell type of the liver and function in protein 
production, breakdown or toxins and waste products and are key mediators of lipid and 
carbohydrate metabolism. Hepatocytes are the predominant cellular component of the liver 
parenchyma and have considerable proliferative capacity, able to maintain tissue homeostasis 
independently of hepatic stem cells and undergo compensatory growth to restore liver mass 
when up to 75% is lost through trauma14. There is evidence for a hepatocyte maturational 
lineage and functional spectrum spanning the hepatic plate15, where ‘small’ hepatocytes 
originate from peri-portal regions and migrate and mature into larger, often polyploid cells in 
centri-lobular and peri-venular locations3.  
!
Biliary epithelial cells (BEC) 
Biliary epithelial cells form the lumen of the entire biliary tree and function in the transport of 
bile and production of mucus and factors maintaining bile consistency. It is increasingly 
recognised that functional and phenotypic heterogeneity exists amongst biliary epithelial 
cells16. The larger, proximal branches of the biliary tree contain peri-biliary glands that 
produce mucus and facilitate mucus transport. A high proportion of cells within peri-biliary 
glands have been shown to express primitive endodermal stem cells markers and have be 
shown to have hepatocytic, biliary and pancreatic beta cell differentiation potential in 
vitro11-13. As hepatic stem cells have also been identified in the most distal portion of the 
biliary tree, the Canals of Hering10, it is possible that all cells of the biliary tree have a degree 
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of stem/progenitor potential and plasticity but to date this has proved difficult to definitively 
assess.  
!
Liver sinusoidal endothelial cells (LSEC) 
Liver sinusoidal endothelial cells LSEC form the liver sinusoids, the not-continuous 
fenestrated endothelium of the hepatic lobule. LSEC are key mediators of lympocyte 
recruitment in liver injury and inflammation and secrete factors controlling hepatocyte 
function and influencing patterning and differentiation of activated hepatic stem cells3, 17.  
!
Fibroblasts 
Fibroblasts are the main structural cell type of liver and are mainly found in peri-portal 
regions, associated with large vessels and biliary epithelium. Portal fibroblasts contribute to 
fibrosis and may have particularly prominent role in biliary fibrosis and cirrhosis18, 
contributing to the ‘cocooning’ phenomenon commonly observed in chronic biliary disease 
where bile ducts become enveloping by thick layers of fibrosis19. Portal fibroblasts appear to 
be important for the maintenance of patterning of BEC, in a similar manner to that of LSEC 
and hepatocytes3, 17. 
!
Stellate cells 
Hepatic stellate cells (HSCs) are peri-sinusoidal mesenchymal cells located within the Space 
of Disse of adult liver. The origin of stellate cells is yet to be definitively elucidated but 
embryological fate tracing experiments suggest a mesodermal origin; deriving from the 
primitive mesothelium of the developing septum transversum and later integrating with 
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invading epithelial cells of the hepatic bud to form the foetal liver20, 21. In normal liver HSCs 
are quiescent lipid storing cells with characteristic cytoplasmic protrusions that interact 
closely with surrounding endothelium and epithelium. In response to injury HSCs rapidly 
transdifferentiate into myofibroblasts playing key roles in scar formation, inflammation and 
regeneration via the secretion of extra-cellular matrix proteins, cytokines and growth 
factors22. Stellate cells are also thought to be the key mediators of injury resolution23. 
!
Kupffer cells and infiltrating mononuclear cells 
The liver is an important immunological organ as it directly receives blood from small 
intestine via hepatic portal vein, including all nutrients and consumed pathogens. Liver 
immunity is usually conferred by specialised, resident macrophages termed Kupffer cells24. In 
injury and liver inflammation, monocytes are recruited by LSEC and differentiate into 
macrophages and have important roles in the regulation of fibrogenesis, injury resolution and 
activation/patterning of hepatic stem cells25-27. 
!
!
!
!
!
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1.3. LIVER EMBRYOLOGY 
Liver ontogenesis begins with specification of primitive endoderm by Nodal signaling from 
the surrounding mesenchyme of the septum transversum, shown to be necessary for correct 
specification and alignment of mesendoderm. A strong graded patterning signal is established 
across the primitive endoderm where high concentrations of WNT and FGF4 in the most 
dorsal regions specify gastrointestinal fate and low concentration in ventral regions results in 
the ventral foregut endoderm escaping restriction to GI fate to subsequently form the 
pancreas, liver, lung and thymus.  
!
Liver ontogeny and maturation is a continuous process involving a number of cell types and 
complex regulatory mechanisms. Our increased understanding of these interactions has 
greatly enhanced our knowledge of hepatic stem cell maturation and improved our ability to 
culture, maintain and differentiation hepatic stem cell in vitro6, 28. The first stage of liver 
ontogeny involves the formation of the ‘hepatic bud’, derived from the primitive endoderm of 
the ventral foregut At this point the epithelial layer begins to change from a columnar pattern 
to pseudostratified through thickening and. A layer of endothelial precursors lie between the 
hepatic diverticulum and cells of the septum transversum. Signals from the developing heart 
(mainly FGF1/2) and from the septum transversum (BMPs), assist in the patterning of the 
hepatic bud and development of hepatic competence20. Hepatic competence is achieved early 
in development, demonstrated be experiments showing only a small proportion of the 
primitive endoderm ie. the foregut, is capable of developing into liver by engraftment and in 
vitro studies. At this point the key transcription factor HHEX becomes enriched in the cells of 
the hepatic diverticulum. HHEX is thought to be responsible for activating key early hepatic 
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genes ie. albumin, AFP, HNF4. Gata4 and Gata6 also play important roles at this point29. The 
hepatic diverticulum delaminates, with the loss of laminin and other associated matrix 
proteins. The endothelial progenitors (Flk1+ as per adult angioblasts30) are absolutely required 
for delamination indicating their key role in patterning the endodermal cells. The cells of the 
hepatic diverticulum and associated endeothelial precursors then invade the septum 
transversum and mix with the mesenchymal cells that will go on to form the fibroblast and 
stellate cell populations of the liver. This interaction is then maintained throughout hepatic 
development and signalling between cell types is key to the patterning of the adult lobules20, 
31, 32. At this early point the mix of cells is supplied by 2 pairs of symmetrical vitellin and 
umbilical veins. From here, the newly formed hepatic bud grows disproportionately, 
vascularises and is invaded by primitive HSCs becoming the first, and at this stage only, 
source of haemopoeitic cells in the foetus. Growth continues and the vascular structures of the 
liver become assymetrical and begin to form shunts that will eventually form the adult 
vessels. Sinusoidal cells begin to aggregate and form the earliest hepatic plates. At first the 
parenchyma is populated be a homogeneous population of bipotential hepatoblasts that 
restrict to cholangiocytes in periportal regions and hepatocytes in centrilobular regions. This 
process is largely mediated by signals from the endothelial cells and mesenchyme of the 
portal regions. The formation of the biliary tree involves a number of complex remodeling 
steps of the primitive ductal plates. At embryological day 12 (e12) the liver parenchyma is 
comprised entirely of hepatoblasts (Fig 1.2AB). By embryological day 14 (e14), hepatoblasts 
adjacent to portal vein have specified into biliary epithelium and at embryological day 18 
remaining hepatoblasts commit to the hepatocytic lineage forming immature hepatocytes. 
Shortly before birth, biliary epithelial cells surrounding the portal vein condense into the 
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structures of the biliary tree and immature hepatocytes undergo terminal differentiation into 
mature, functional hepatocytes. 
!
In the fully developed adult liver, mature cellular population are derived from: 
1. Endodermal cells of the hepatic diverticulum; giving rise to hepatocytes and biliary cells 
2. Mesenchymal cells of the septum transversum; giving rise to haematopoietic cells, stellate 
cells, kupffer cells, hepatic arteries and connective tissue 
3. Endothelial precursors found between the hepatic diverticulum, and septum transversum 
before delamination; forming the hepatic arteries 
4. Endothelial cells of the vitelline and umbilical veins; forming the hepatic veins and 
sinusoids and endothelial cells 
!
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Figure 1.2. Human hepatic stem cells and hepatoblasts in foetal liver. A, EpCAM 
expression in ductal plate cells and AB, parenchymal cells throughout the developing hepatic 
lobule (nuclear counterstaining with hematoxylin; 10x magnification). C, AFP expression 
(red) found in the hHBs but not in the ductal plates, whereas both stain for EpCAM (green; 
membranous staining). D, ICAM1 expression is not found on the ductal plate nor in bile duct 
cells but rather is largely in E, cells lining the sinusoids within the parenchyma, although 
hHBs can show a membranous pattern (nuclear counterstaining with hematoxylin). F,The 
ductal plate (DP) cells stain intensely for CK19, whereas CK19 in hHBs is fainter and in a 
particulate staining pattern (nuclear counterstaining with hematoxylin; 40x original 
magnification). Figure replicated, and legend adapted, from review33 !
!
!
!
!
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1.4. LIVER DISEASE AETIOLOGIES 
1.4.1. Primary biliary cirrhosis. Primary biliary cirrhosis (PBC) is a progressive, chronic 
disease affecting the intra-hepatic bile ducts with unclear pathogenesis. The disease is 
characterised by inflammation and destruction of intra-lobular and septal (<100µm) bile ducts 
leading to a progressive fibrogenic response that initially ‘cocoons’ florid granulomatous peri-
portal infiltrates that may progress to bridging fibrosis and ultimately cirrhosis. In response to 
inflammation of the biliary epithelium hepatic stem cells proliferate in response to signals 
predominately produced by adjacent, activated stellate cells and fibroblasts with notch 
signaling thought to play a particularly prominent role26. These signals restrict hepatic stem 
cells to the biliary lineage ensuring regeneration of the bile ducts without inappropriate 
production of cells of the hepatocyte lineage. 
!
1.4.2. Hepatitis C virus cirrhosis. Chronic hepatitis C virus (HCV) infection causes 
hepatocellular injury leading to reduced liver function and progressive fibrosis resulting in 
cirrhosis. Incidence rates of HCC in patients with HCV-cirrhosis are estimated between 3 and 
5% per year, with HCC representing a leading cause of death in patients chronically infected 
with HCV in the Western world34.  
!
1.4.3. Definition and prevalence of non-alcoholic liver disease. Non-alcoholic fatty liver 
disease (NAFLD) encompasses a spectrum of liver pathologies ranging from simple steatosis 
at its mildest form to non-alcoholic steatohepatitis (NASH) and progression to cirrhosis at its 
most severe35. NAFLD is now recognised as a growing epidemic in western populations36, 
correlating with increasing obesity, with prevalence estimates ranging from 20% to 30% in 
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the general population37, 38 and up to 90% in obese cohorts39. A diagnosis of NAFLD requires 
the exclusion of alcohol or drug-induced liver disease, cholestatic disease, autoimmune and 
viral hepatitis and other metabolic or genetic liver disorders40. Liver biopsy is currently the 
only definitive method of diagnosing NASH; the more severe manifestation of NAFLD. Over 
the past decade significant effort has been directed at developing a non-invasive method of 
diagnosis including; improved liver functions tests (LFTs)41 which include biomarkers e.g. 
CK1842, a marker of hepatocyte apoptosis; non-invasive imaging techniques such as magnetic 
resonance spectroscopy and elastography (Fibroscan)43; and scoring systems designed to 
identify afflicted patients44. However many of these non-invasive methods for diagnosis of 
NASH remain crude or have yet to be validated in practice and consequently liver biopsy 
remains the only truly reliable means of confirming a NASH diagnosis45. NASH patients are 
also at increased risk of HCC46. Although much of this risk may be conferred by other 
characteristics in NASH patients, most notably the metabolic syndrome47, the presence of 
NASH may independently increase risk of HCC development even in the absence of 
cirrhosis48. 
!
1.4.4. Pathogenesis of non-alcoholic liver disease. NAFLD is closely associated with the 
metabolic syndrome, and is often described as the ‘hepatic manifestation’ of the multiplex of 
metabolic risk factors that define the metabolic syndrome: atherogenic dyslipidaemia; raised 
blood pressure; abdominal obesity; insulin resistance ± glucose intolerance; proinflammatory 
state and prothrombotic state49. Insulin resistance is recognised as the underlying cause of the 
metabolic syndrome and the link with NAFLD50, 51, although whether hepatic insulin 
resistance is the precipitating factor or develops later as a consequence of peripheral insulin 
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resistance is still unclear. Worryingly, NAFLD is being increasingly reported in children and 
is, as in adults, tightly associated with the metabolic syndrome52, 53 highlighting the growing 
health problem posed by rising obesity levels not just regarding cardiovascular diseases and 
diabetes but also chronic liver disease54. Our understanding of the progression of NAFLD 
from simple steatosis to cirrhosis and liver failure is incomplete and consequently our ability 
to predict which patients with benign steatosis will progress to more serious liver dysfunction 
is significantly impaired. It is recognised that simple steatosis alone is relatively benign55, 
although long-term follow up reveals that a small yet significant proportion of these patients 
do progress to much more serious disease and ultimately liver failure56, 57. The first hypothesis 
providing a cohesive explanation of the mechanisms underlying the progression of steatosis to 
the inflammation and fibrosis observed in NASH and cirrhosis was postulated by James and 
Day with the popular ‘two hit hypothesis’58. This model proposed that the progression to 
steatohepatitis firstly requires the accumulation of fat within the hepatocytes of the liver – 
steatosis, followed by a second hit for which they suggest oxidative stress to be the most 
likely candidate. More recently it has been accepted that, while the original hypothesis is still 
valuable with many of its propositions likely to be found correct, this model is unable to 
completely explain the fundamental mechanisms underlying the original cause of steatosis 
and subsequent sequelae of NASH and cirrhosis. Although steatosis is undoubtedly associated 
with NASH, current opinion suggests that the observation of steatosis may be an effect of 
other initial causal factors established earlier in the pathogenesis of NAFLD and that hepatic 
steatosis may even be a protective phenomenon. This phenomenon was demonstrated in mice 
over-expressing diacylglycerol acyltranferase (DGAT), the enzyme responsible for the final 
step in the synthesis of triglycerides. Over-expression of DGAT resulted in severe steatosis 
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and lipid accumulation in the livers of these mice, however these mice were found to have 
normal glucose metabolism, blood glucose levels and did not develop insulin resistance 
indicating steatosis may not be responsible for the development of insulin resistance in 
humans and may even be a protective mechanism59. Current challenges to our complete 
understanding of the pathogenesis of NAFLD include: delineating the relationship between 
insulin resistance and changes in liver metabolism, specifically lipid and glucose homeostasis; 
understanding the contribution of adiposity, particularly visceral, in light of the strong 
association with NAFLD and progression to NASH60-63; deciphering the mechanisms through 
which genetic risk factors confer increased susceptibility to NAFLD; and increasing our 
knowledge of the complex relationship between liver metabolism, inflammation and injury 
and how these processes are resolved or progress. 
!
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1.5. LIVER DISEASE HISTOLOGY 
1.5.1. Liver fibrosis. In chronic liver disease, excess accumulation of extracellular matrix 
molecules, most notably collagen type I, occurs in the liver ultimately leading to cirrhosis and 
liver failure. A number of cell types are thought to contribute to collagen and matrix 
deposition including portal fibroblasts, activated stellate cells and their myofibroblastic 
progeny. Hepatic stellate cells are considered the most important mediators of fibrogenesis 
and injury resolution. When activated, hepatic stellate cells secrete a number of pro-
inflammatory cytokines and transdifferentiate in myofibroblasts, secreting substantial 
amounts of matrix components and collagen18. Fibrosis is progressive and is usually first 
observed in peri-portal regions64. In biliary diseases, fibrosis is usually more prominent 
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around biliary epithelium, the site of injury, and is generally observed as thick layers of 
collagen enveloping bile ductules. Fibrosis may also be observed within the liver parenchyma 
to the extent where wide fibrotic septa are observed bridging portal tracts, characteristic of 
liver fibrosis26. In hepatocytic liver injury, liver fibrosis is predominantly observed in the 
hepatic lobule, first around portal triads and central veins, and then progressing to bridging 
and cirrhosis. Hepatic stem/progenitor cells are often observed in close association with 
fibrotic septa and may represent a common physiological process leading to the migration of 
hepatic stem cells from the biliary epithelium in portal tracts into the surrounding liver 
parenchyma before differentiating into mature hepatocytes. Stellate cells have been shown in 
vitro to augment the activation and differentiation of hepatic stem cells and release factors that 
pattern hepatic stem cells towards the hepatocyte lineage17.  
!
1.5.2. Ductular reaction. In many disease states cholangiocytes can be observed proliferating 
in inappropriately large numbers in patterns that do not result in the formation of normal bile 
ducts. This phenomenon is referred to as “ductular reaction”10, 65 and is generally 
acknowledged to have two major types; typical and atypical. Typical ductular reaction is often 
precipitated by occlusion of bile ducts e.g. gall stones and tumours and results in proliferation 
of existing ductules forming extra lumen but which do not fully function by carrying bile. 
This is the type of reaction observed in bile duct ligation experiments conducted in rodent 
models66. Atypical ductular reaction is usually associated with regeneration of the liver after 
insult, vanishing bile duct diseases and proliferation of liver progenitor cells.  This form of 
ductular reaction does not form discernible lumen and is characterised by the observation of 
strands of cells extending into the parenchyma in a highly irregular fashion66-68. 
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It is now recognised that in many scenarios of chronic liver disease the ductular reaction is, at 
least in part, mediated by the activation of liver stem cells. Ductular cells within the ductular 
reaction can express a wide heterogeneous array of markers covering both biliary and 
hepatocytic lineages including CK19, CK7, EpCAM, HepPar1 and NCAM10, 69-71. The field 
has progressed sufficiently in the last couple of years such that subpopulations of ductular 
reactive cells can be identified by their expression of specific markers. NCAM is currently 
regarded as the most important marker in identifying bipotential stem/progenitor cells in 
ductular reactive processes72 however recent evidence suggests NCAM+ cells are more likely 
to be in senescence that other ductular reactive cells in chronic disease which may indicate 
exhaustion of these cells or that a different subpopulation are responsible for much of the 
proliferation and reconstitution of mature liver populations73. Expression of CK19 indicates a 
more differentiated progenitor cell phenotype primed towards the biliary lineage, whilst 
progenitor cells primed towards the hepatocytic lose expression of both CK19 and NCAM but 
may retain EpCAM74. Subsequent work in murine models has supported this early hypothesis 
describing liver stem and progenitor cell phenotypes and have again emphasised the 
importance of sox9 as a marker of more primitive liver stem cells75, 76. 
!
One of the most commonly misinterpreted observations in two-dimensional liver sections, 
specifically when using markers of liver progenitor cells, is the presence of “isolated 
cholangiocytes” or liver progenitor cells in peri-portal regions. Often the identification of 
liver progenitor cells in this scenario is erroneous and more likely cross-sections of the Canals 
of Hering resulting in the observation of single, or small strands, of positively stained cells10. 
Distinguishing between cholangiocytes and liver progenitor cells in this scenario is extremely 
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challenging using single markers by immunohistochemistry due to shared morphology77, 
expression of markers78, and the demonstration that ductules can extend through the lobule79, 
80. 
!
1.5.3. Histological phenomena related to activation of the hepatic stem cell niche. 
Activation of the hepatic stem cell niche is observed in all chronic liver diseases7, 81. 
Histologically, activation is characterised by remodeling of peri-portal regions, in tight 
association with fibrogenesis, and the proliferation, differentiation and migration of hepatic 
stem cells into adjacent intra-lobular parenchyma7, 27.  
!
Intermediate hepatobiliary cells 
Intermediate hepatobiliary cells (IHCs) are defined as cells with hepatocytic morphology, 
located in intra-lobular regions and expressing characteristically biliary markers, most notably 
CK7 and, to a lesser extent, CK1982. The origin of these cells remains controversial. IHCs 
may represent a population of hepatoblasts; cells that are derived from hepatic stem cells but 
have not fully differentiated into mature hepatocytes and retain expression of biliary and/or 
hepatic stem cell markers72. However, as these cells are often observed some distance from 
periportal regions, the accepted location of the hepatic stem cell niche, how these cells 
migrate from periportal regions to intralobular regions without obvious adjacent parental/
ancestral cells remains to be elucidated. It is possible that these cells represent mature 
hepatocytes that have re-expressed biliary markers in response to injury-mediated signals10. 
!
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Hepatocytes newly derived from hepatic stem/progenitor cells 
One of the most important markers of human hepatic stem cells in both the adult and foetal 
liver is epithelial cell adhesion molecule (EpCAM), with the use of EpCAM antibodies and 
immunoselection techniques forming the basis of the most commonly used current techniques 
for the isolation of hepatic stem cells. EpCAM is a homophilic type I transmembrane 
glycoprotein83 reported to be normally expressed in; almost all epithelial tissues84; the 
mammalian germ line85; normal adult stem and progenitor cells86, including liver stem cells2 
and progenitor cells87; and cancer-initiating cells88. This has led to great interest in EpCAM as 
a marker of cancer-initiating cells and as a prognostic tool since EpCAM-positive tumours 
have been shown to be more aggressive and tumourigenic in vitro88, 89. EpCAM is exclusively 
expressed by cells of the biliary epithelium in normal liver. However, EpCAM has recently 
been described as marking hepatocytes that have newly been derived from proliferating 
hepatic stem cells74. EpCAM+ hepatocytes are found in peri-portal and peri-septal regions of 
diseased liver and display a distinctive membranous pattern of EpCAM expression in contrast 
with the cytoplasmic distribution observed within biliary cells. 
!
1.5.4. Histological techniques for the identification of hepatic stem cells. Sox9 has been 
shown to mark somatic stem cell populations in organs derived from the primitive endoderm 
of the foregut, namely the intestine, pancreas, biliary tree and liver90. Cell fate tracing 
experiments have elegantly shown that, over time, the progeny of Sox9+ cells reconstitute the 
entire epithelial lining of the intestine, biliary tree and parenchymal cells of the liver 
indicating the presence of adult stem cells within the Sox9+ population in these organs. In 
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liver, injury stimulates increased proliferation and accumulation of progeny of Sox9+ cells 
that include mature hepatocytes and biliary epithelial cells9. 
!
The objective quantification of immunohistochemical (IHC) staining of liver specimens is an 
ongoing challenge in pathology. Many liver-related histological phenomena, including 
fibrosis, steatosis and inflammation44, are currently quantified using semi-quantitative scoring 
systems which rely upon the expertise of experienced pathologists. Scoring systems for the 
quantification of NAFLD were originally designed to allow the standardisation of histological 
endpoints in clinical trials but are now frequently used in basic research, including assessment 
of animal models, despite being prone to large inter-rater variability and low reducibility91. As 
such, the development of an objective, computer-assisted method to quantify and analyse 
immunohistochemical staining would remove user bias and issues associated with inter-rater 
variability improving on currently used scoring systems. Many reports have demonstrated the 
use of image analysis in quantifying hepatic fibrosis by calculating collagen percentage area 
(CPA)92 and steatosis by quantification of oil red O staining93. However, standardised 
techniques for the quantification of histological phenomena and cell populations involved in 
hepatic stem cell mediated liver regeneration remain lacking. Previous studies have defined 
criteria for the presence or absence of CK19+ or CK7+ intermediate hepatobiliary cells94, total 
quantification of hepatic progenitor cell numbers per portal tract95 and quantification of total 
area covered by biliary and ductular epithelium by CK7 immunohistochemistry96.  
!
Although each of the markers described above identify hepatic stem/progenitor cells, none of 
them do so specifically. CK19, CK7 and EpCAM are observed on all cells of the biliary 
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epithelium. There are conflicting reports of the proportion of biliary cells that express Sox9 
under normal conditions, ranging from a small proportion to all cells. In injured liver, Sox9 is 
also upregulated by activated stellate cells undergoing transdifferentiation to myofibroblasts. 
Currently no markers have been described that exclusively mark adult hepatic stem cells, 
although markers that define an increasingly restricted population continue to be regularly 
reported, the most recent including Foxl176, 97, CD13398, Lgr5 and CD2499. As such, the use of 
a combination of different markers is required to identify hepatic stem cells. Further, as these 
cells give rise to multiple lineages in response to injury, whose antigenic profiles vary during 
the process of proliferation, lineage restriction and differentiation, assessing and quantifying 
hepatic stem cells in during liver injury and regeneration remains challenging. 
!
1.5.5. Hepatic stem cell activation in chronic liver disease. The activation and 
differentiation of hepatic stem cells is observed in a wide range of acute and chronic liver 
disease aetiologies100, 101. The presence of ductular reactive cells, or cells with intermediate or 
combined phenotypes, is observed in all common chronic aetiologies, including viral, biliary, 
alcohol-induced, autoimmune and fatty liver diseases. In biliary disease, hepatic stem cells are 
restricted to a biliary fate and contribute to regeneration of the biliary epithelium with few, if 
any, hepatocytes thought to be derived from activated hepatic stem cells. Ductular reactions 
are often prominent in primary biliary diseases, with increasing evidence suggesting these 
structures are at least partly derived from hepatic stem/progenitor cells. Consequently, in these 
diseases the proportion of cells with a predominantly biliary phenotype, ie. Sox9, CK19, CK7, 
is greatly increased in peri-portal areas with hepatic stem/progenitor cells contributing to the 
expansion of biliary and ductular structures9. 
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In chronic metabolic, or hepatocytic, liver disease hepatic stem cells can be seen proliferating 
from biliary epithelium and peri-portal regions into adjacent parenchymal areas and 
contribute to regeneration of lost hepatocyte numbers and function. Ductular reactive 
structures with predominantly biliary (also stromal78 but rarely hepatocytic) phenotypes are 
also commonly seen in these aetiologies, potentially representing intermediate, or transitional, 
cells, or cells that are proliferating and/or differentiating in an abnormal manner in response 
to inappropriate patterning. Hepatic stem cells differentiating towards mature hepatocytes 
progress through a maturational lineage, commonly described as hepatic stem/progenitor cell, 
hepatoblast, immature/small hepatocyte and functional mature hepatocytes2. Whether 
‘intermediate hepatobiliary cells’94 belong within this lineage remains controversial but would 
most likely constitute immature/small hepatocytes. 
!
!
1.6. HEPATIC STEM CELLS 
1.6.1. Historical overview of the identification and characterisation of hepatic stem cells. 
The liver has long been known to possess substantial regenerative capacity. In 1902, 
McCallum was first to provide a clinical description of the regenerative process in a John 
Hopkins Hospital Report where “regenerative changes are represented by an ingrowth of 
sprout from the interlobular bile ducts toward the central veins” resulting from acute yellow 
atrophy102. Higgins and Andersen reported the first experimental model of liver regeneration 
in 1932 using partial hepatectomy (PHx) in rats103. During the same year azo dyes were 
shown to reliably induce hepatocellular tumour formation in rats104 leading to the liver being 
adopted as the model organ for the study of the effects of carcinogens105-108. Among the 
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myriad of changes observed in response to these toxic agents, there is invariably an increased 
proliferation of biliary ductules with an accompanying accumulation of cells in periportal 
regions with distinctive oval-shaped nuclei that commonly abut biliary ductules. In early 
reports these cells were commonly referred to as ‘oval’ cells and were distinguished by their 
distinctive histological characteristics; small (relative to mature hepatocytes); high nuclear to 
cytoplasmic ratio; basophilic; oval-shaped nuclei; peri-portal location109. At this time there 
was much controversy regarding the fate of ‘oval’ cells. One hypothesis stated oval cells 
could be transformed into hepatocytes whilst the counter argument suggested oval cells 
underwent cell death upon removal of the precipitating insult. Most studies into the 1970’s 
reported similar findings, ie. circumstantial evidence for oval cells being derived from 
proliferating ductules and potentially giving rise to hepatocytes and/or hepatomas110, 111.  
Alpha-foetoprotein (AFP) is largely absent in adult liver, but is ubiquitous in the foetal liver 
and highly over-expressed in the majority of HCC lesions, allowing its use clinically as a 
serum biomarker for HCC. However, AFP levels in adult liver are significantly elevated from 
negligible levels in response to partial hepatectomy112. In response to this observation, the 
source of AFP production in this scenario was widely debated, with hypotheses including; 
retro/dedifferentiating hepatocytes to allow proliferation; transformed hepatocytes, or a 
separate cell type, ie oval cells. Ultimately it was conclusively demonstrated that oval cells 
were the sole source of AFP in regenerating adult liver; a critical step in the definition of oval 
cells as a distinct cellular entity in adult liver.  
!
The first crucial demonstration of a distinct stem or progenitor cell within the liver was the 
pharmacological blockade of hepatocyte proliferation (usually with retrorsine or 2-AAF) in 
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rodent models. Under these conditions, liver regeneration occurs but is mediated by the rapid 
proliferation of a distinct population of cells located within the Canals of Hering10, then 
termed ‘oval cells’ due to their distinct morphology, capable of differentiating into mature 
hepatocytes113. Oval cells were characterised as being smaller than the surrounding mature 
cholangiocytes and hepatocytes, have a high nucleus/cytoplasm ratio, distinctive ovoid 
nucleus. Oval cells proliferate rapidly in response to liver injury with or without inhibition of 
hepatocyte proliferation, although their proliferation is more muted when hepatocytes retain 
some proliferative and functional capacity. It is currently unclear to what extent the activation 
and proliferation of hepatic stem cells contributes to the restoration of lost mature cell types in 
chronic liver disease, although it is entirely feasible that liver stem cells convey the liver with 
its ability to remain in a ‘compensated’ state of cirrhosis for years despite severe ongoing 
injury. 
!
1.6.2. Currently unresolved aspects of hepatic stem cell biology and function. The study 
of hepatic stem cells, from the first description over 100 years ago to the present day, has been 
controversial due to a number of apparent contradictions in reported observations and/or 
hypotheses. Our understanding of hepatic stem cells remains incomplete and many 
contentious issues remain.  
Firstly, the question of whether adult hepatic stem cells fully meet the criteria for true somatic 
stem cells remains inconclusively addressed. The liver has an extraordinary capacity for 
regeneration in response to injury and yet the contribution of hepatic stem cells to this process 
is largely unknown and perhaps negligible in many scenarios where damage is limited or 
transient due to the significant regenerative capacity of mature hepatocytes. In many tissues 
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where cell turnover is high (ie. skin, gut) all epithelial cells are apparently derived from 
somatic stem cells, however it is unclear whether this is the case for liver. Our current 
benightedness permits the potential role of hepatic stem cells to range from a self-contained 
reservoir, necessary only in cases of severe injury, through to the source of all mature hepatic 
parenchymal cell types. 
Further, the location and source of hepatic stem cells are in the process of being redefined 
whilst the mechanisms underlying the maintenance and activation of the hepatic stem cell 
niche are are in the early stages of being fully elucidated. Early work described a small 
distinct niche for hepatic stem cells within the most proximal branches of the biliary tree; the 
Canals of Hering. However recent studies have contributed compelling evidence for the 
presence of multipotent stem cells throughout the entire biliary tree, perhaps in all biliary 
epithelia. Whilst chemokines and mitogens known to activate hepatic stem cells have been 
identified along with many of the major signaling cascades, the precise mechanisms and 
complex interactions between hepatic stem cells and their environment, including other 
closely associated cells types, are poorly described. Specifically, how appropriate; patterning 
to biliary or hepatocytic fate; maintenance in quiescent or activated states; and niche 
remodeling and recovery after injury, are mediated remains to be elucidated. 
The clinical implications of hepatic stem cell activation potentially represents a double edged 
sword. Greatly increased numbers of hepatic stem cells are seen to accumulate in all chronic 
liver disease aetiologies and presumably contribute positively to regeneration. Yet, hepatic 
stem cells are closely associated with the ductular reaction and fibrogenesis, processes 
considered to adversely effect outcomes and increased numbers of hepatic stem cells and the 
duration of their activation may be associated with an increased risk of hepatocellular and 
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cholangiocarcinoma. Thus, the consequences of increasing hepatic stem cell numbers, either 
through stimulating increased proliferation of the native stem cell niche or by the 
administration of non-autologous hepatic stem cells, are as yet unknown. Further, there is 
growing evidence suggestive of a direct link between hepatic stem cells numbers and risk of 
primary liver carcinogenesis and in some cases hepatic stem cells may be the cell of origin. 
Hepatic stem cells also hold great promise as a cellular therapy for liver disease yet many 
technological hurdles and unknowns regarding the true potential of adult hepatic stem cells 
remain. Studies of freshly isolated cells in vitro have demonstrated extensive long-term 
undifferentiated proliferation yet the differentiation of cultured hepatic stem cells to fully 
functional daughter cells, particularly hepatocytes, has yet to be demonstrated to an extent 
comparable to mature cells in vivo.  
However, despite recent advances in the prospective isolation and fate-tracking of hepatic 
stem cells, our understanding of the contribution of hepatic stem cells to the development and 
progression of disease remains limited whilst many technical challenges remain in the 
development of hepatic stem cell-based cellular therapies. 
!
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1.6.3. Evidence for hepatic stem cells as true somatic stem cells. The two defining 
characteristics of a stem cell are potency; the capacity to give rise to multiple different mature 
cell types, and continuous self-renewal; the ability to generate daughter cells without loss of 
potency or proliferation potential114.  
!
Thus the term ‘adult hepatic stem cell’ should specifically refer to a cell that is: 
1. found in adult 
2. located in the liver 
3. multipotent, able to give rise to all hepatic cell types of at least one lineage, through tissue 
homeostasis or regeneration in response to injury, ie. hepatocytes and cholangiocytes for 
epithelial cells, stellate and endothelial cells for mesodermal cells types or all parenchymal 
types for a multipotent stem cell (for liver this would require hepatocyte and cholangiocyte 
differentiation for an endodermal cell type) 
4. self-renewing with considerable proliferative capacity. Experimentally, the ability to 
repopulate numerous livers by serial transplantation using a suitable recipient model, ie. 
FRG mice 
!
Studies that have provided evidence contributing to the confirmation of adult hepatic stem 
cells are summarised below (Table 1). 
!
!
!
!
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Table 1.1. Studies contributing to the evidence required for the definition of an adult 
hepatic stem cell. !
!
!
!
!
!
!
!
!
!
!
!
!
!
!
Requirement Demonstration Reference
Location; adult, 
liver
Canals of Hering 1, 9, 10, 79, 115
Biliary tree 9, 12
Self-renewal Serial transplantation 196, 197
Proliferative 
capacity
Long-term undifferentiated in vitro 
growth
11, 12, 75, 76
Fate tracing 9, 97, 115
Multipotency Hepatocyte and cholangiocyte 
differentiation
1, 13, 75, 115
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To fully define hepatic stem cells by these criteria involves the use of several complimentary 
approaches. Firstly, the antigenic profile of a candidate cell must be fully defined to allow 
robust identification of a homogeneous population. A major limitation of the hepatic stem cell 
field has been the lack of a single, specific marker of hepatic stem cells which has 
subsequently precluded the use of cre-lox lineage tracing models to definitively trace the 
progeny of hepatic stem cells. However, the use of inducible cre-lox models has furthered our 
understanding of the location, expansion and contribution of hepatic stem cells to the 
generation of other cell types. Currently Sox99, 75, Foxl176 and Lgr5115 mark the most 
restricted population of cells encompassing hepatic stem cells, but each also captures a more 
differentiated population of biliary epithelial cells (Table 1.2).  
Interestingly, none of the 3 inducible models detect tracing events in the developing liver 
other than Sox9 at E16.5. In adult liver, Sox9 marks all cells of the biliary epithelium and 
tracing labels all hepatocytes over a period of 12 months suggesting continuous supply of 
mature hepatocytes from Sox9+ cells even in the absence of hepatic injury. A smaller 
proportion of biliary epithelial cells are marked by Foxl1 but there is no evidence of tracing 
events in hepatocytes. No tracing events are observed using Lgr5 in adult liver. These studies 
in uninjured adult liver demonstrate the variability of results produced by models targeting 
hepatic stem cells, most likely as a result of marking cells at different stages of the 
maturational lineage with Lgr5 presumably marking the most primitive cells, followed by 
Foxl1 and Sox9 the most mature populations that possibly include cells restricted to a biliary 
fate.  
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A multitude of injury models can be utilised to stimulate proliferation of hepatic stem cells. 
Hepatic stem cells are activated in commonly used models of hepatocellular injury (DDC, 
APAP, MCD - with further stimulation possible with the inclusion of ethionine; MCDE), 
biliary injury (BDL), fibrosis (CCl4) and liver regeneration (PHx, the use of retrosine, an 
inhibitor of hepatocytes proliferation, results in entirely stem-cell mediated regeneration). 
!
The results of hepatic stem cell fate tracing experiments in liver injury models are varied 
between strains (summarised in Table 1.2). Whilst Lgr5, Sox9 and Foxl1 marked cells 
generate mature hepatocytes and biliary epithelial cells in response to injury, the results from 
specific injury models can vary considerably between strains. Using MCDE, the most 
commonly used model for the generation of a robust hepatic stem cell response, Lgr5+ cells 
generate small clusters of mature hepatocytes, Sox9+ cells generate substantial numbers of 
peri-portal hepatocytes, whilst no mature hepatocytes appear to be derived for Foxl1+ cells. 
Taken together, the results from these studies conclusively demonstrate the generation of 
mature hepatocytes and biliary epithelial cells from rare populations of peri-portal cells with 
expression of stem cell related markers, yet each marker, Lgr5, Sox9, and Fox1, appears to 
label populations that yield differing progeny in response to injury.  
!
!
!
!
!
!
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Table 1.2. Summary of observations from lineage tracing experiments designed to target 
hepatic stem cells !
DDC, 3,5-dietheoxycarbonyl-1,4-dihydrocollidine; MCDE, methionine choline deficient diet 
supplemented with ethionine; BDL, bile duct ligation; APAP, acetaminophen; PHx, 70% 
partial hepatectomy; CK19, cytokeratin 19; AFP, alpha-foetoprotein 
Condition Strain
Lgr5 Sox9 Foxl1-cre 
Foetal No studies Extra-hepatic bile ducts but not 
liver at E13.5. Observed in 
intrahepatic bile ducts at E16.5
Not observed in hepatic bud at 
E12.5.
Adult Virtually undetectable. No 
tracing events
99.4% of traced cells found in 
biliary epithelium after 1 day. 
Numbers of labelled 
hepatocytes increased over 
time. All of parenchyma 
labelled 12 months after 
induction
0.1% of total cells, 10% of 
CK19
DDC Small clusters of hepatocytes 
and a small proportion of 
biliary epithelial cells 9 days 
after induction
Biliary epithelium with 
minimal contribution to 
hepatocytes 21 days after 
induction
Up to 1% of total cells, >30% 
of CK19
predominantly hepatocytes 21 
days after induction
MCDE Small clusters of hepatocytes 
and a small proportion of 
biliary epithelial cells 
observed 9 days after 
induction
Biliary epithelium with 
substantial numbers of peri-
portal hepatocytes labelled 3 
weeks after induction. Not all 
AFP+
cells
Subpopulation of CK19
biliary epithelial cells. No 
traced hepatocytes observed 35 
days after induction
CCl Observation of small 
proliferative cells 2 days after 
induction that evolved into 
fully mature hepatocytes from 
2 days onwards
Biliary epithelium with 
substantial numbers of peri-
portal hepatocytes labelled 4 
days after induction
No studies
BDL No studies Biliary epithelium with 
substantial numbers of peri-
portal hepatocytes labelled 10 
days after induction
Up to 0.3% of total cells, 
>30% of CK19
predominantly biliary up to 
day 7, then hepatocytes by day 
14
APAP No studies Biliary epithelium with 
minimal contribution to 
hepatocytes 21 days after 
induction
No studies
PHx ?No studies Biliary epithelium with 
minimal contribution to 
hepatocytes 21 days after 
induction
?No studies
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1.6.4. The maturational lineages of hepatic stem cells. Foetal and adult hepatic stem cells 
have now been extensively described both in vitro and in vivo1, 2, 69. In foetal liver hepatic 
stem cells derive from the primitive endoderm and go on to form functional cholangiocytes 
and hepatocytes as the liver develops. In adult liver the presence of adult hepatic stem cells in 
small numbers at the finer branches of the biliary tree, the Canals of Hering, in peri-portal 
regions of the hepatic lobule has been well described for many years. More recent work has 
described the presence of multipotent biliary tree/hepatic stem cells throughout the biliary tree 
from the sphincter of Oddi, at the most proximal point, through all regions of the biliary tree 
through to the Canals of Hering12. However it has not been conclusively shown that these 
cells represent a single, connected population where cells migrate through the biliary tree 
toward the liver undergoing progressive maturation and patterning. It is possible that at 
different points of the biliary tree, multipotent stem cells observed that are distinct 
populations with roles specific to their location, whereby hepatic stem cells of the Canals of 
Hering are solely responsible for stem-cell mediated liver regeneration in response to chronic 
hepatocytic liver disease. As such the contribution of biliary tree stem cells to liver 
regeneration, and specifically reconstitution of hepatocytes, is currently unknown and so were 
not studied.  
!
In adult liver the intra-lobular hepatic stem cells are located within the Canals of Hering, the 
most proximal branches of the biliary tree found in portal regions abutting the hepatic plate10. 
There is increasing evidence for the presence of small proportions of hepatic stem cells in all 
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biliary epithelia but most studies focussed on hepatic injury and stem-cell mediated 
regeneration have focussed on cells of the Canals of Hering71, 79, 116. The location of these 
cells, between mature cholangiocytes and mature hepatocytes, suggests that these may be the 
only hepatic/biliary stem cells that contribute to hepatocytic regeneration.  
!
The peribiliary glands of the extrahepatic bile duct are thought to harbour potent tri-potential 
(hepatocyte, cholangiocyte, pancreatic beta cell) stem cells. Detailed anatomical studies have 
demonstrated cells expressing the most primitive markers11 are located in the crypts of the 
peribiliary glands with more distal cells expressing proportionately less. Further studies have 
demonstrated the growth and differentiation potential of these cells both in vitro and in 
vivo11-13 posing the hypothesis that potent stem/progenitor cells may be found throughout the 
intra and extrahepatic biliary tree. 
                            
1.6.5. Techniques for the isolation of hepatic stem cells. The robust isolation of a pure, 
well-defined, homogeneous population of adult hepatic stem cells is an ongoing challenge. 
Varying methods have been utilised to isolate, maintain in long-term culture and fully 
differentiate hepatic stem cells, particularly in attempts to address the technological hurdle of 
producing functional hepatocytes. The isolation of hepatic stem cells is now routine from 
foetal and adult liver of human and mouse (Table 1.3) using FACS or immunoselection. 
Challenges still remain in defining conditions allowing the long-term undifferentiated culture, 
expansion and directed terminal differentiation of pure populations. To date, the 
demonstration of terminally differentiated functional hepatocytes and cholangiocytes from 
hepatic stem cells with comparable function to mature cells has not been demonstrated. 
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Where with production of proteins associated with mature hepatocyte function levels and 
function are often orders of magnitude less than mature hepatocytes.  
Prospective isolation by FACS is currently the gold standard for defining and selecting 
populations based on antigenic profile. However, the isolation of homogeneous populations of 
hepatic stem/progenitor cells is currently hampered by the lack of single, or combinations of, 
markers specific for cells early in the maturational lineage. Further, it is possible that cell-cell 
interaction, either between hepatic stem cells or with companion cells, are necessary for the 
growth and maintenance of phenotype that is necessarily lost in producing single cell 
suspensions. Many approaches for the isolation of epithelial stem cells take the approach of 
isolating the entire niche rather than single cell types115. Many commonly used surface 
markers are also expressed by mature biliary epithelial cells, whilst more specific markers 
(Sox9, Lgr5) are not expressed on the cell surface precluding their use for prospective 
isolation of live populations by FACS. Consequently alternative methods that isolate less pure 
populations have been used in combination with hormonally defined media and growth 
conditions that specifically select for immature hepatic stem cell/progenitor populations.  
!
!
!
!
!
!
!
!
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Table 1.3. Summary of methods for isolating hepatic stem cells from adult human and 
mouse liver. !
!
!!
!
!
Isolation Method
Magnetic 
immunoselection
Fluorescence activated cell 
sorting (FACS) by antigen
FACS by enzymatic activity
Group Reid, LM Grompe, M van Grunsven, LA 
Species Human Mouse Human and Mouse
Antigen Epithelial cell adhesion 
molecule (EpCAM)
Lgr5, Sox9 Aldehyde dehydrogenase
Marker 
expression
CK7, CK19, Sox9, Cd44, Prom1, CK7, 
CK19
EpCAM, CK7, CK19, Sox9
Growth 
conditions
Adherent; plastic; Modified 
Kubota’s medium 
Matrigel embedded; 
AdDMEM/F12, B27, N2, 
NAC, gastrin, EGF, Rspo1, 
Fgf10, nicotinamide; noggin 
and Wnt3a for first 4 days.
Adherent; Collagen type I; 
DMEM+10% FCS
Growth 
duration
Long >8 months (P30) Short (not passaged, 23 days)
Proliferation Rapid Rapid (estimated doubling time 
= 3 days)
Rapid (estimated doubling time 
= 2 days)
Hepatocyte 
differentiation
Y Matrigel embedded; 
AdDMEM/F12, B27, N2, 
NAC, gastrin, Fgf10, EGF, 
A8301, DAPT.
For mouse: DMEM/F12, ITS, 
HGF, EGF for 6 days; 
William’s E, HGF, OSM, dex 
for 6 days.
Cholangiocyte 
differentiation
Y N, but undifferentiated cultures 
have biliary phenotype
N
In vivo 
engraftment
Y Y; increased survival in FAH
mice; 500-800k cells, intra-
splenic injection
N
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1.6.6. The hepatic stem cell niche and factors necessary for the long-term culture and 
maintenance of undifferentiated hepatic stem cells. Maintaining phenotype and 
differentiation potential is critical for the study or therapeutic use of hepatic stem cells 
cultured long-term. Culture conditions must provide appropriate signals that both maintain the 
undifferentiated growth and prevent inappropriate differentiation/restriction of hepatic stem 
cells that also allow for controlled experimentation or expansion. More recent techniques, that 
include embedding in gels/matrices, organoid culture and organ specific stroma/feeder layers, 
have improved on conventional 2D approaches on plastic or collagen by more accurately 
recreating the conditions of the quiescent hepatic stem cell niche.  
!
!
The local extracellular matrix is known to play critical roles in patterning the proliferation and 
restriction of hepatic stem cells. Laminin has been shown to be specifically expressed in 
regions adjacent hepatic stem cells and is required for appropriate expansion and 
differentiation of stem cells in response to injury. Much work has been conducting in 
elucidating the presence and role of several types of collagen in the hepatic stem cell niche. 
Culture on collagen type I, predominantly found in scar tissue, has been shown to increase the 
proliferation of hepatic stem cells and induce rapid differentiation to hepatoblasts. Culture on 
collagen III and IV, more commonly located in peri-portal regions, appear to maintain the 
phenotype of hepatic stem cells and slow proliferation. Co-culture with hepatic stromal 
populations has demonstrated the ability of stromal layers to maintain undifferentiated hepatic 
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stem cells long-term, whilst culture on activated myofibroblasts/ stellate cells results in rapid 
proliferation and differentiation similar to that seen with culture on collagen type I. Many 
studies have repeatedly demonstrated the close spatial association between hepatic stem cells 
and stromal populations, particularly during niche remodeling in response to injury, indicating 
important functions of stroma in regulating and patterning the growth and expansion of 
hepatic stem cells. Stroma are also thought to play key roles in ECM remodeling and 
chemokine/cytokine production thereby altering the niche and allowing expansion of hepatic 
stem cell populations towards parenchyma and ensuring appropriate differentiation to 
hepatocyte or cholangiocyte lineages dependent on type of injury. 
  
Harry Kubota conducted many detailed experiments defining the most minimal media 
components necessary for the survival and growth of hepatic stem cells. These experiments 
demonstrated the selection and growth of hepatic stem cells in serum-free media containing 
essential ions/minerals and only insulin and hydrocortisone as growth factors1. Usefully, this 
media precludes the survival of mature epithelial cells and slows, or even prevents, 
proliferation of stromal cells except when in close association with hepatic stem cell colonies. 
The nature of the selection method used, immunoselection without the need for strict single 
cell suspensions, may allow for the isolation of clumps of cells that are presumably mixed 
with respect to maturation status and potentially including associated stromal/companion cells 
that may contribute to the survival and patterning of hepatic stem cell colonies cultured in this 
method. Indeed cells with distinct stromal morphology and antigenic profiles are commonly 
observed at the peripheries (also infiltrating bands in the case of larger colonies) of hepatic 
stem cell colonies. There is growing literature not only describing detailed cross talk between 
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epithelial and mesenchymal populations within stem cell niches but also of the supportive role 
stroma plays in providing nutrients and factors required for the quiescent maintenance and 
rapid expansion of stem cell niches. In particular to liver, it is thought that during liver 
regeneration adjacent stromal cells17 access energy (lipid) stores to produce and secrete lactate 
then utilised by rapidly proliferating hepatic stem cells essentially fuelling the rapid hepatic 
stem cell-mediated regeneration of the liver observed in response to acute injury117. This 
process may be occurring in cultured hepatic stem cell colonised isolated in this manner, with 
stromal cells allowing the survival of hepatic stem/progenitor populations in such minimal 
media by maintaining their undifferentiated state through secretion of patterning factors 
whilst also producing nutritional molecules hepatic stem cells, with limited metabolic 
machinery, are unable to produce. 
!
Our understanding of the milieu soluble and bound factors in normal and injured liver is far 
from complete. Many of the soluble factors increased in response to acute and chronic liver 
injury that stimulate activation of the hepatic stem cell niche have been described (TNFa, IL6, 
TWEAK etc.) and the producing cell type, mechanism of action and functional effects are 
also well characterised in many cases19, 26. Yet, factors critical for hepatic stem cell function 
continue to be identified and our understanding of the complex interaction between each of 
these signals remain limited. In addition, there is an increasing appreciation of the importance 
of conformational state and availability of growth factors on signaling outcomes, further 
complicated by the discovery that growth factors can convey differing, and even opposing, 
signals when bound to ECM molecules or in free solution29, 118. This is particularly pertinent 
in the case of liver regeneration where substantial ECM remodeling occurs in peri-portal 
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regions surrounding the hepatic stem cell niche, potentially leading to the release of growth 
factors or modulation of signaling outcomes as a result of altered ECM conformation or 
composition. 
Gradients of signaling molecules are commonly observed in development and allow 
information regarding relative spatial positioning to be received by a substantial numbers of 
cells over considerable distances119. Similar mechanisms are thought to contribute to 
patterning of hepatic stem cell identity and maturation in both developing and adult liver, with 
particular functional importance in regeneration and hepatic stem cell activation. Firstly, 
oxygen concentrations decrease from their highest levels in peri-portal regions, where hepatic 
stem cells reside, as oxygenated blood enters the hepatic plates, perfuses the hepatic lobules 
and drains into the hepatic vein where oxygen concentrations are lowest. Consequently a 
gradient of oxygen concentration exists across the liver lobule from the portal triad to the 
central vein. This is the same axis through which hepatic stem cells migrate and differentiate 
into mature hepatocytes. More work is required in assessing the importance of this signaling 
gradient in the patterning hepatic stem cells, but is of note that the hepatic stem cells is highly 
vascularised and oxygenated, in contrast to many other stem cell niches. This may be a 
necessity due to the need for rapid increases in metabolic output of hepatic stem cells and 
progeny during differentiation in mature hepatocytes. 
!
1.6.7. Hepatic stem cell niche remodeling and fibrogenesis. The extra-cellular matrix of the 
hepatic stem cell niche is closely associated with the basement membrane, principally 
composed of fibronectin, laminin7, 19, collagen type III27, hyaluronan120, chondroitin 
sulphates121 and minimally sulphated proteoglycans122, 123. The remodeling and expansion of 
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laminin has been shown to be particularly important for the activation of hepatic stem cells. 
Laminin is exclusively expressed in the hepatic stem cell niche in normal liver. In response to 
injury, hepatic stem cells contribute to increased laminin secretion during activation and 
laminin is observed in peri-portal parenchyma areas in close association with ductular reactive 
cells and proliferating stem/progenitor cells. Studies have shown the remodeling and secretion 
of laminin is required for effective activation and maturation of hepatic stem cells19, 124. Other 
structural proteins, particularly collagens and proteoglycans, have been shown to play 
important roles in the regulation and patterning of hepatic stem cells and are thought to 
convey lineage specific cues through compositional differences between ductal and hepatic 
plates. Appropriate remodeling of ECM is thought to be critical for the effective expansion 
and differentiation of hepatic stem cells in response to injury118. Histologically, ECM 
remodeling can be observed as increased deposition of ECM components, increased numbers 
of fibroblasts and hepatic stem/progenitors and architectural changes in peri-portal regions 
(Fig 1.3.125). In chronic injury, these processes are tightly associated with fibrogenesis, with 
scarred regions composed of myofibroblasts, hepatic progenitors, inflammatory and 
endothelial cells, observed forming bridges between peri-portal regions and eventually 
encapsulating regenerative nodules. 
!
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Figure 1.3. Hepatic stem cell niche remodeling in response to chronic liver disease. 
Lineage traced Foxl1+ hepatic progenitors (aqua blue) encapsulated by elastin+ portal 
fibroblasts (dark blue) are seen expanding from peri-portal regions into the surrounding 
parenchyma in response to DDC-induced liver injury. Brown precipitates are breakdown 
products of DDC. Image replicated from review125 !
!
!
!
!
!
!
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1.7. LIVER REGENERATION 
The suggestion of the liver’s extraordinary ability to regenerate at least dates back to the 
ancient Greek myth of Prometheus, whilst it was Higgins and Anderson who were the first to 
scientifically demonstrate this phenomenon using partial hepatectomy in rats103. Their study 
involved the surgical removal of a significant proportion of the rat’s liver and observation of 
its regeneration. Higgins and Anderson noted that after removal of as much as two-thirds of 
the liver the entire mass could be reconstituted in as little as a week, a remarkable 
regenerative capability not observed in other viscera. It is now understood that this 
regeneration is mediated entirely by the mature cell types of the adult liver, namely 
hepatocytes and cholangiocytes14. This is notable as other constantly regenerating organs such 
as the skin and gut126, 127 are replaced by the proliferation and differentiation of stem cell 
populations. Upon two-thirds partial hepatectomy, an estimated minimum of 95% of mature 
hepatocytes rapidly enter mitosis followed by a smaller proportion of hepatocytes undergoing 
a second round of division to fully reconstitute original liver mass and function. This process 
was first demonstrated using continual administration of tritiated thymidine (a means of 
labelling cells that have undergone DNA replication and thus proliferation) after PHx. This 
resulted in the labelling of 99% of hepatocytes, significantly more than the 2/3 that would be 
expected if the hepatocytes of the remnant liver had not proliferated, as would be the case if 
liver regeneration was performed but an alternate, distinct population of stem cells128. A 
subsequent study by the same lab highlighted the enormous regenerative capacity of mature 
hepatocytes by demonstrating complete regeneration of the liver after up to 12 sequential 
hepatectomies in the same animal129. Further work has shown that hepatocytes transplanted 
into models of liver failure can rescue liver failure and repopulate the liver completely130 and 
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serial transplantation, isolation and re-transplantation of labelled of hepatocytes can fully 
regenerate consecutive livers up to 10 times131. How the proliferation of hepatocytes is 
controlled in such a way that the original liver mass is restored almost exactly to its original 
size is unknown, but clearly feedback mechanisms are present ensuring sufficient 
regeneration whilst preventing excessive or uncontrolled growth. 
!
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1.8. LIVER CANCER 
The majority of tumours found in the liver are metastases from distant sites, however primary 
liver cancers are increasingly prevalent with a poor prognoses. Hepatocellular carcinoma 
(HCC) is the most common primary adult liver cancer and is characterised by tumours with 
predominantly hepatocellular features46, 132. The major risk factors for HCC are chronic liver 
injury, viral infection or alcoholism, and cirrhosis, all increasing in Western populations. HCC 
surveillance is recommended for all patients with cirrhosis, usually involving bi-annual 
ultrasound screening and measurement of circulating α-fetoprotein (AFP) levels. As early 
diagnosis of HCC significantly improves outcome, identifying patients with end-stage liver 
disease at particularly high risk of developing HCC could allow the use of more frequent, 
targeted and accurate surveillance methods, notably MRI. however current strategies are 
problematic with not all patients being screened routinely and modest decreases in mortality 
observed in those that are133. Consequently, there is a need for more accurate tests for the 
prediction of risk of liver cancer development with preliminary studies indicting potential 
utility of biopsy material through assessment of hepatic stem cell activation. 
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Cholangiocarcinoma (CCC), the second most common primary adult liver cancer, is 
characterised by tumour cells with biliary characteristics as opposed to the hepatocellular 
features seen for HCC. However, it is increasingly recognised that a spectrum exists between 
HCC and CCC, and combined HCC-CCC (mixed carcinoma) has been well described. With 
increasing understanding of the characteristics of hepatic stem cells and their activation in 
chronic liver diseases and cirrhosis, it has been hypothesised that mixed carcinomas may be 
derived from primitive, bi-potential hepatic stem/progenitor cells. Further, there is substantial 
experimental evidence of a direct causal contribution of hepatic stem cells to the development 
of both HCC and CCC, although this association has proved difficult to test clinically88, 89, 94, 
134. 
!
!
!
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CHAPTER 2 
MATERIALS AND METHODS 
!
!
!
!
!
!
!
!
!
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2.1. HUMAN TISSUE SAMPLES 
2.1.1. Formalin-fixed paraffin-embedded (FFPE) explanted tissue and liver biopsies 
FFPE explanted tissue blocks were obtained from the Centre for Liver Research (CLR) tissue 
collection. FFPE blocks were obtained from the archives of the Department of Pathology 
(Queen Elizabeth Hospital, Birmingham, UK).  
!
2.1.2. Fresh explanted liver tissue 
Human liver explants were obtained from consenting patients undergoing liver transplantation 
or resection at the Queen Elizabeth Hospital, Birmingham. Livers were evaluated and 
prepared by Dr. Gary Reynolds. For hepatic stem cell isolation a slice of tissue was cut and 
placed in cold Dulbecco’s Modified Eagle Medium (DMEM) prior to use. 
!
2.1.3. Fresh common bile duct tissue from Whipple’s procedures 
Common bile duct was obtained from consenting patients undergoing Whipple’s procedures 
at the Queen Elizabeth Hospital, Birmingham. Fresh tissue was placed in cold Dulbecco’s 
Modified Eagle Medium (DMEM) prior to use and stored at 4°C until processed. 
!
2.1.4. Whole peripheral blood from healthy volunteers 
Whole blood was obtained from with research ethics approval from consenting volunteers at 
the Queen Elizabeth Hospital, Birmingham.  
!
!
!
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2.2. IMMUNOHISTOCHEMISTRY 
2.2.1. Sectioning and fixation of formalin-fixed paraffin-embedded (FFPE) tissue 
FFPE sections were cut at 4µm and fixed to microscope slides (X-tra Adhesive, Leica, 
Wetzlar, Germany).  
!
!
2.2.2. De-waxing and rehydration of FFPE tissue sections 
All FFPE sections were de-waxed and rehydrated before tinctorial or histochemical staining. 
Sections were passed sequentially through Clearene solvent (Leica, Wetzlar, Germany) three 
times, industrial methylated spirit (IMS) twice, and water for 2 minutes each. 
!
2.2.3. Haematoxylin and Eosin (H&E) staining 
Previously de-waxed and rehydrated sections were sequentially moved through the following 
reagents: Harris Haematoxylin (Leica, Wetzlar, Germany) for 4 minutes; water for 2 minutes; 
Acid Alcohol (Leica, Wetzlar, Germany) for 30 seconds; water for 2 minutes; Scott’s Tap 
Water Substitute (Leica, Wetzlar, Germany) for 30 seconds; Eosin (aqueous) (Leica, Wetzlar, 
Germany) for 1 minute; and water twice for 2 minutes each before dehydration and mounting. 
!
2.2.4. Van Gieson staining 
Previously de-waxed and rehydrated sections were sequentially moved through the following 
reagents: Celestine Blue (Leica, Wetzlar, Germany) for 5 minutes; water twice for 2 minutes 
each; Harris Haematoxylin for 4 minutes; water for 2 minutes; Acid Alcohol (Leica, Wetzlar, 
Germany) for 30 seconds; water for 2 minutes; Scott’s Tap Water Substitute (Leica, Wetzlar, 
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Germany) for 30 seconds; and water for 2 minutes; Van Gieson’s solution for 3 minutes; and 
rinsed with industrial methylated spirit (IMS) before dehydration and mounting. 
!
2.2.5. Chromogenic immunohistochemistry 
Sections previously de-waxed and rehydrated underwent antigen retrieval using Dako Target 
Retrieval Solution (Dako UK Ltd. Ely, UK). Buffer was microwaved for 5 minutes at full 
power then sections added and heated for a further 10 minutes before being left to stand for 
10 minutes. Sections were then cooled by the slow addition of cold tap water to the hot buffer. 
Sections were removed, dried and then circled with a wax pen to allow damming of 
subsequent buffers. Subsequent steps were conducted at room temperature with slow rocking. 
Sections were blocked in 0.3% MeOH in H2O2 for 20 minutes to block endogenous hydrogen 
peroxidase activity and casein buffer (Vector Laboratories Ltd., Peterborough, UK) for 1 hour 
to block non-specific antibody binding. Primary antibodies were diluted in Tris-buffered 
saline (TBS) (pH 7.4) and sections were incubated in primary antibody for 1 hour directly 
after blocking steps. Sections were washed with three, five minute washes in TBS plus 0.1% 
Tween20 (Sigma-Aldrich Chemie Gmbh, Munich, Germany). Sections were then incubated 
with appropriate immPRESS (peroxidase) Polymer Detection Kits (Vector Laboratories Ltd., 
Peterborough, UK). Sections were again washed as before in TBS plus 0.1% Tween20 then 
incubated in fresh 3,3'-Diaminobenzidine (DAB) reagent (AbD Serotec, Kidlington, UK) with 
agitation until brown staining was clearly visible on liver tissue. Excess substrate was then 
washed off using tap water and sections were counterstained in Mayer’s Haematoxylin (Leica, 
Wetzlar, Germany) for 30 seconds before bluing by incubation in tap water. All experiments 
included a negative control section (no primary antibody) and a section treated with an 
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isotype control matched to the primary antibody. This allowed detection of nonspecific 
binding of the primary or secondary antibodies to the liver sections resulting in false positive 
results. 
!
!
!
2.2.6. Dehydration and mounting and stained sections 
Sections were passed sequentially through industrial methylated spirit (IMS) twice, and 
Clearene solvent (Leica, Wetzlar, Germany) three times before mounting glass coverslips with 
DPX mountant (Sigma-Aldrich Chemie Gmbh, Munich, Germany). 
!
2.2.7. Fixation of cultured cells for immunohistochemistry 
Cells were washed twice in phosphate-buffered saline (PBS) and then incubated in 100% 
methanol at -20°C for 10 minutes. Fixed cells were then washed three times in PBS to remove 
methanol and stored in PBS at 4°C until further use. 
!
!
!
!
!
!
!
!
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Table 2.1. Anti-human antibodies used !
!
!
!
!
!
!
!
!
!
!
!
!
Antigen Host Clone Supplier Concentration 
Used (µg/ml)
Albumin Rabbit F0117 Dako, Glostrup, 
Denmark
1
CK7 Mouse OV-TL 12/30 Dako, Glostrup, 
Denmark
2
CK18 Mouse CD10 Dako, Glostrup, 
Denmark
2
CK19 Mouse RCK108 Dako, Glostrup, 
Denmark
2
EpCAM Mouse MOC-31 Dako, Glostrup, 
Denmark
5
NCAM Mouse 0567 Ebiosciences, 
Hatfield, UK
2
panCK Rabbit Z0622 Dako, Glostrup, 
Denmark
2
Sox9 Rabbit ab5535 Millipore, Billerica, 
MA, USA
1
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Table 2.2. Anti-mouse antibodies used !
Antigen Host Clone Supplier Concentration 
Used (µg/ml)
AFP Rabbit A0008 Dako, Glostrup, 
Denmark
13
αSMA Rabbit E184 Abcam, Cambridge, 
MA, USA
1:1000 dilution*
β-catenin Goat SC-1496 Santa Cruz 
Biotech., Santa 
Cruz, CA, USA
1
CAM 5.2 Mouse CAM 5.2 BD biosciences, San 
Jose, CA, USA
5
CD45-PE Rat 30-F11 BD biosciences, San 
Jose, CA, USA
0.2
CK18 Mouse ab668 Abcam, Cambridge, 
MA, USA
40
Desmin Rabbit ab8592 Abcam, Cambridge, 
MA, USA
2
Glutamine 
Synthetase
Mouse MAB302 Millipore, Billerica, 
MA, USA
5
Ki67 Rabbit ab9260 Millipore, Billerica, 
MA, USA
0.4
Pan-CK Rabbit Z0622 Dako, Glostrup, 
Denmark
2
PDGFRα Rat APA5 Ebiosciences, 
Hatfield, UK
2
PDGFRα Goat AF1062 R&D systems, 
Minneapolis, MN
2
PDGFRα-APC Rat APA5 BD biosciences, San 
Jose, CA, USA
0.2
Sca1 Rat E13 161-7 Abcam, Cambridge, 
MA, USA
1
Sca1-FITC Rat E13 161-7 BD biosciences, San 
Jose, CA, USA
0.2
Ter119-PE Rat TER119 BD biosciences, San 
Jose, CA, USA
0.2
Ubiquitin Rabbit Z0458 Dako, Glostrup, 
Denmark
1:1000 dilution*
Ubiquitin Rabbit ab19247 Abcam, Cambridge, 
MA, USA
5
Vimentin Rabbit SP20 Abcam, Cambridge, 
MA, USA
2
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*Antibody concentration not supplied with this product. !
2.2.8. Fluorescent immunohistochemistry 
Either sections or cells fixed in situ were blocked for one hour in casein buffer (Vector 
Laboratories Ltd., Peterborough, UK), incubated with primary antibody diluted in TBS for 2 
hours, washed three times for 5 minutes in TBS plus 0.1% Tween20 and incubated in 
appropriate secondary antibodies for 2 hours. Further steps were conducted with cells or 
sections protected from light using aluminium foil. Cells or sections then underwent three, 
five minute washes in TBS plus 0.1% Tween20 before incubation in 4',6-diamidino-2-
phenylindole (DAPI) solution (0.5µg/ml in water, Sigma-Aldrich Chemie Gmbh, Munich, 
Germany) for 2 minutes. Cells or sections were then washed with PBS three times to remove 
excess DAPI. All steps were conducted at room temperature with rocking. Fixed cells were 
left under PBS. Coverslips were mounted using VECTASHIELD mounting medium with 
DAPI (Vector labs, Peterborough, UK). 
!
2.2.9. Oil Red O staining 
Cells were stained in 96-well plates. Cells were incubated in 60% isopropanol (diluted in DI 
water) for 5 minutes, Oil Red O working solution for 60 minutes and 60% isopropanol again 
for 5 minutes. Cells were then wasted twice in water and counterstained with Mayer’s 
haematoxylin for 1 minute. Haematoxylin was rinsed with tap water and cells were left under 
PBS before imaging. 
!
!
!54
!
!
2.3. IMAGE CREATION AND ANALYSIS 
2.3.1. Imaging 
Images of chromogenic immunohistochemistry were taken with a conventional light 
microscope (Carl Zeiss AG, Oberkochen, Germany). Images of fluorescent staining of fixed 
cells were taken with an inverted microscope (Carl Zeiss AG, Oberkochen, Germany). Images 
of fluorescent staining of sections were taken with a confocal microscope (Carl Zeiss AG, 
Oberkochen, Germany).  
!
2.3.2. ImageJ 
ImageJ was used for quantitative analysis of chromogenic and tinctorial staining. Total area of 
biopsies was calculated by manually drawing around tissue fragments and using the ‘measure’ 
function within ImageJ. DAB and Van Gieson staining was quantified using the ‘Color 
Threshold’ function of ImageJ. The ‘Color Threshold’ function of ImageJ produces 
histograms quantifying the hue, saturation and brightness of the overall image and allows 
pixels within user defined ranges for each parameter to be excluded. 
!
2.3.3. NAFLD activity and fibrosis scoring 
The NAFLD activity score (NAS) was assigned to each section through blinded assessment 
by an experienced liver pathologist (Prof. Stefan Hübscher) according to the Kleiner scoring 
system44. The Kleiner system generates a composite score (out of a total of 8) based on the 
degree of steatosis (0-3), lobular inflammation (0-3), and hepatocyte ballooning (0-2), with a 
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separate score for fibrosis (0-4). Steatosis scores are assigned according to the extent of 
steatosis as: 0 for <5%; 1 for 5-33%; 2 for 33-66%; and 3 for >66%. Lobular inflammation 
scores are assigned according to the number of inflammatory foci as: 0 for no foci; 1 for <2 
foci per 200x field; 2 for 2-4 foci per 200x field; and 3 for >4 foci per 200x field. Hepatocyte 
ballooning scores are assigned according the number and prominence of ballooned 
hepatocytes as: 0 for none; 1 for few, or borderline, cases of ballooning; and 2 for many cases 
of ballooned hepatocytes that typically contain Mallory’s hyaline. Fibrosis is assessed 
separately for the NAS composite and scores are assigned based on the degree and location of 
fibrosis as: 0 for none; 1 for peri-sinusoidal or peri-portal; 2 for peri-sinusoidal and peri-
portal; 3 for bridging; and 4 for cirrhosis. A score of 1 is often subdivided into: 1a, mild, or 
delicate, peri-sinusoidal; 1b, moderate, or dense, peri-sinusoidal; and 1c, portal or peri-portal 
fibrosis without the presence of peri-cellular or peri-sinusoidal fibrosis. 
!
2.4. ISOLATION OF PRIMARY HUMAN CELLS 
2.4.1. Immunoselection of biliary epithelial cells (BEC) 
Slices of approximately 100g of explanted, resected or donor liver were stored at 4°C in 
DMEM for up to 2 days (liver progenitor cells may be viable in cadaveric liver for up to 6 
days). Slices were removed from DMEM and diced finely with scalpels before digestion with 
0.2% collagenase Type 1A (Sigma-Aldrich, UK) in PBS for between 20 and 45 minutes at 
37°C depending on the condition of liver tissue. After digestion the liver suspension was 
passed through a fine mesh with moderate pressure and washed with PBS until 200ml of cell 
suspension was obtained. The suspension was transferred to eight 25ml universal tubes and 
spun at 2000rpm for 5 mins. Supernatant was discarded and pellets were combined and 
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resuspended in 25ml PBS in four 25ml universal tubes. Pellets were combined 2:1 
resuspended and spun as above until a single pellet was obtained. Eight tubes for density 
centrifugation gradients were set up each containing 3ml of 77% Percoll (GE Healthcare Life 
Sciences, Little Chalfont, UK) in PBS layered under 3ml of 33% Percoll in PBS. The pellet 
was resuspended in 25ml of PBS and 3ml layered over each of the Percoll gradients. Percoll 
gradients were then spun at 2000rpm for 20 mins with no brake. Bands formed at the second 
interphase were removed and combined 2:1 in four 25ml universal tubes, resuspended in PBS 
and spun at 2000rpm for 5 mins with brake. All pellets obtained were transferred into a single 
universal, resuspended and spun again at 2000rpm for 5 mins. The final pellet was 
resuspended in 500µl PBS and EpCAM primary antibody. Cells were incubated in primary 
antibody for 30 mins at 37C with periodic shaking. Cells were then washed in PBS and spun 
at 2000rpm for 5 mins with the pellet resuspended in 500µl ice-cold PBS with anti-mouse IgG 
dynal beads. Cells were incubated on ice with shaking for 30 minutes then made up to a final 
volume of 5ml in further ice-cold PBS. Cell suspensions were then placed on magnet for 5 
mins and all PBS removed. Remaining cells represent all EpCAM+ parenchymal cells present 
in the liver and consist largely of mature biliary epithelial cells (BEC). These cells can be 
plated on type I collagen coated plates or flasks in media containing insulin, IT3, EGF, HGF 
and cholera toxin, cultured to confluence and subsequently passaged using trypsin. 
!
2.4.2. Selection of hepatic stem cells from EpCAM+ cells from explanted liver tissue 
Immunoselected EpCAM+ cells from explanted liver were plated onto culture plastic in 
modified Kubota’s medium resulting in the selection and growth of hepatic stem cells only. 
Media was changed weekly. 
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2.4.3. Isolation of biliary tree stem cells from explanted common bile duct 
Common bile duct was removed from DMEM and diced finely with scalpels before digestion 
with 0.2% collagenase Type 1A (Sigma-Aldrich, UK) in PBS for 20 minutes at 37°C. After 
digestion tissue was passed through a fine mesh and washed in 5mM EDTA in PBS for 30 
minutes at 37°C to dissociate peri-biliary glands. The resulting suspension was passed 
through fine mesh, spun at 2000rpm for 5 mins and seeded in collagen-coated plates in 
modified Kubota’s medium for 1 hour. Non-adherent cells/glands were then transferred to 
fresh collagen-coated plates and incubated in modified Kubota’s medium. 
!
2.4.4. Isolation of CD14+CD16+ monocytes from peripheral blood 
Monocyte subsets from peripheral blood were isolated using the CD16 nonocyte isolation kit 
and CD14 Microbeads (Miltenyi Biotec, Bisley, Surrey, UK) according to manufacturer’s 
instructions.  
!
2.5. ANIMAL HUSBANDRY 
2.5.1. Housing 
All mice were housed in accordance with the animal care protocols at the University of 
Birmingham, UK. Mice were maintained on a 12:12 hour light-dark schedule at 22°C, with up 
to 4 mice per cage.  
!
2.5.2. Genotyping 
Tissue for genotyping was obtained from ear clippings used to number and identify animals. 
Genomic DNA (gDNA) was isolated by digesting tissue in 100µl of sodium hydroxide 
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(NaOH) for 40 minutes at 95°C with occasional agitation. The resulting solution was 
neutralised with 8µl of Tris-HCl (pH 8.0). All genotyping PCR reactions were performed 
using the following mixture: 12.5µl 2x BioMix Red (Bioline, London, UK); 0.3µl of each 
primer; 2.9µl water; and 4µl of isolated gDNA solution (total 25µl). FAH primers were 
designed to yield a product of 250bp. Cycling conditions for FAH were as follows: 94°C for 3 
mins; 35 cycles of (94°C for 30 seconds, 60°C for 30 seconds and 72°C for 60 seconds); and 
finally 72°C for 7 minutes. RAG-2 primers were designed to yield a product of 200bp. 
Cycling conditions for RAG-2 were as follows: 94°C for 5 mins; 35 cycles of (94°C for 45 
seconds, 58°C for 45 seconds and 72°C for 60 seconds); and finally 72°C for 5 minutes. 
IL2RG primers were designed to yield a product of 250bp. Cycling conditions for IL2RG 
were as follows: 94°C for 3 mins; 35 cycles of (94°C for 30 seconds, 60°C for 30 seconds and 
72°C for 60 seconds); and finally 72°C for 7 minutes. Products were run on a 2% agarose gel 
for 40 minutes at 124V. Band size was determined using Hyperladder IV (Bio-rad, Hemel 
Hempstead, UK). 
!
2.5.3. American Lifestyle-Induced Obesity Syndrome (ALIOS) diet 
ALIOS mice were fed a trans-fat custom diet (TD.06303 Harlan Teklad, Madison, WI, USA) 
containing 45% kcal from fat (30% of the fat was from hydrogenated vegetable oil, which 
contains 30% trans-fat), 37% from carbohydrate and 18% from protein. Drinking water was 
replaced by a HFCS equivalent, prepared by adding 42ml/litre of a 55% fructose and 45% 
glucose solution. Control mice were fed a standard chow diet with normal drinking water. 
Food and drink was provided ad libitum to all animals.  
!
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2.5.4. Preparation of Nitisinone stock and drinking water 
NTBC drinking water was prepared as a 2mg/ml stock solution by firstly dissolving 3g of 
sodium bicarbonate (Sigma-Aldrich Chemie Gmbh, Munich, Germany) in 30ml of sterilised 
water at 42ºC for 2 hours with agitation. A further 220ml of sterilised water was then added to 
make a total of 250ml before dissolving 500mg of NTBC (Nitinisone, Swedish Orphan 
Biovitrum, Stockholm, Sweden) by heating at 50ºC for 3 hours with stirring. The resulting 
solution was then sterilised by filtering in a laminar flow hood. Stock solution was protected 
from light and stored at 4ºC for up to 3 months. Drinking water was autoclaved with the 
addition of food colouring to distinguish from normal drinking water. NTBC stock was then 
added to the cooled, coloured water under sterile conditions at 8ml/L to a final NTBC 
concentration of 16mg/L. The amount of NTBC stock added was adjusted accordingly to 
prepare 25% (4mg/L), 12.5% (2mg/L) and 6.25% (1mg/L) NTBC drinking water for cycling. 
NTBC was administered to mice in lieu of normal drinking water. 
!
2.5.5. Adoptive transfer via intra-venous (i.v.) tail vein infusion 
Freshly isolated cells were resuspended in a total volume of 230µl of PBS and kept on ice 
before infusion into the tail vein. Mice were observed for 5 minutes then returned to normal 
conditions. 
!
2.5.6. Tissue preservation and preparation for histological assessment 
Mice were killed by cervical dislocation under terminal general anaesthesia using isoflurane. 
Livers were excised and tissue placed in formalin for paraffin embedding or snap frozen in 
liquid nitrogen. For formalin-fixed paraffin embedded (FFPE) samples, tissue was left to fix 
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in formalin overnight, then paraffin wax embedded. Sections were cut at 3.5µm and and fixed 
to microscope slides (X-tra Adhesive, Leica, Wetzlar, Germany). Frozen tissue was used for 
RNA isolation.  
!
2.6. ISOLATION OF PRIMARY MURINE CELLS 
2.6.1. Isolation of non-parenchymal cells from murine liver 
Mice were killed by cervical dislocation and whole livers dissected and transferred to a sterile 
petri dish 56.5cm2 petri dish (Fisher Scientific, Hampton, NH, USA). Livers were 
mechanically dissociated by fine chopping with two scalpels until a homogenous paste was 
formed. Tissue was then placed in a first digestion buffer (2mg/ml collagenase in DMEM) 
and incubated at 37°C for 10 minutes with robust agitation (200rpm). Digested tissue was 
placed over coarse mesh (pore size 0.45µm, Millipore, Billerica, MA, USA)  and debris was 
washed through with PBS and discarded. Remaining tissue was transferred to a second 
digestion buffer (1mg/ml collagenase in DMEM) and re-digested at 37°C for 40 minutes with 
robust agitation. The resulting suspension was placed over fine mesh (pore size 0.45µm, 
Millipore, Billerica, MA, USA) and washed through with HBSS wash buffer with firm 
pressure applied to dissociate and force through any remaining tissue fragments. The resulting 
suspension was made up to 200ml with HBSS, split into four 50ml conical tubes and spun at 
2000rpm for 5 minutes to remove debris. Pellets were resuspended in 100ml HBSS, split into 
two conical tubes and spun again at 2000rpm for 5 minutes. Pellets were resuspended in 
100ml of HBSS and spun at 50g for 10 minutes to remove mature hepatocytes. Supernatant 
was collected and spun again at 50g for 10 minutes. Supernatant was collected and spun at 
2000rpm for 5 minutes to collect remaining cells. Pellets were resuspended and pooled in 
!61
10ml of Red Cell Lysing Buffer (Sigma-Aldrich Chemie Gmbh, Munich, Germany) and 
incubated at room temperature for 5 minutes with agitation. The suspension was made up to 
50ml with HBSS and spun at 2000rpm for 5 minutes to collect cells. Cells were resuspended 
in 120ml 30% Percoll (GE Lifesciences, Pittsburgh, PA, USA) in PBS and split into four 
50ml conical tubes. Percoll suspensions were spun at 2000rpm for 20 minutes with no brake 
applied. Supernatants were removed and pellets resuspended and pooled in HBSS and spun at 
2000rpm for 5 minutes to collect viable non-parenchymal cells. 
!
2.6.2. Fluorescence activated cell sorting of hepatic stem cell populations 
Isolated murine hepatic non-parenchymal cells were resuspended in 1ml HBSS and incubated 
with CD45 (PE; 1µl/liver), Ter-119 (PE; 1µl/liver), Sca-1 (FITC; 1µl/liver) and PDGFRα 
(APC; 2µl/liver) (all antibodies from eBiosciences, Hatfield, UK) on ice for 30 minutes 
protected from light. The suspension was made up to 15ml with HBSS and spun at 2000rpm 
for 5 minutes to wash out conjugated antibodies. Cells were then resuspended in 1ml HBSS 
with 2µg/ml propidium idodide (PI) (Sigma-Aldrich Chemie Gmbh, Munich, Germany) and 
incubated on ice for 15 minutes protected from light. Cells were strained through a 50µm 
filter and placed on ice protected from light until sorting.  
!
2.7. FLUORESCENCE ACTIVATED CELL SORTING (FACS) 
2.7.1. Equipment setup 
Cells were sorted using the MoFlo XDP high-speed cell sorter (Beckman Coulter, Brea, CA, 
USA). Both the blue (488nm) and red (640nm) lasers were used. The blue laser was used for 
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forward scatter (FS) and side scatter (SS) detection. The following channels were used for 
detection of fluorescence: FL1 (FITC), FL2 (PE), FL3 (PI), FL9 (APC). 
The cell sorter was initialised and optimised before each sort. Briefly, this consisted of a crude 
and fine stream alignment, drop delay using Flowcheck beads (Beckman Coulter, Brea, CA, 
USA), and compensation of fluorescent bleeding between channels using small samples of 
cells stained for each individual antibody.  
!
2.7.2. Sorting strategy 
Cells were stained with: PI, CD45-PE, Ter119-PE, Sca1-FITC and PDGFRα-APC and 
identified through the combination of the following plots: PI (X axis)/FSC-height (Y axis)
(Fig 2.1A), PE/FITC (Fig 2.1B), PE/FSC-Height (Fig 2.1C) and FITC/APC (Fig 2.1D). PI 
was used to positively identify and exclude dead cells (R1; PI+,) from further analysis. 
Haematopoietic lineage cells (CD45+, Ter119+) were positively identified and excluded on 
PE/FSC-Height plots (R3) (Fig 2.1A) from further analysis. The presence and intensity of 
PDGFRα and Sca1 staining was visualised on a FITC/APC plot (Fig 2.1D) after exclusion of 
dead and lineage positive cells allowing identification of populations of interest. 
!
2.7.3. Prospective isolation of cells from adult murine liver 
Gates were drawn around viable (R3; PI-,) and haematopoietic lineage negative (R4) cells and 
distinct populations of Lin-Sca1+ cells (R6) and PαS cells (R5) observed on the FITC/APC 
plot. Lin-Sca1+ cells were sorted from all cells found inside gates R3, R4 and R6 and outside 
gates R1, R2, and R5. PαS cells were sorted from all cells found inside gates R3, R4 and R5 
and outside gates R1, R2 and R6. 
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!  
Figure 2.1. Gating strategy for the prospective isolation of stem/progenitor cell 
populations from adult murine liver. A, live/dead cells identified with PI/FSC-Height, B, 
visualisation of PE/FITC compensation, C, haematopoietic lineage cells identified with a 
combination of CD45 and Ter119 (PE) against FSC-Height, D, Two distinct, non-
haematopoietic, resident hepatic cell populations with Sca1 (FITC) and PDGFRα (APC) 
antigenicity. !
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2.8. IN VITRO CELL CULTURE 
2.8.1. Cell culture conditions 
All cells were maintained in two-dimensional culture conditions at 37°C in 5% CO2 in 
Corning plastic cell culture flasks or wells (Sigma-Aldrich Chemie Gmbh, Munich, 
Germany).  
!
2.8.2. Preparation of coated culture flasks and plates 
Collagen solution type I from rat tail (Sigma-Aldrich Chemie Gmbh, Munich, Germany) was 
diluted to a final dilution of 0.01% (w/v) in sterile water. The diluted preparation was added to 
plates or flasks at 10µg/cm2 and left for 4 hours at room temperature. Diluted collagen was 
stored at 4°C for up to 2 weeks. Coated plates were washed once with PBS and cells plated 
directly. 
!
2.8.3. Preparation of collagen gels 
Collagen gels were prepared using the 3D Collagen Cell Culture System (Millipore, Billerica, 
MA, USA) according to manufacturer’s instructions. Collagen gel solutions were made and 
kept on ice before cells were added a density of 100,000/ml and allowed to set at 37°C. 
!
2.8.4. Preparation of stock solutions 
100µM Dexamethasone stock solution. 100mg of dexamethasone powder (Sigma-Aldrich 
Chemie Gmbh, Munich, Germany) was added to 250ml of ddH2O resulting in a 1mM stock 
solution. Dexamethasone stock was stored at 4°C until further use.  
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200µg ml-1 EGF stock solution. 500µg of lyophilised recombinatn murine epidermal growth 
factor (EGF) (Peprotech, Rocky Hill, NJ, USA) was added to 2.5ml ddH2O resulting in a 
200µg ml-1 stock solution. Stocks were aliquoted and stored at -20°C until further use.  
40µg ml-1 HGF stock solution. 20µg of lyophilised hepatocyte growth factor (HGF) 
(Peprotech, Rocky Hill, NJ, USA) was added to 0.5ml of ddH2O resulting in a 40µg ml-1 (?
molarity) stock solution. Stocks were aliquoted and stored at -20°C until further use.  
100x Insulin-transferrin-sodium selenite (ITS) stock solution. 50ml of ddH2O was added 
to 1 vial (≈40mg) of insulin-transferrin-sodium selenite (ITS) media supplement  (Sigma-
Aldrich Chemie Gmbh, Munich, Germany) to form a 100x stock. Stocks were aliquoted and 
stored at -20°C until further use.  
20mM Y-27632 stock solution. Y-27632, a molecular inhibitor of rho-associated protein 
kinase (ROCK) was prepared as a 20mM stock solution from 1mg of Y-27632 
dihydrochloride (Sigma-Aldrich Chemie Gmbh, Munich, Germany) by diluting in 200µl of 
ddH2O. Stocks were aliquoted and stored at -20°C and used at a working concentration of 
20µM. 
40µg ml-1 mrOSM stock solution. 25µg of lyophilised murine recombinant oncostatin-M 
(Peprotech, Rocky Hill, NJ, USA) was reconstituted in 625µl of ddH2O resulting in a 40µg 
ml-1 stock solution. Stocks were aliquoted and stored at -20°C until further use.  
10µg ml-1 mrFGF4 stock solution. 25µg of lyophilised murine recombinant fibroblast 
growth factor-4 (FGF-4) (Peprotech, Rocky Hill, NJ, USA), was reconstituted in 2.5ml of 
ddH2O resulting in a 10µg ml-1 stock solution. Stocks were aliquoted and stored at -20°C until 
further use. 
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1.25M 2-DG stock solution. 1g of lyophilised 2-deoxy-D-glucose (2-DG,(Sigma-Aldrich 
Chemie Gmbh, Munich, Germany) was reconstituted in 4.8ml of ddH2O to a final 
concentration of 1.25M solution. Stocks were aliquoted and stored at -20°C until further use. 
2-DG was used at a final concentration of 1.25mM. 
50µg ml-1 mrTNFα stock solution. 5µg of murine tumour necrosis factor-alpha (TNFα) 
recombinant protein (eBiosciences, San Diego, CA, USA) was reconstituted in 100µl of 
ddH2O to a concentration of 50µg ml-1. Stocks were aliquoted and stored at -20°C until 
further use. 
!
2.8.5. Preparation of culture media 
Stromal expansion media. 10% foetal calf serum (FCS) and glutamine-penicillin-
streptomycin (GPS) antibiotic media supplement (Life Technologies Ltd., Paisley, UK) were 
added to alpha-minimal essential media (αMEM) (Life Technologies Ltd., Paisley, UK). 
Hank’s Balanced Salt Solution (HBSS) wash buffer. 5ml of glutamine-penicillin-
streptomycin (GPS) antibiotic media supplement, 5ml of foetal calf serum (FCS) and 1M 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, Sigma-Aldrich Chemie Gmbh, 
Munich, Germany) were added to 500ml of hank’s balanced salt solution (HBSS) (Life 
Technologies Ltd., Paisley, UK). 
OC- medium. To make up 100ml of OC- medium, 45ml of DMEM and 45ml Ham’s F12 
were mixed then the following supplements were added; 10ml FCS; 250µl 1M HEPES; 1ml 
100x ITS stock;10µl EGF stock; 100µl HGF stock; and 1ml dexamethasone stock. Media was 
stored at 4°C until further use. 
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OC complete (OC+) medium. Before use, 100ml of OC- medium was completed with the 
addition of  12.2mg nicotinamide and 10µl Y-227632 stock.  
Murine hepatocyte differentiation medium (MKM-H). For 10ml of hepatocyte 
differentiation medium, 4.5ml of DMEM (Life Technologies Ltd., Paisley, UK) and 4.5ml 
Ham’s F12 (Life Technologies Ltd., Paisley, UK) were mixed then the following supplements 
were added; 1ml FCS; 25µl 1M HEPES; 100ul  100x ITS stock; 5ul HGF stock, 10ul FGF-4 
stock, 10ul OSM stock, 10ul dexamethasone stock and 20% Matrigel. 
Murine cholangiocyte differentiation medium (MKM-C). For 10 mL of cholangiocyte 
differentiation medium, 4.5ml of DMEM and 4.5ml Ham’s F12 were mixed then the 
following supplements were added; 1ml FCS; 100ul  100x ITS stock; 5ul HGF stock; and 
TNFα (50ng/ml). 
Modified Kubota’s Medium (MKM). Modified Kubota’s Medium contains albumin 0.3mM 
calcium (Sigma-Aldrich Chemie Gmbh, Munich, Germany), 4.5mM Nicotinamide (Sigma-
Aldrich Chemie Gmbh, Munich, Germany), 0.1nM Zinc Sulfate heptahydrate (Sigma-Aldrich 
Chemie Gmbh, Munich, Germany), 10nM hydrocortisone (Sigma-Aldrich Chemie Gmbh, 
Munich, Germany), 1x Insulin-Transferrin-Selenium (Life Technologies Ltd., Paisley, UK) 
and a mixture of free fatty acids (FFA supplement, Sigma-Aldrich Chemie Gmbh, Munich, 
Germany) bound to 0.1% bovine serum albumin (BSA) (Sigma-Aldrich Chemie Gmbh, 
Munich, Germany) in RPMI 1640 medium (Life Technologies Ltd., Paisley, UK). 
!
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2.8.6. Preparation of miscellaneous solutions 
Preparation of digestion solutions (collagenase). Digestion solutions were prepared at 0.2% 
w/v and 0.1% w/v collagenase by adding 40mg and 20mg of collagenase (WAKO, Odawara, 
Japan) respectively to 20ml of dulbecco’s modified eagle medium (DMEM) . 
Propidium iodide (PI) stock solution. - SXS 
0.4% w/v Trypan Blue solution. Trypan blue powder (Sigma-Aldrich Chemie Gmbh, 
Munich, Germany) was dissolved in PBS to a 0.5% w/v solution and boiled briefly before 
cooling to room temperature. The solution was further diluted to 0.4% w/v with PBS and 
stored at room temperature until further use. 
14.3mM (5mg/ml) 4′,6-diamidino-2-phenylindole (DAPI), dihydrochloride solution.  
DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride, Life Technologies Ltd., Paisley, UK) 
was prepared as a 5 mg/ml (14.3mM) stock solution by dissolving 10mg of DAPI in 2ml of 
ddH2O. DAPI stock solution was stored at 4°C and protected from light until further use. 
1mg/ml propidium iodide (PI) stock. Propidium iodide (Sigma-Aldrich Chemie Gmbh, 
Munich, Germany) was dissolved in ddH2O to a concentration of 1mg/ml and stored at 4°C 
until further use. 
Preparation of Oil Red O stock and working solutions. Oil red O stock solution was made 
up by adding 300mg of Oil Red O powder (Sigma-Aldrich Chemie Gmbh, Munich, Germany) 
to 100 ml 99% isopropanol (Sigma-Aldrich Chemie Gmbh, Munich, Germany). Stock 
solution was stored at room temperature. Oil red O working solution was made by adding 2 
part ddH2O to 3 parts oil red O stock. Working solution was left at room temperature for 10 
minutes before filtering with filter paper and funnel. Working solution of oil red O was used 
immediately. 
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2.8.7. Cell passage 
Spent media was removed and cells were washed twice in PBS. Pre-warmed (37°C) TrypLE 
Express (Life Technologies Ltd., Paisley, UK) was added to cells at 100µl/cm2 and incubated 
at 37°C for 5 minutes or until cells were fully detached. TrypLE was quenched in DMEM
+10% FCS and pipetted over the flask or plate several times to ensure all cells were collected. 
Cells were transferred to conical tubes and pelleted by spinning at 2000rpm for 5 minutes. 
Cells were then resuspended and plated in appropriate media. 
!
2.8.8. In situ fixation of cultured cells 
Media was removed and cells were washed twice in PBS. Cells were then covered with ice-
cold 100% methanol (Sigma-Aldrich Chemie Gmbh, Munich, Germany) and incubated at 
-20°C for 20 minutes. Methanol was removed and cells were washed twice with PBS to 
remove excess methanol before storage at 4°C under PBS until further use. 
!
2.8.9. Preparation of cell lyses for RNA isolation 
Media was removed and cells were washed twice in PBS. Cells were then either trypsinised, 
pelleted and frozen at -20°C or RLT buffer was added directly to cells after PBS wash and 
cells were scraped, collected and stored at -20°C. 
!
2.9. IN VITRO FUNCTIONAL ANALYSES 
2.9.1. Hepatocyte differentiation of murine hepatic stem cells 
For hepatocyte differentiation of murine hepatic stem cells, 0.5 x 10-6 cells were plated onto 
6-well collagen-coated plates and placed in hepatocyte differentiation media for 2 weeks with 
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media changed weekly. Cells were then fixed with 100% methanol and stored at 4°C until 
further use. 
!
2.9.2. Cholangiocyte differentiation of murine hepatic stem cells 
For cholangiocyte differentiation of murine hepatic stem cells, cell were suspended in 
collagen gels at a density of 100,000 cells per ml. Cholangiocyte differentiation media was 
then added on top of the set gels and cells were incubated for 7 days. Cells were then fixed 
with 100% methanol and stored at 4°C until further use. 
!
2.9.3. Fibroblast differentiation of murine hepatic stem cells 
For fibroblast differentiation differentiation of murine hepatic stem cells, 0.5 x 10-6 cells were 
plated onto 6-well culture plastic plates and placed in αMEM for 2 weeks with media changed 
weekly. Cells were then fixed with 100% methanol and stored at 4°C until further use. 
!
2.10. GENERIC LAB TECHNIQUES 
2.10.1. RNA isolation 
Total ribonucleic acid (RNA) was isolated using RNeasy Minikits (Qiagen, Gaithersburg, 
MD, USA) according to manufacturer’s instructions. Whole tissue, either snap frozen or 
stored in RNA later (Life Technologies, Paisley, UK) was added to appropriate amounts of 
RLT buffer and homogenised with a hand-held homogeniser. Cells were either scraped in RLT 
buffer or pelleted and resuspended in RLT buffer before homogenisation using QIAshredder 
kits (Qiagen, Gaithersburg, MD, USA). Isolated RNA was eluted in ddH2O for all 
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downstream applications. RNA concentration and quality was determined using Nanodrop 
spectrophotometers (Nanodrop, Wilmington, DE, USA). 
!
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2.10.2. Quantitative polymerase chain reaction (qPCR) 
Taqman 20x gene expression singleplex quantitative real-time polymerase chain reaction 
(qPCR) assays (Applied Biosystems, Carslbad, CA, USA) were used to measure mRNA 
expression. Reactions were performed in singleplex and levels were normalised to the 18S 
housekeeping gene. For the gene of interest in a single 10µl reaction the following 
components were added: 5µl of 2x MasterMix (Applied Biosystems, Carlsbad, CA, USA), 
0.5µl of 20x expression assay or 18S primers and probes, 1µl cDNA, and nuclease-free H2O 
up to a final volume of 10µl. Samples were run on the 7500 real-time PCR system (Applied 
Biosystems, Carlsbad, CA, USA). Data were expressed as Ct values, (Ct = cycle number at 
which logarithmic PCR plots cross a calculated threshold line), and used to determine ΔCt 
values (ΔCt = Ct of the target gene – Ct of the housekeeping gene). Fold changes were 
calculated using transformation [fold increase = 2^- difference in ΔCt]. 
!
2.11. STATISTICS 
Statistical analyses were performed using GraphPad Prism software All data were tested for 
normal distribution. Comparison of grouped data was performed using student’s t-test or 
Welch’s t-test where variances were significantly different. Statistical analysis of qPCR data 
was performed using ΔCt values. Glucose tolerance was analysed by 1-way ANOVA and 
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student’s t-test comparison of the mean (± standard error of the mean (SEM)) area under the 
curve (AUC) of the different groups. A value of p≤0.05 was considered statistically 
significant. Significance was represented as: *≤0.05; **≤0.01; ***≤0.001; ****≤0.0001. 
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CHAPTER 3 
HEPATIC STEM CELL ACTIVATION AND HEPATOCELLULAR CARCINOMA IN 
A MOUSE MODEL OF NON-ALCOHOLIC STEATOHEPATITIS 
!
(Modified from May 2014 publication in the American Journal of Pathology) 
!
I am grateful to Dr. Joanna Dowman, a previous PhD student, for setting up the mouse 
model and collecting the data contributing to Figure 3.1A-G 
!
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3.1. RATIONALE FOR STUDY 
Non-Alcoholic Fatty Liver Disease (NAFLD) is an increasingly common disease with 
severe complications. Non-alcoholic fatty liver disease (NAFLD) represents one of the most 
common causes of liver disease in the western world135, ranging in severity from steatosis to 
non-alcoholic steatohepatitis (NASH) and cirrhosis40. Although simple steatosis alone is 
relatively benign, the presence of steatohepatitis greatly increases the risk of progression to 
cirrhosis, with its concomitant risk of developing hepatocellular carcinoma (HCC)46 and 
death136. Currently, our knowledge of the pathogenesis of NAFLD is incomplete and there are 
no pharmacological therapies for the specific treatment of NAFLD. As such further research, 
and the continued development of appropriate models, is critically needed. 
!
Hepatic stem cells are activated in clinical NAFLD yet their contribution to repair or 
progression remains unclear. Chronic liver diseases (including NAFLD) lead to the 
activation of a secondary proliferative pathway of human hepatic stem cells (hHpSC). hHpSC 
constitute 1-2% of the cells of the adult biliary tree and are slow-cycling under normal 
conditions11. Whilst hHpSC have been implicated in the reconstitution of parenchymal cell 
populations in situations where the proliferative capacity of mature parenchymal cells is 
impaired74, 79, 137, they have also been linked to the promotion of a peri-portal ductular 
reaction, which in turn may provoke progressive peri-portal fibrogenesis138. Moreover, 
hHpSC proliferation has been associated with increased risk of HCC94, although a direct link 
has not been proven in murine or human settings. Thus, the overall impact of hHpSC in 
chronic liver damage remains uncertain. In murine models of liver injury where endogenous 
!75
hepatocyte proliferation is inhibited139, or where injury is extensive140, proliferation of murine 
hepatic stem cells (mHpSC) contributes to tissue repair. However, our understanding of the 
initiating mechanisms, and subsequent consequences, of mHpSC activation during fatty liver 
injury remains limited due to a lack of suitably representative murine models. 
!
There is a need for more pathophysiologically relevant in vivo models of NAFLD. Current 
rodent models of fatty liver disease rely upon strains carrying spontaneous mutations (ob/
ob141, db/d142), genetic manipulations143, or formulated diets (MCD144, HFD145), yet none of 
these models accurately reproduce the broad range of factors that contribute to the 
histological spectrum of human NAFLD and its sequelae. More recently, combinatorial use of 
diets with high proportions of fat, trans-fatty acids, oxidised lipoproteins146 or high fructose 
drinking water147 have resulted in patterns of liver injury closer to that observed in NASH, 
although aspects such as significant fibrogenesis and carcinogenesis are still lacking. Tetri et 
al. added a sedentary lifestyle to a diet rich in trans-fatty acids (TFA), and high-fructose corn 
syrup (HFCS) for a 16-week period, and demonstrated that mice developed glucose 
intolerance and hepatic steatosis and inflammation148. However, the activation of human 
HpSC in this, or much more extended versions (12 months) of the ‘American Lifestyle-
Induced Obesity Syndrome’ (ALIOS) model had not previously been studied. 
!
!
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3.2. RESULTS 
3.2.1. American lifestyle induced obesity syndrome (ALIOS) mice develop metabolic 
changes and liver injury characteristic of NAFLD. Weight gain was greater in ALIOS mice 
than NC mice after 6 months, although their weights converged by 12 months (Fig 3.1A). 
Glucose tolerance was reduced in ALIOS mice compared with NC mice at 6 months, but this 
difference was not maintained at 12 months, by which time NC mice were similar (Fig 3.1B). 
Liver to body weight ratios (LWBR) were higher in ALIOS mice compared to chow-fed mice 
at both 6 and 12 months (Fig 3.1C) with greater levels of hepatic triglycerides measured in 
livers of ALIOS mice compared to NC mice (Fig 3.1D). ALIOS mice had elevated levels of 
serum alanine aminotransferase (ALT) (Fig 3.1E) and aspartate aminotransferase (AST) (Fig 
3.1F) at 12 months compared to NC mice. Expression of TNFA and COL1A1 was increased in 
the ALIOS cohort at 6 and 12 months compared with chow-fed mice at the same time points 
in keeping with induction of inflammatory and fibrogenic processes in response to ALIOS 
diet (Fig 3.1G). Mature hepatocytes are known to proliferate in response to hepatic injury. To 
assess the proliferation of hepatocytes in response to the ALIOS diet, sections were stained 
with Ki67, a protein closely associated with cell proliferation and specifically found in the 
nucleus of proliferating cells. Proliferation index, quantified by nuclear Ki67 staining, was 
significantly higher in mice fed ALIOS for 12 months than those fed normal chow for 12 
months or baseline animals (Fig 3.1H). Activated stellate cells demonstrated by alpha-smooth 
muscle actin (αSMA) immunohistochemistry were clearly increased in number in the ALIOS 
cohort at 12 months but were infrequent or absent at 6 months and in the other cohorts (Fig 
3.2). 
!
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Figure 3.1. ALIOS mice develop metabolic changes and liver injury characteristic of 
NAFLD. A, Combined body weight curves for co-housed NC mice (blue) or ALIOS diet (red) 
for 6 months and 12 months. B, Area under the curve (AUC) of intra-peritoneal (i.p.) glucose 
tolerance tests (GTT). C, Liver to body weight ratios. D, Liver triglyceride content. E, 
Circulating concentrations of alanine aminotransferase and F, aspartate aminotransferase. G, 
Fold change in expression levels of TNFA and COL1A1 in ALIOS mice at 6 and 12 months 
over NC mice. H, Proliferation index calculated from Ki67 immunohistochemistry. Error bars 
represent SEM *p ( 0.05; **p ( 0.01; ***p ( 0.001; ****p ( 0.0001 (student’s t-test) 
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Figure 3.2. Alpha smooth muscle actin (#SMA) immunohistochemistry demonstrates 
hepatic stellate cell activation in ALIOS mice. Representative examples of livers from mice 
fed: A, normal chow for 6 months; B, ALIOS for 6 months; C, normal chow for 12 months; 
and D, ALIOS for 12 months. Numerous !SMA-positive perisinusoidal cells, in keeping with 
activated stellate cells, are present in mice fed ALIOS for 12 months (D). In the other groups, 
!SMA staining is largely confined to blood vessels 
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3.2.2. Increased expression of lipid metabolism and insulin signalling genes in ALIOS 
mice. Expression of ACACA (acetyl-CoA carboxylase 1) and FASN (fatty acid synthase), 
genes coding for key regulators of lipogenesis, were increased in ALIOS mice at 6 months 
and decreased at 12 months compared to NC mice (Fig 3.3A,B). Expression of CPT1A 
(carnitine palmitoyltransferase 1), a rate-limiting enzyme necessary for beta-oxidation of long 
chain fatty acids, was increased in ALIOS mice at 6 months compared to NC mice (Fig 3.3C). 
Although the activity of these gene products is mainly regulated at the post-transcriptional 
levels, these data represent increased lipid turnover (increased lipogenesis and beta-oxidation) 
in livers of ALIOS mice. Expression of INSR (insulin receptor), IRS1 (insulin receptor 
substrate 1) and IRS2 (insulin receptor substrate 2) were increased in ALIOS mice at 6 months 
compared to NC mice but not at 12 months (Fig 3.3D,E,F). Up-regulation of these genes at 6 
months that is lost by 12 months may demonstrate a failure to compensate for dietary stresses 
in ALIOS mice by 12 months. 
!!!!!!!!!!
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Figure 3.3. Increased lipid turnover in ALIOS mice at 6 months. Hepatic mRNA 
expression of: A, acetyl CoA carboxylase; B, fatty acid synthase; C, carnitine 
palmitoyltransferase; D, insulin receptor; E, insulin receptor substrate 1; and F, insulin 
receptor substrate 2 measured by real-time PCR in mice fed normal chow (black bars) or 
ALIOS diet (grey bars) for either 6 or 12 months. Additional comparisons are made against 
baseline liver samples (white bars)   (* p<0.05, **p<0.01 vs. baseline, † p<0.05, ‡ p<0.01 vs. 
normal chow). Data are expressed as arbitrary units (A.U.) with data from 8-10 animals in 
each group !
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3.2.3. ALIOS mice develop histological features of NASH. Baseline (8-week old) mice 
displayed no evidence of liver injury or steatosis (Fig 3.4A), whereas NC mice developed 
mild steatosis with mixed droplet size which had a predominantly peri-venular distribution at 
12 months (Fig 3.4B). In mice on ALIOS steatosis was more severe and diffuse, and 
progressed with time. Moderate steatosis was observed in NC mice by 12 months. 
Moderate macro-vesicular steatosis with a predominantly peri-portal distribution was 
typically seen at 6 months (Fig 3.4C). This pattern of steatosis persisted for ALIOS mice at 12 
months by which time there was also prominent micro-vesicular steatosis in peri-venular 
regions (Fig 3.4D). Steatosis was mild or moderate after 6 months of ALIOS diet (Fig 3.4C) 
and severe in 9/10 mice at 12 months (Fig 3.4D). The presence of ballooned hepatocytes and 
Mallory-Denk bodies are characteristic features of NASH149.  
Distinction of ballooned hepatocytes from the frequently extensive micro-vesicular steatosis 
made assessment of this histological feature difficult. Although occasional cells with a 
ballooned appearance were initially thought to be present in H&E stained sections from 
ALIOS mice at 6 and 12 months (Fig 3.6A), no definite Mallory-Denk bodies were identified 
by immunostaining for ubiquitin or K18 (Fig 3.5).  
!
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Figure 3.4. ALIOS mice develop moderate steatosis at 6 months becoming severe at 12 
months. All sections stained with haematoxylin and eosin. A, Baseline mouse (8 weeks old) 
shows no evidence of steatosis. B, Normal chow mouse at 12 months shows very mild peri-
venular steatosis. C, Moderate macro-vesicular steatosis with a predominantly peri-portal 
distribution in an ALIOS mouse at 6 months. D, Severe pan-lobular steatosis in an ALIOS 
mouse at 12 months. Macro-vesicular steatosis still has a mainly peri-portal distribution. 
Micro-vesicular steatosis is more prominent in peri-venular regions. H = hepatic vein, P = 
portal tract !
!
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Figure 3.5. CK18 and ubiquitin immunohistochemistry fail to detect evidence of 
hepatocyte ballooning in response to ALIOS. A, 100x image and B, 200x image of CK18 
immunohistochemistry of 12 month ALIOS liver showing prominent staining of ductular 
reactive cells and less intense membranous staining of hepatocytes. C-F, CAM5.2 
immunohistochemistry of 12 month ALIOS liver showing both patchy, predominantly peri-
venular cytoplasmic staining of hepatocytes (C, 100x, D, 200x) and diffuse sinusoidal 
staining (E, 100x, F, 200x) in different regions of the same section. G, 200x image and H, 
400x image of ubiquitin immunohistochemistry of 12 month ALIOS liver demonstrating 
presence of highly stained aggregates in hepatocytes (arrows). H = hepatic vein, P = portal 
tract 
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For all animals the ballooning component of the NAS was thus scored as 0. ALIOS induced 
lobular inflammation in 7/10 ALIOS-fed at 6 months that was not observed in any NC mice at 
this time point. At 12 months lobular inflammation was present in 9/10 of the ALIOS cohort 
and 2/9 chow-fed mice. Lobular inflammatory cells comprised a mixed population of 
lymphocytes and neutrophils (Fig 3.6B), with peri-portal inflammatory infiltrates observed in 
4/10 ALIOS mice at 12 months (Fig 3.6C). Fibrosis was observed histologically in 8/10 
ALIOS and 1/9 chow-fed mice at 12 months. In all cases, fibrosis had a peri-sinusoidal 
pattern similar to that observed in human NASH. Amongst ALIOS mice at 12 months, 
fibrosis severity ranged from mild peri-portal through to bridging fibrosis. The latter was 
characterised by the presence of diffuse dissection of the parenchyma by delicate strands of 
peri-sinusoidal collagen without the development of broader fibrous septa (Fig 3.6D). The 
single NC mouse with fibrosis at 12 months only had mild peri-portal fibrosis. Cirrhosis was 
not observed in any mice. 
The use of the Kleiner histological system (NAS) demonstrated significantly increased 
severity of steatosis grade (Fig 3.7A, p=0.003), lobular inflammation (Fig 3.7B, p<0.0001) 
and fibrosis stage (Fig 3.7C, p=0.001) in ALIOS mice compared to NC mice at 12 months. At 
6 months, 0/10 NC mice scored for any components of NAS, whilst ALIOS fed mice had a 
mean NAS of 2.4 (SEM 0.6). By 12 months, NC mice had a mean NAS of 1.3 (SEM 0.4) and 
ALIOS-fed mice a mean NAS of 5.0 (SEM 0.6) (Fig 3.7D, p<0.001). 
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Figure 3.6. ALIOS mice develop histological features of NASH. A, Mixed large and small 
droplet fatty change in an ALIOS mouse at 12 months. The arrow indicates a cell thought to 
have possible ballooning. However, no definite Mallory-Denk bodies were demonstrated by 
immunostaining for ubiquitin and K18 (data not shown). B, Portal inflammation and C, 
lobular inflammation in an ALIOS mouse at 12 months. D, Peri-cellular and bridging fibrosis 
in an ALIOS mouse at 12 months. Figs A-C - Haematoxylin and Eosin, Fig D - Van Gieson !
!
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Figure 3.7. Histological scoring of non-alcoholic liver disease severity in ALIOS mice. A, 
Steatosis grade scores, B, lobular inflammation scores, C, fibrosis stage scores and D, total 
NAFLD activity scores (NAS) according to the Kleiner histological scoring system. Error 
bars represent SEM *p ( 0.05; ***p ( 0.001; (student’s t-test).!
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3.2.4. Hepatic stem cell activation in ALIOS mice correlates with histological features of 
NASH. Pan-CK immunohistochemistry has been previously used to identify hepatic 
progenitor (oval cells) and ductular reactive cells in rodents150. More recently Sox9, a nuclear 
transcription factor, has been reported as a marker of hepatic progenitor cells75, allowing a 
more specific population of stem/progenitor cells to be identified by immunohistochemistry 
than with pan-CK. Pan-CK and Sox9 expression in livers of baseline mice had a similar 
pattern to those of NC mice at 12 months. Pan-CK expression was largely restricted to the 
biliary epithelium (Fig 3.8A), and  Sox9 immunostaining was likewise positive within the 
biliary epithelium (Fig 3.8B). In contrast, by 12 months ALIOS mice had greatly increased 
numbers of pan-CK+ and Sox9+ cells observed throughout the parenchyma in addition to cells 
located within the biliary epithelium seen in chow-fed animals (Fig 3.8C,D). This observation 
was confirmed by quantification of the percentage area covered by pan-CK+ cells and the 
number of observed Sox9+ cells per area (Fig 3.8E,F). Increased accumulation of pan-CK+ 
and Sox9+ cells was seen with severe steatosis (score = 3), lobular inflammation (score ≥ 2) 
and fibrosis severity (Fig 3.8G,H). 
!
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Figure 3.8. Hepatic stem cell activation in ALIOS mice correlates with histological 
features of NASH. Representative examples of A, pan-CK and B, Sox9 
immunohistochemistry of livers from NC mice at 12 months. Representative examples of C, 
pan-CK and D, Sox9 immunohistochemistry of livers from ALIOS mice at 12 months. E, 
Mean percentage area covered by pan-CK+ cells and F, average number of Sox9+ per 200x 
field, in liver sections from baseline, NC and ALIOS mice. Correlation between histological 
scores and G, mean percentage covered by pan-CK+ cells and H, average number for Sox9+ 
cells per 200x field. Error bars represent SEM *p ( 0.05; **p ( 0.01; ***p ( 0.001 (ANOVA 
with Bonferroni’s correction) 
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3.2.5. ALIOS mice develop hepatocellular neoplasms containing perivascular Sox9+ 
tumour cells. At 12 months mice were killed and organs were harvested for analysis and 
storage. At this time point some livers excised from ALIOS mice had macroscopically visible 
growths. As tumours had not previously been reported in murine dietary models of steatosis 
or liver disease we undertook a detailed histological examination of all livers from both 
ALIOS and NC mice at 12 months.  
A total of 9 lesions (5 macroscopic and 4 microscopic) were observed in 6/10 (60%) ALIOS 
mice (Table 3.1).  Macroscopically visible nodules (diameter >3mm) developed in 4/10 
(40%) of ALIOS mice at 12 months (Fig 3.9A), of which two were found in one mouse. No 
macroscopic nodules or microscopic foci of atypical hepatocytes were seen in any NC mice.  
All of the lesions identified macroscopically and microscopically were well–circumscribed 
and well-differentiated. Macroscopic lesions (Fig 3.9A) were associated with compression of 
adjacent non-lesional tissue, but no invasion of blood vessels, portal tract stroma or 
surrounding liver tissue was seen. Histological examination showed lesions composed of 
hepatocytes with low-grade cytological atypia in the form of mild nuclear pleomorphism, a 
slightly increased nuclear/cytoplasmic ratio and occasional mitoses. Microscopic foci (< 1mm 
diameter) composed of atypical hepatocytes with a similar appearance were present in a 
further two ALIOS-fed mice (Fig 3.9B). In the absence of evidence of invasion to confirm a 
definite diagnosis of malignancy lesions were further characterised using additional markers 
(Table 3.1) that have been shown to be altered in previous studies of rodent models151, 152, 
and/or human HCC153, 154.  
!
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Table 3.1. Characteristics of hepatic lesions in mice fed ALIOS diet for 12 months 
Glutamine synthetase, 1-normal perivenular pattern, 2-diffuse upregulation, 3-absence; 
β-cat, presence of nuclear accumulation of β-catenin; AFP, presence of alpha-foetoprotein; 
PI-FC, Proliferation index (% Ki67+) fold change in tumour vs. background liver !
!
!
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Lesion 
Number
Animal 
Number
Lesion 
Description
Size Reticulin 
Fibre 
Depletion
Glutamine 
Synthetase
β-cat Sox9 AFP PI-FC
1 2 Microscopic <1mm + 2 - - - 1.61
2 2 Microscopic <1mm + N/A - + - 2.05
3 3 Macroscopic 3mm + 3 - + - 2.82
4 3 Macroscopic 3mm + 2 + - - 17.58
5 3 Microscopic <1mm + 2 + - - 14.17
6 4 Microscopic <1mm - 2 + - - 7.89
7 4 Macroscopic 6mm + 2 - + + 3.42
8 5 Macroscopic 5mm + 1 - + + 6.8
9 6 Macroscopic 10mm + 3 - + + 6.96
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Alpha-foetoprotein (AFP) is expressed by hepatoblasts during liver development but is absent 
in rodent and adult liver2. AFP has been shown to be re-expressed by a subset of HCC 
associated with increased aggression and worse prognosis with features characteristic of 
hepatic stem/progenitor cells. Detection of circulating AFP is routinely utilised clinically in 
the screening and early detection of HCC in high-risk patients133. A small proportion of AFP+ 
tumour cells in 3/5 macroscopic lesions were observed in ALIOS mice (Fig 3.9C) but absent 
in microscopic lesions and background liver of all mice. Loss of the normal reticulin fibre 
pattern is a characteristic feature of human HCC, although reticulin fibres are sometimes 
retained in well-differentiated neoplasms. Reticulin staining was difficult to assess as it was 
somewhat patchy in non-lesional liver tissue. However, a clear reduction in the number of 
reticulin fibres present could be observed in all (5/5) macroscopically visible nodules from 
ALIOS-fed mice (Fig 3.9D). Reticulin fibres also appeared to be reduced, to a lesser extent, 
in 3/4 microscopic foci. Up-regulation of glutamine synthetase (GS) expression is a feature 
that has been used to distinguish well-differentiated HCC from pre-malignant lesions in the 
human liver155. In non-lesional liver, a peri-venular distribution of GS was observed, similar 
to the pattern of expression seen in normal human liver (Fig 3.10A). Diffuse staining for GS 
was present in 3/4 of the atypical microscopic foci seen in ALIOS-fed mice, similar to the 
pattern that has been described in human HCC (Fig 3.10B). Interestingly, 3/5 macroscopic 
nodules appeared to have a reduced expression of GS, with loss of the normal peri-venular 
pattern of staining (Fig 3.10A,B). Aberrant nuclear accumulation of β-catenin is indicative of 
tumourigenesis and associated with increased tumour progression and a worse prognosis156. A 
small proportion (<5%) of tumour cells in three lesions (one macroscopic and two 
microscopic) displayed nuclear accumulation of β-catenin (Fig 3.10C). 
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Figure 3.9. ALIOS mice develop hepatocellular carcinoma after 12 months duration. 
A, Representative example of macroscopic hepatocellular lesion from ALIOS mouse at 12 
months. B, Representative example of microscopic hepatocellular lesion from NC mouse at 
12 months by H&E staining. C, AFP immunohistochemistry of macroscopic hepatocellular 
lesion demonstrating presence of AFP+ tumour cells. D, Representative example of absent 
reticulin staining in a macroscopic hepatocellular lesion from ALIOS mouse at 12 months. 
There is compression of the normal reticulin framework in surrounding non-lesional tissue !!!!!!!!!!!!!!
A.
C. D.
B.
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Figure 3.10. Hepatocellular lesions from ALIOS mice have aberrant glutamine 
synthetase expression and contain Sox9+ tumours cells. Examples of glutamine synthetase 
immunohistochemistry of A, liver from baseline mice and B, microscopic lesion from ALIOS 
mouse at 12 months. C, Example of nuclear accumulation of β-catenin (arrows) in cells of 
hepatocellular lesion from ALIOS mouse at 12 months. D, Example of perivascular Sox9+ 
tumour cells (arrows) of hepatocellular lesion from ALIOS mouse at 12 months !
!
!
!
!
!
!
A. B.
C. D.
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Sox9, a marker of mHpSC and primitive stem cells of the biliary and intestinal epithelium9, 
was observed in the nuclei of neoplastic hepatocytes in five nodules (four macroscopic and 
one microscopic). These appeared to be preferentially located in a perivascular distribution, 
but otherwise had a similar morphology to surrounding tumour cells, without obvious 
evidence of biliary differentiation (Fig 3.10D).  
Using Ki67 immunohistochemistry (Table 3.1), increased proportions of proliferating 
hepatocytic tumour cells were observed when compared with the proportion of proliferating 
hepatocytes in background liver (16.0±7.3% vs. 3.0±1.6%, p=0.001). Moreover, turnover was 
higher in nodules containing tumour cells with nuclear accumulation of β-catenin; fold 
change in proliferation index over background (13.2±4.9 vs. 3.9±2.4, p=0.005). 
!
!
!
!
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Figure 3.11. Glutamine synthetase immunohistochemistry of baseline liver and a 
representative hepatic neoplasm from ALIOS mouse at 12 months. A, Glutamine 
synthetase immunohistochemistry in liver of baseline mouse demonstrating perivenular 
pattern of expression. B, Glutamine synthetase immunohistochemistry in liver of ALIOS 
mouse demonstrating perivenular pattern of expression in background liver and absence in 
hepatic neoplasm (dashed line) 
!
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3.3. DISCUSSION 
Mice exposed to the ALIOS lifestyle for an extended period of 12 months develop a broad 
spectrum of NAFLD-related histological changes including severe steatosis, lobular 
inflammation, fibrosis and hepatocellular neoplasia. This study demonstrates for the first time 
in a clinically relevant model of NASH, a marked expansion of mouse HpSC, and their close 
association with neoplastic foci in response to high fat diet alone. 
NAFLD is an increasingly prevalent cause of liver disease, but no satisfactory murine model 
of NAFLD has been developed restricting our ability to dissect disease processes and the 
development of new treatments. Combination of TFA and HFCS, two common dietary 
components implicated in NAFLD pathogenesis, with restricted access to exercise was 
reported to induce features of NASH after 16 weeks by Tetri et al., although histological 
fibrosis was not seen148. In this study, extending the ALIOS diet in mice for up to 12 months 
recapitulated the full spectrum of disease with inflammation (NASH), advanced fibrosis and 
the development of hepatocellular neoplasia.  
The distribution of steatosis observed in ALIOS mice was of an initial predominantly macro-
vesicular peri-portal steatosis with relative sparing of acinar zones 2 and 3. With time and 
disease progression, increasing micro-vesicular steatosis extending into the centri-lobular 
region was observed. A similar zonal variation in the distribution of micro and macro-
vesicular steatosis in ALIOS mice was also observed in the study by Tetri et al.148. The 
mechanisms accounting for these differences in fat distribution remain to be elucidated, 
however possible explanations include differences in lipid and/or glucose metabolism, or a 
differential responsiveness of hepatocytes to insulin signalling in different acinar zones. Of 
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note, the extensive microvesicular steatosis observed with the ALIOS diet may also reflect 
more progressive disease, as a recent large study demonstrated that this feature correlated 
with more severe histological changes in human NAFLD liver biopsies157. Quantification of 
liver triglyceride confirmed these histological findings, with significantly greater triglyceride 
in the ALIOS livers compared with controls at 6 months, although by 12 months this 
difference was reduced by a significant increase in the control group. This observation is 
again consistent with the predisposition of ageing mice to the development of a metabolic 
phenotype158.   
Although developed for assessing the severity of NAFLD in human liver tissue, the NAS has 
also been used in other murine studies. In the current study NAS was significantly higher in 
the ALIOS cohort at both 6- and 12-months. By 12 months, although several of the control 
mice had developed some features of NAFLD (i.e. mainly steatosis), NAS scores in the 
ALIOS group were significantly higher. The assessment of hepatocyte ballooning in humans 
is used diagnostically, yet our understanding of the causative contribution of hepatocyte 
ballooning in the pathogenesis of NASH remains unclear. Despite applying three staining 
techniques routinely used for the assessment of ballooning (H&E, Ubiquitin, and K18) the 
presence of hepatocyte ballooning was not observed in response to ALIOS. The use of 
haematoxylin and eosin staining revealed occasional cells that had changes potentially 
suggestive of ballooning that was difficult to fully discern from the presence of micro-
vesicular steatosis. Ubiquitin and CK18 immunohistochemistry allow for more specific 
identification of ballooned hepatocytes through the detection of ubiquitinylated cytokeratin 
aggregates (Mallory-Denk bodies) that are characteristic of ballooning resulting from 
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NASH149. The use of a CK18 primary antibody (Dako) routinely used in the Histology 
Department at the QEHB and predicted to cross-react with mouse yielded a pattern of 
expression in mouse that significantly differed to that seen in humans. CK18 
immunohistochemistry of clinical liver specimens demonstrates prominent membranous 
staining of hepatocytes, the condensation and aggregation of which into Mallory-Denk bodies 
signifies hepatocyte ballooning. However in murine sections from ALIOS mice, CK18 
immunohistochemistry predominantly stained ductules and ductular reactive cells with weak, 
patchy staining of hepatocytes that was variably cytoplasmic and membranous making 
assessment of hepatocyte ballooning difficult. The use of a second antibody utilised clinically 
(CAM5.2, Dako) again yielded different expression patterns in mouse versus human samples. 
CAM5.2 immunohistochemistry demonstrated areas of both hepatocytic and sinusoidal 
staining within the same section suggesting non-specific staining possibly due to variation in 
fixation levels. CAM5.2 staining of hepatocytes was largely cytoplasmic with no obvious 
examples of hepatocyte ballooning observed. Ubiquitin immunohistochemistry revealed 
infrequent staining of apparent protein aggregates in parenchymal cells that possibly represent 
Mallory-Denk bodies. These observations appear to be similar to those of Tetri et al. who 
observed in their 16-week model of ALIOS that “some cytoplasm alterations and clumping 
suggestive of “ballooning” and possible Mallory hyaline were noted in zone 3”148. However, 
only H&E staining was reported in this study and additional immunohistochemistry was not 
used to confirm the presence of Mallory-Denk bodies. It was not possible to discern whether 
the lack of ballooning in this study was due to intrinsic variation between rodent and human 
liver injury, or the extended duration of the ALIOS diet to 6 and 12 months. Severe steatosis, 
bridging fibrosis and hepatic stem cell activation was observed in the ALIOS model at 12 
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months. However, differences between murine and human histopathology was observed in the 
pattern and distribution of steatosis, fibrosis and stem cell proliferation (Table 3.2).  
Histological fibrosis was observed in only two of the ALIOS mice and no control animals at 6 
months, and in both cases was in a peri-portal (stage 1c) distribution. However COL1A1 
mRNA expression was 4.2-fold higher in the ALIOS mice at this time point, providing 
additional evidence of an early fibrotic response.  By 12 months, fibrosis was observed in 
only one (10%) of the controls but in eight (80%) of the ALIOS mice, four of which 
demonstrated bridging fibrosis. The >10-fold increase in Col1α1 expression in the ALIOS 
cohort at this time point was consistent with these findings.   
The presence of hHpSC was originally suggested by immunohistochemical studies that placed 
the intra-hepatic stem cell niche within the canals of Hering79. Isolation of adult human 
hepatic and biliary stem cells has since demonstrated substantial expansion potential in vitro 
with differentiation to both biliary and hepatocyte lineages, prompting interest in hepatic stem 
cells as a potentially viable therapeutic option for liver disease. Complementary studies 
utilising transgenic mice have identified and characterised bipotential mHpSCs that readily 
proliferate and differentiate to cholangiocytes and hepatocytes in culture75. However, murine 
models of liver injury that faithfully replicate the complex pathogenesis of human liver 
disease are currently lacking and as such the role of hepatic stem cells, and the mechanisms of 
their activation, in these settings remains poorly understood. 
!
!
!100
Table 3.2. Comparison of human NASH and the murine ALIOS model 
!
Human NASH Murine ALIOS
Clinical features
Cause Multifactorial (Diet/environment/
genetics)
Diet alone
Body weight Significant association with obesity 
and central adiposity
Weight gain (then subsequent loss 
with severe disease burden)
Hepatomegaly Clinical sign (not present  in all cases) Increased liver to body weight ratios 
at 6 and 12 months
Glucose intolerance 
(diabetes)
Significant association with insulin 
resistance and type 2 diabetes. 
Reciprocal risk factors
Glucose intolerance observed at 6 
months 
Blood markers Elevated ALT and AST, but can have 
significant disease with normal LFTs
Elevated ALT and AST at 12 months
Hepatic Tumourigenesis Significant risk of HCC development 
in NASH cirrhosis (vs. normal 
population)
Hepatocellular lesions observed in 
50% of animals at 12 months
Histopathology
Steatosis distribution and 
pattern
Early stages = perivenular 
macrovesicular 
Later stages = panacinar with mixture 
of macro- and microvesicular steatosis
6-months = Periportal 
macrovesicular steatosis 
12-months =  Periportal 
macrovesicular and perivenular 
microvesicular steatosis
Steatosis severity Variable. In end-stage cirrhosis 
steatosis may be absent
6-months = Moderate 
12-months = Severe
Inflammation Portal and lobular inflammation Portal and lobular inflammation
Hepatocyte ballooning Diagnostic of ‘definite’ NASH (AGA 
guidelines 2012)
Not identified
Fibrosis Perisinusoidal +/- periportal 
progressing to bridging fibrosis. Broad 
septa and nodules (cirrhosis) in late 
stage disease
Perisinusoidal +/- periportal 
progressing to bridging pericellular 
fibrosis at 12 months. No broad 
septa or cirrhosis at 12 months
Hepatic stem/progenitor cells Activation of hepatic progenitor cells 
commonly seen in periportal and 
periseptal ductular reactions
Periportal expansion of hepatic 
progenitors into surrounding 
parenchyma observed as single cells 
and ductules
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Currently used rodent models of chronic hepatic injury, HpSC activation and 
hepatocarcinogenesis rely upon the use of toxic agents159 or genetic manipulations160 that fail 
to replicate the complex pathogenesis of NAFLD. This study provides the first detailed 
characterisation of a clinically relevant murine model of metabolic liver injury and provides 
new data on the spatio-temporal association between NAFLD, mHpSC activation and the 
development of hepatic dysplasia/cancer. In human disease, loss of mature biliary epithelial 
cells and hepatocytes, as occurs in chronic biliary diseases and metabolic liver disease 
respectively, results in a marked accumulation of hHpSC10, 100, 138. Activation of the mHpSC 
niche has been extensively studied in a range of murine liver injury models, including 
genetic140, diet116, bile duct ligation97 and alcohol161, but activation in non-toxic diet models 
using wild-type mice has previously not been reported. This study demonstrates activation of 
the mHpSC niche in response to the ALIOS model of chronic metabolic liver injury using 
pan-CK and Sox9 immunohistochemistry. The number of mHpSC observed increased with 
duration, and severity of liver injury, but were largely absent from NC mice. These findings 
support the observation of a close association between hHpSC activation and histological 
features of chronic liver injury in humans69.  
The novel finding of hepatocellular neoplasms in 6/10 ALIOS mice has not been previously 
reported, and is of significant concern given the high population consumption of both HFCS 
and TFA. HCC is a well-recognised complication of advanced NASH in humans, and is also 
increasingly recognised to occur in non-cirrhotic NASH162. Most cases of HCC in this study 
developed on a background of significant fibrosis, however one occurred in the absence of 
any detectable fibrosis in the surrounding liver. Potential carcinogenic mediators associated 
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with both the metabolic syndrome and NASH include hyperinsulinaemia, lipid peroxidation 
and oxidative stress, which may promote cellular proliferation or epigenetic aberrations.  
Previous rodent models of HCC have described the development of a spectrum of similar 
focal hepatocellular lesions151, 152, which have been variously classified as  “pre-neoplastic 
foci”, “dysplastic foci” “adenoma” and “benign hepatoma” as well as hepatocellular 
carcinoma. Similar problems have been encountered with the classification of precursor 
lesions and early HCC in human livers153, 154.  
The extent to which the murine lesions are comparable to hepatocellular neoplasms in human 
liver has not been fully established. In an attempt to address this problem, detailed 
characterisation was carried out, using many of the markers used to diagnose early HCC in 
human livers. This revealed many features consistent with that of early human HCC including 
the loss of biliary structures, disruption or loss of reticulin fibres, aberrant expression of 
glutamine synthetase and AFP and nuclear accumulation of β-catenin. These changes were 
accompanied by varying degrees of cytological atypia that are also recognised as a feature of 
human HCC, establishing this as a novel model for the study of HCC development on the 
background of NASH. 
Sox9 is a marker of endodermal stem cells in liver, pancreas, biliary tree, and intestine9 and its 
expression is associated with progression of a number of tumours163-165. Whilst studies have 
suggested a causal link between hHpSC and HCC development140, a direct link between 
Sox9+ hHpSC and HCC development and progression has yet to be described. In this study 
we report for the first time the presence of small foci of perivascular Sox9+ tumour cells in 
murine HCC, which also notably express higher levels of Ki67 indicative of higher 
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proliferative rates. Increasing evidence suggests small populations of tumour cells possess 
significantly greater abilities for self-renewal and tumour initiation than other cells of the 
tumour bulk166. These cells also frequently express stem cell-related markers and are found in 
peri-vascular locations167 suggesting the presence of peri-vascular Sox9+ tumour cells may 
represent a cancer stem cell niche within HCC tumours of ALIOS mice. It is possible that 
these Sox9+ cells represent a form of transitional cell between a stem cell and a neoplastic 
hepatocyte. We are unable to determine the cell of origin for the tumours observed in ALIOS 
mice or assess the contribution of Sox9+ tumour cells to the development and progression of 
HCC, although their close spatial association requires further research. Further work utilising 
cell fate tracking experiments specifically labelling mHpSC in a relevant injury model will 
aid in determining the origin of Sox9+ HCC tumour cells but was not possible in this study. 
This clinically relevant murine model of NASH replicates many of the features seen in human 
disease as well as demonstrating activation of the hepatic stem cell niche. This study increases 
our limited understanding of stem cell mediated-regeneration and hepatocarcinogenesis in 
response to chronic metabolic liver injury and validates ALIOS as an appropriate model for 
further studies of NAFLD and HCC.  
!
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CHAPTER 4 
PROSPECTIVE ISOLATION OF STEM/PROGENITOR CELLS FROM ADULT 
MURINE LIVER      
!
!
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4.1. RATIONALE FOR STUDY 
Tissue-resident adult mesenchymal stem/progenitor cells have been described in the 
bone marrow, heart, lung and kidney. The presence of mesenchymal stem cells (MSCs) in 
adult bone marrow with the ability to form fat, bone, and cartilage is well accepted168-170. The 
selective isolation of multipotent mesenchymal stem cells from adult murine bone marrow 
using PDGFRα and Sca-1 was originally reported by Matsuzaki et al.168, 171. Tissue resident 
stromal stem/progenitor cell populations enriched for these antigens have subsequently been 
described in the heart172-174, lung175, kidney176, and synovium177. Isolation of Sca-1+ cells from 
murine adult178 and foetal/neonatal liver31 has previously been described, where isolated cells 
display a predominantly stromal morphology with the appearance of small proportions of 
hepatocytic, ductal and endothelial cells observed after long-term in vitro culture. Although 
these studies have been unable to conclusively exclude the possibility that these cultures 
contained mixed populations of mature resident liver cells, they do provide evidence 
suggesting the presence of a rare, homogeneous population of somatic stem cells with liver-
specific multipotency, including hepatocytic, biliary and stromal potential. 
!
The presence of adult mesenchymal stem/progenitor cells in the liver is currently 
controversial. The presence of tissue specific somatic mesenchymal progenitors cells is 
increasingly accepted.  In visceral organs, similar cells have been described and are variously 
termed angioblasts, vascular wall stem/progenitor cells or endothelial progenitor cells30, 179. 
These terms are likely to refer to similar, overlapping populations of cells found in, or directly 
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adjacent to, adult vasculature with the ability to differentiate into mesodermal lineages, 
notably endothelium and smooth muscle.  
!
Prospective isolation of stromal populations from wild-type mouse liver has not been 
previously demonstrated. The prospective isolation of both murine hepatic stem cells 
(mHpSCs) and hepatic stellate cells from adult mouse liver remains challenging due to the 
lack of specific markers and culture conditions allowing long-term undifferentiated growth. 
Recent methods for the isolation of mHpSCs have relied upon the use of liver injury in 
transgenic mice to induce, and/or increase the number of, mHpSCs labelled by specific cre-
lox recombination in Lgr5+115,Sox9+75 or Foxl1+76 cells. Hepatic stellate cells are most 
commonly isolated through density centrifugation by virtue of their lower density due to high 
lipid content180. The prospective isolation of HSCs, either by immuno-selection or cell 
sorting, has not been previously reported. 
!
Stellate cells, or their precursors, may give rise to epithelial populations during 
regeneration. Recent studies have reported expression of markers of mature hepatocytes and 
cholangiocytes on freshly isolated stellate cells with lineage tracing experiments utilising 
markers specific to stellate cell markers in liver demonstrating the presence of mature 
hepatocytes and cholangiocytes derived from stellate cells in response to liver injury18, 181. 
!
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PDGFRα has previously been reported as having a role in liver development and 
regeneration182, Sca1 has been described as a marker of hepatic stem cells178 and the 
combination of these antigens has been shown to identify potent mesenchymal stem/
progenitor cells in many visceral organs. Therefore, PDGFRα+, Sca-1+ cells from adult, wild-
type, uninjured mouse liver were isolated and their fibrogenic potential and capacity to give 
rise to epithelial stem/progenitor cells was assessed. 
!108
4.2. RESULTS 
4.2.1. Presence of cells with characteristic mesenchymal stem cell expression profile in 
adult (6-8 week old) murine liver. Platelet derived growth factor-alpha (PDGFRα) 
immunohistochemistry on normal liver demonstrated the presence of PDGFRα+ cells in 
predominantly peri-vascular locations with small numbers of positive cells observed in 
parenchymal regions. Immunohistochemistry with two PGFRα antibody clones stained the 
walls of all major vessels including the hepatic artery, portal and central veins. No obvious 
staining was observed in biliary epithelium or on mature hepatocytes. Parenchymal staining 
appears to mark cells with elongated, spindle-like morphology characteristic of stromal cells, 
although it was not possible to distinguish between fibroblasts and hepatic stellate cells by 
morphology alone. Positive cells were commonly observed in clusters forming strands in a 
pattern typical of peri-sinusoidal fibrosis despite the absence of injury (Fig 4.1A-D). 
Stem cell antigen-1 (Sca1) immunohistochemistry on normal liver demonstrated the presence 
of Sca1+ cells in predominantly peri-vascular locations, and possibly adjacent to biliary 
epithelium, with fewer numbers of positive cells observed than with PDGFRα 
immunohistochemistry. The majority of staining was restricted to vascular walls with staining 
more intense in the walls of hepatic arteries and portal veins than central veins. Sca1+ cells are 
present in parenchymal locations commonly adjacent to vasculature. It was not possible to 
definitely determine the parenchymal cell type expressing Sca1 due to more diffuse and less 
intense staining on parenchymal cells (Fig 4.1E,F). 
!
!109
$  
Figure 4.1. PDGFRα and Sca1 immunohistochemical staining localises to peri-vascular 
regions in uninjured adult murine liver. Representative examples of immunohistochemical 
staining of adult mouse liver sections using AB, PDGFRα (ebiosciences), CD, PDGFRα 
(R&D Systems), and EF, Sca1 antibodies !
!
!
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4.2.2. Prospective isolation of PαS and Sca1+ cells from adult normal uninjured liver. 
Non-parenchymal cells were isolated by fluorescence-activated cell sorting (FACS) from 
excised adult, wild-type, uninjured liver by mechanical dissociation, collagenase digestion, 
red cell lysis and density centrifugation (detailed in methods chapter). Viability was 
consistently >80% as determined by propidium iodide (PI) staining (Fig 4.2A). CD45+/
Ter119+ haematopoietic lineage-positive (PE+) cells constituted roughly a third of all viable 
cells and were excluded (Fig 4.2B). PDGFRα+ Sca1+ (PαS) cells constituted 0.2% of the 
viable, lineage-negative fraction yielding roughly 2,000 cells per digested liver. PDGFRα- 
Sca1+ (Sca1) cells constituted roughly 1% of all viable, lineage-negative cells with an 
approximate yield of 10,000 cells per digested liver (Fig 4.2C).  
To optimise the isolation of single cell preparations from digested adult murine liver density 
centrifugation was used to select conditions to improve overall yield and purity of isolated 
PαS cells. A 1.033g/ml solution (33% Percoll in phosphate buffered saline) was selected 
based on previous reports of methods for the isolation of hepatic stem cells from adult 
rodent75. The use of gradient centrifugation allowed the segregation of cellular populations 
based on density into those denser (pellet, Fig. 4.3A) and lighter (supernatant, Fig. 4.3B) than 
the solution used. Cells in the supernatant (<1.033g/ml) were less viable than those in the 
pellet (>1.033g/ml) (14.2% vs 51.2%). Of the viable cells, similar proportions of lineage 
negative (CD45- Ter119-) cells were found in both populations. Higher yields of PαS and 
Sca1+ cells were detected in the pellet faction than the supernatant fraction (0.20% and 0.46% 
vs. <0.01% and  0.02% of total sorted cells respectively). 
!
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Figure 4.2. Gating strategy for isolation of PDGFRα+ Sca1+ cells from adult murine liver. 
Fluoresnce-activated cell sorting of viable CD45- Ter119- Sca1+ PDGFRα+ (PαS) cells by 
sequential excluding gates: A, Forward side scatter vs. propidium iodide allowing exclusion 
of dead cells. B, Forward side scatter vs. CD45/Ter119 allowing exclusion of haematopoietic 
lineage populations. C, Sca1 Vs. PDGFRα allowing selection of PαS and Sca1+ populations 
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Figure 4.3. Density centrifugation improves viability and yield of PDGFRα+ Sca1+ cells. 
FACS plots from prospective isolation of PαS and Sca1+ cells from A, pellet fraction (density 
>1.033g/ml) and B, supernatant fraction (density <1.033g/ml) after density centrifugation 
A.
B.
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Three selection protocols were selected with varying length of collagen digestion (30 minutes 
vs 60 minutes) and the use of density centrifugation to assess the effect on viability and yield 
of isolated cells. Due to the cost of the experiment this optimisation experiment was only run 
once. The total viability of sorted cells was found to increase across the groups, with 30 
minutes digestion with no Percoll (30 min -) having the lowest viability followed by 30 
minutes with Percoll (30 min +) and 60 minutes digestion with Percoll (60 min +) having the 
highest viability (43.7% vs. 47.9% vs. 65.8%, Fig 4.4A). The total proportion of viable 
lineage negative (CD45-Ter119-) cells was decreased when a Percoll gradient density 
centrifugation step was utilised (42.8% and 42.1% vs. 79.0%, Fig 4.4B). The total proportion 
of viable lineage negative cells with PαS and Sca1 expression was highest with 60 minutes 
digestion with a Percoll gradient step (0.30% PαS and 2.26% Sca1+), and less in the other 
conditions, 30 minutes digestion with a Percoll gradient step (0.07% PαS and 0.44% Sca1+) 
and 30 minutes digestion without a Percoll gradient step (<0.01% PαS and 0.05% Sca1+) (Fig 
4.4C). As a result, 60 minutes collagenase digestion with a Percoll gradient centrifugation 
step was used for all subsequent isolations. 
!!!!!!!!!!!!!!!
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Figure 4.4. Increased digestion time further improves viability and yield of PDGFRα+ 
Sca1+ cells. Bar charts showing A, viability; B, proportion of haematopoietic lineage (CD34/
Ter119) negative cells; and C, proportions of PαS and Sca1+ cells after 30 minutes 
collagenase digestion without density centrifugation (30 min -), 30 minutes collagenase 
digestion with density centrifugation (30 min +) and 60 minutes collagenase digestion with 
density centrifugation (60 min +) 
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4.2.3. Prospectively isolated hepatic PαS and Sca1+ cells can be cultured in vitro. Freshly 
isolated PαS and Sca1+ cells can be cultured on plastic in αMEM + 10% foetal calf serum 
(FCS), conditions designed for the expansion and maintenance of mesenchymal stem cells. 
Under these conditions PαS and Sca1+ cells adhered, proliferated readily to confluence and 
could be passaged. PαS cells were small and spindle-shaped in the first few days post-
isolation and grew as individual cells suggesting contact inhibition between adjacent cells, 
morphology characteristic of stromal cells (Fig 4.5B). After 7 days culture on plastic PαS had 
characteristic myofibroblast morphology and strongly expressed alpha smooth muscle actin 
(Fig 4.5A). Sca1 cells were not viable on plastic in αMEM + 10% foetal calf serum (FCS) but 
were viable on type I collagen if plated at much higher densities than PαS cells. Viable Sca1 
cells take longer to emerge than PαS cells, are commonly observed in small clusters and are 
larger with more substantial cytoplasm than PαS cells (Fig 4.5C). Oil red O staining failed to 
demonstrate presence substantial amount of intracellular lipid in PαS cells after 3 days (Fig 
4.5D) or 7 days (Fig 4.5E) culture on plastic in αMEM + 10FCS. 
Colony forming unit assays were utilised to quantify colony forming potential of PαS cells 
and Sca1+ cells. Cells were plated at very low density (40 cells/cm2). Cultured in αMEM on 
plastic, 2.7% of freshly isolated PαS cells and 0.10% of Sca1+ cells formed colonies. In OC+ 
media on collagen type I, 0.61% of PαS and 0.07% of Sca1+ cells formed colonies (Fig 4.6A). 
PαS colonies were larger with greater numbers of cells than those formed by Sca1 cells. PαS 
colonies were comprised of cells with a more stromal morphology and were generally more 
homogeneous (Fig 4.6B). Sca1+ colonies typically comprised large, occasionally binucleate 
cells, with adjacent smaller spindle-shaped cells (Fig 4.6C). 
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Figure 4.5. In vitro culture of freshly isolated cells from adult murine liver. A, Vimentin 
immunohistochemistry with DAPI nuclear counterstain of a single representative PαS cell 
cultured for 7 days on plastic in αMEM +10% FCS. Light microscopy of B, PαS cells after 3 
days culture on plastic in αMEM +10% FCS and C, Sca1+ cells after 3 days culture on 
collagen in OC. Oil red O staining fails to detect intracellular lipid (stained red) in freshly 
isolated  PαS cells after  D, 3 days and E, 7 days culture on plastic in αMEM +10% FCS 
B. C.
A.
D. E.
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Figure 4.6. Colony formation assays of P#S and Sca1+ cells. A, Proportion of freshly 
isolated P!S (black bars) and Sca1+ cells (white bars) forming colonies after 2 weeks culture 
in !MEM +10% FCS or OC media. Crystal violet staining of colonies formed by B, P!S and 
C, Sca1+ cells 
A.
B.
C.
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4.2.4. Hepatic PαS cells proliferate on plastic and gain expression of myofibroblast 
markers over time which is further augmented by culture on type I collagen. 
Freshly isolated PαS cells were plated at a density of 160 cells per mm2 and cultured in 
αMEM + 10% foetal calf serum on plastic to assess proliferation. PαS cells rapidly gain 
expression of markers associated with activated myofibroblasts, including αSMA, and lose 
expression of PDGFRα. Expression of PDGFRα is only maintained on infrequent clusters of 
small, rounded cells after 7 days culture that may represent slowly proliferating cells with 
stem/progenitor characteristics. Culture on type I collagen resulted in almost complete loss of 
PDGFRα expression after 7 days with only infrequent clusters of small, rounded PDGFRα+ 
cells observed (Fig 4.7A). PαS cells were viable and proliferated readily on plastic (number 
of cells per field = 13.1 at day 3 vs 23.3 at day 7 , p=0.018, student’s t test). PαS cells plated 
on collagen type I proliferated at a faster rate than on cultured on plastic (number of cells per 
field at 7 days = 23.3 on plastic vs 52.3 on collagen type I, p=0.005) (Fig 4.7B). Staining with 
markers associated with hepatic fibroblast and stellate lineages allowed assessment of the 
activation of PαS cells over time on plastic and in response to culture on collagen type I. The 
proportion of cells expressing alpha small muscle actin (αSMA) was found to increase with 
time in culture on plastic from around 70% at day 3 to almost 100% at day 7. All cells were 
αSMA+ after 7 days culture on collagen type I. Around a third of cells were positive for 
desmin and all cells were positive for vimentin across all 3 conditions utilised. PαS cells were 
consistently around 20-40% desmin-positive across all conditions. 
!
!
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Vimentin, an intermediate filament protein, was expressed by all PαS cells across all 
conditions and allowed the morphology and distribution of cells across the 3 conditions to be 
visualised in greater detail. After 3 days culture on plastic PαS cells were small and spindle 
shaped with minimal branched cytoplasm and long cellular processes characteristic of 
fibroblasts or quiescent stellate cells. Cells were distributed throughout the plate and were 
most often observed as isolated single cells. After 7 days culture on plastic PαS cells were 
larger than at day 3 with greater cytoplasm and more extensive cellular processes 
characteristic of myofibroblasts. At day 7 PαS cells were more densely distributed due to 
increased size and number but do not form obvious cell-cell adhesions or nexi characteristic 
of epithelial cells. After culture on collagen type I for 7 days PαS cells were confluent due to 
increased cell number. Cells were slightly smaller than after 7 days on culture on plastic most 
likely due to spatial restriction. Cells appeared to display appropriate contact inhibition with 
no evidence of cells growing atop each other instead forming homogenous sheets without 
characteristic muscle fibre polarity (Fig 4.7C).  
!
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Figure 4.7. Freshly isolated PαS cells lose PDGFRα expression and gain morphology and 
phenotype characteristic of hepatic stellate cells. A, PDGFRα immunofluorescent staining 
of PαS cells after 7 days culture on plastic demonstrating a small cluster of cells maintaining 
PDGFRα expression. B, Proliferation of PαS cells after 3 and 7 days culture on plastic and 7 
days culture on collagen type I. C, Alpha smooth muscle actin, desmin and vimentin 
immunofluorescent staining of PαS cells after 3 and 7 days culture on plastic and 7 days 
culture on collagen type I. Counterstained with DAPI (blue) was performed for all 
immunofluorescent analyses 
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4.2.5. 2-deoxyglucose inhibits proliferation and activation of PαS cells cultured on plastic 
and type I collagen. Isolated primary stellate cells activate in response to culture on plastic 
within the first few days of culture and this process is augmented by culture on type I 
collagen. 2-deoxyglucose (2-DG) has previously been described as a potent inhibitor of the 
activation of freshly isolated hepatic stellate cells through the inhibition of glycolysis183. 2-
DG was added to αMEM media at a concentration of 5mM to assess its effects on PαS cell 
proliferation and activation on plastic and type I collagen and its potential use in maintaining 
PαS cells in a quiescent state. 
Freshly isolated PαS cells were plated at a density of 160 cells per mm2 and cultured in 
αMEM + 10% foetal calf serum on plastic or collagen type I with or without addition of 
1.25mM 2-DG. All PαS cells in all conditions were positive for vimentin (Fig 4.11B). 
Vimentin immunohistochemistry demonstrated PαS cells cultured in the presence of 2-DG 
were small with scanty cytoplasm and maintained spindle-like morphology characteristic of 
quiescent or freshly isolated stellate cells after 7 days (Fig 4.8). PαS cells cultured in the 
absence of 2-DG took on myofibroblastic morphology described previously (Fig 4.7). PαS 
cells cultured on type I collagen proliferated more rapidly than on plastic with a greater 
number of cells observed per field at day 7 (52.4 Vs. 26.4, p=0.01). 2-DG inhibited the 
proliferation of freshly isolated PαS cells and the activating effect of type I collagen with 
significantly fewer cells observed after 7 days culture with 2-DG on both plastic and collagen 
type I (plastic, 13.1 vs. 26.4, p<0.001; collagen type I, 12.5 vs. 52.4, p<0.001). There was no 
difference in the total number of PαS cells observed after 7 days culture with 2-DG between 
culture on plastic or collagen type I (Fig 4.11A).  
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Figure 4.8. Vimentin immunohistochemistry of PαS cultured in the presence of 2-DG. 
Vimentin staining of PαS cells after 7 days culture on: A, plastic without 2-DG; B, plastic 
with 2-DG; C, collagen type I without 2-DG; and D, collagen type I with 2-DG !
!
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Figure 4.9. Alpha-smooth muscle actin (αSMA) immunohistochemistry of PαS cultured 
in the presence of 2-DG. αSMA staining of PαS cells after 7 days culture on: A, plastic 
without 2-DG; B, plastic with 2-DG; C, collagen type I without 2-DG; and D, collagen type I 
with 2-DG !
!
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αSMA immunohistochemistry demonstrated a high proportion of PαS cells cultured in the 
absence of 2-DG expressed αSMA at day 7 after culture on plastic and collagen type I 
(plastic, 91%; collagen type I 95%). However, a significantly smaller proportion of cells were 
found to express αSMA after culture with 2-DG on both plastic and collagen (plastic, 26% vs. 
91%, p<0.001; collagen type I, 19% vs. 95%, p<0.001) suggesting failure of PαS to undergo 
myofibroblastic differentiation and maintenance of a quiescent state. There was no significant 
difference in the proportion of cells expressing αSMA between culture on plastic of collagen 
type I with 2-DG. (Fig 4.9, 4.11B). 
The proportion of cells expressing desmin was consistently around 30% across culture 
conditions with no significant difference observed (Fig 4.10, 4.11D). 
!
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Figure 4.10. Desmin immunohistochemistry of PαS cultured in the presence of 2-DG. 
Desmin staining of PαS cells after 7 days culture on: A, plastic without 2-DG; B, plastic with 
2-DG; C, collagen type I without 2-DG; and D, collagen type I with 2-DG !
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Figure 4.11. 2-DG inhibits proliferation and maintains quiescent phenotype of freshly 
isolated PαS cells. PαS cells were cultured on plastic or collagen type I in αMEM +10% 
foetal calf serum with or without 2-DG for 7 days. Mean values from 4 wells for A, average 
numbers of cells per field and proportions of cells expressing B, vimentin; C, alpha smooth 
muscle actin; and D, desmin. Error bars represent standard error of means. ***p<0.001 vs. 
identical culture conditions without 2-DG, † p<0.05 vs. plastic without 2-DG !!
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4.2.6. Selection of rapidly proliferating epithelial colonies by culture in conditions 
designed for selection and maintenance of hepatic stem/progenitor cells. When cultured in 
conditions (OC+) originally designed for the selection of hepatic (epithelial) progenitor cells76 
PαS and Sca1+ cells grew rapidly to confluence and demonstrated morphological 
heterogeneity. As Sca1+ cells were found to have low colony formation potential 
(approximately 1 colony per 1000 freshly isolated cells), freshly isolated Sca1+ cells were first 
plated at very high density in an attempt to increase viability and examine their growth and 
characteristic after long term in vitro culture. 1x105 cells (density approximately 1x105 cells/
cm2) were plated in single wells of a 48-well plate coated with collagen type 1 in OC+ and 
left to proliferate to confluence. Immediately after plating all cells had spindle-shaped 
morphology and proliferated rapidly (estimated doubling time ≈ 2 days). After roughly 7 days 
small clusters of cells with typical epithelial morphology can be observed. After 14 days these 
regions occupied a proportionally larger area than fibroblastic cells After 2 weeks culture cells 
had a large degree of heterogeneity. Areas of cells with characteristic stromal morphology 
(spindle shaped, contact inhibition) were observed (Fig 4.12A) directly abutting cells with 
epithelial morphology (Fig 4.12B). Cells of differing morphology were not observed in mixed 
populations, instead forming clearly demarcated boundaries (Fig 4.12B, dashed line). 
Epithelial cells were generally smaller than accompanying stromal cells, were ovoid, had a 
high nuclear-to-cytoplasmic ratio and grew with a high degree of cell-to-cell contact. 
Interestingly, these cells were frequently observed growing as three dimensional aggregates 
(Fig 4.12C,D). The addition of the ROCK inhibitor Y-27632 to culture media prevented 
formation of aggregates and maintained all cells as a monolayer and was used in all 
subsequent cultures using OC+ media to ease passaging and imaging. 
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Figure 4.12. Heterogeneous morphology of freshly isolated Sca1+ cells cultured on 
collagen type I in OC+ media for 2 weeks. Representative images of light microscopy on 
Sca1+ cells after 14 days culture on collagen type I in OC+ media demonstrating: A, cells with 
predominantly stromal morphology; B, distinct boundaries (dashed line) between regions of 
stromal cells (above) directly abutting cells with epithelial morphology (below); and epithelial 
cells growing in C, monolayers and D, three dimensional aggregates (arrows) !
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Immunohistochemistry with wide spectrum pan-cytokeratin (pan-CK), routinely used as a 
marker of murine hepatic stem/progenitor cells in liver, specifically stained all cells of the 
epithelial colonies and was not observed on surrounding stromal cells. PanCK 
immunohistochemistry demonstrated the rapid growth of the epithelial colonies (Fig 4.13A, 
day 7; Fig 4.13B, day 10; Fig 4.13C, day 14). All cells were positive for vimentin at day 14 
(Fig 4.13D). As all cells expressed vimentin this was used to demonstrate the contrasting 
morphology of the epithelial colonies with surrounding stromal cells. Cells within colonies 
were smaller, oval shaped, had a greater nucleus to cytoplasmic ratio, and grew in tight 
aggregates. After long-term culture (Figure 4.14) single colonies could reach considerable 
size and appeared to proliferate into, and displace the surrounding stroma with occasional 
single, large stromal cells observed within the colony, presumably enveloped. Cells were 
often smallest at the centre of colonies and demonstrated a ‘swirling’ pattern (Fig 4.15) 
previously reported as characteristic of biliary tree/hepatic stem cell cultures. 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Figure 4.13. Selection of highly proliferative epithelial colonies from Sca1 cultures with 
hepatic stem cell expression profiles. Representative images (200x magnification) of pan-
cytokeratin immunofluorescent staining of Sca1 cells cultured in OC+ at A, day 7, B, day 10 
and C, day 14. D, Representative example (100x magnification) of vimentin 
immunofluorescent staining of Sca1 cells cultured in OC+ on collagen type I for 14 days !
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Figure 4.14. Sequential cross-sectional images of a large epithelial stem/progenitor cell 
colony observed after 8 weeks culture. Vimentin immunofluorescent staining of PαS cells 
cultured in OC+ after approximately 8 weeks culture. Panels 1 through 12 are composed of 
consecutive, overlapping images arranged horizontally across from left to right across the 
centre of a single epithelial stem/progenitor colony with surrounding and occasional isolated, 
enveloped stromal cells !
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Figure 4.15. Presence of cells with swirling pattern characteristic of biliary tree stem 
cells at the centre of a large epithelial stem/progenitor cell colony. Vimentin 
immunofluorescent staining of freshly isolated Sca1 cells cultured in OC+for approximately 6 
weeks !
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4.2.7. Characterisation of selected epithelial stem/progenitor cells. Epithelial cells were 
allowed to outgrow surrounding stroma (around 8 weeks culture) and then selected and 
passaged as a homogeneous culture. A 2 minute Trypsin digestion step was used to remove 
remaining stroma whilst sparing epithelial colonies, then a longer Trypsin step was used to 
passage epithelial cells. Selected epithelial cells grew rapidly as a confluent monolayer (Fig 
4.16A). Interestingly, the morphology of cells at the edges of confluent colonies differed from 
those at the centre. Where cells at the centre of colonies had a typical epithelial stem/
progenitor cell phenotype, namely: small; ovoid; densely packed; and with a high nuclear to 
cytoplasmic ratio, those at the peripheries were generally larger, had greater cytoplasmic 
processes and were arranged in a more polygonal pattern, all characteristics of more mature 
epithelial cells (Fig 4.16B). 
Selected epithelial cells proliferated rapidly and were split at a ratio of 1 to 6 twice per week 
for over 3 months. Fluorescent immunohistochemistry demonstrated selected epithelial stem/
progenitor cells were all positive for vimentin (Fig 4.16C) and pan-CK. All selected epithelial 
stem/progenitor cells were negative for αSMA (Fig 4.16D) and desmin (Fig 4.16E) and a 
small proportion displayed patchy alpha-foetoprotein (AFP) staining (Fig 4.16F). 
!
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Figure 4.16. Characteristics of long-term cultured epithelial stem/progenitor cells. 
Representative images (100x magnification) of passage 6 epithelial stem/progenitor cells 
showing the A, centre and B, edge of confluent area of growth 2 days after passaging. 
Examples of fluorescent immunohistochemistry of fixed, confluent passage 6 epithelial stem 
cells stained for myofibroblastic markers C, vimentin (100x magnification); D, αSMA (200x 
magnification); and E, desmin 100x magnification). F, Representative image (100x 
magnification) of fluorescent immunohistochemistry on confluent passage 6 epithelial stem 
cells stained for the hepatoblast marker AFP !
!
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4.2.8. Epithelial stem/progenitor cells cultured long-term in selective media show limited 
hepatocytic differentiation but rapid myofibroblastic differentiation. To assess the 
plasticity of selected epithelial stem/progenitor cells that had been cultured long term, passage 
6 cells were  cultured in conditions to assess myofibroblast, hepatocyte and biliary epithelial 
cell differentiation potential. When cells were cultured in αMEM + 10% foetal calf serum for 
7 days they displayed morphology highly similar to that described for freshly isolated PαS 
cell cultured in the same conditions. Compared to epithelial stem cells cultured in OC+ media 
for the same duration (Fig 4.17A), cells were significantly fewer in number, most likely due 
to decreased proliferation, larger with greater, branched cytoplasma and demonstrated contact 
inhibition (Fig 4.17B). 
!
Hepatocyte differentiation assays, utilising media previously reported to induce hepatocytic 
differentiation of isolated murine hepatic stem/progenitor cells, were conducted in triplicate to 
assess the potential of selected cells to form functional, mature hepatocytes. Prolonged culture 
of cells in normal growth conditions resulted in very dense cultures with cell shedding and 
evidence of cell death observed (Fig 4.17C) due to over-confluence. Shedding and cell death 
was also observed in cells cultured in hepatocyte differentiation media for 14 days, although 
cells appeared larger (Fig 4.17D). Morphological changes other than size were subtle and 
may be a result of slightly decreased proliferative rate, a known effect of oncostatin-M 
including in differentiation media used. Immunohistochemical analysis of cells cultured in 
differentiation media for 14 days revealed patchy AFP expression (Fig 4.17E) and absent 
albumin staining (Fig 4.17F) that was not significantly different from previous analysis (Fig 
4.16) of undifferentiated epithelial stem/progenitor cells derived from Sca1+ cells. 
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Figure 4.17. Selected epithelial stem/progenitor cells demonstrate rapid differentiation 
to myofibroblasts and limited differentiation to hepatocytes. Representative examples of 
vimentin immunohistochemistry of passage 6 epithelial stem/progenitor cells after 7 days 
culture in: OC+ on collagen type I A, with, and B, without 2-DG. Light microscopy of 
passage 6 cells after 7 days culture in E, OC+ and F, hepatocyte differentiation media on 
collagen type I. Immunohistochemical analysis of cells after 14 days culture in hepatocyte 
differentiation media showing E, patchy AFP expression and F, absent albumin expression !
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Suspension of epithelial stem/progenitor cells in three-dimensional collagen gels for biliary 
differentiation resulted in non-viable cultures where passaged cells failed to migrate or 
proliferate, preventing assessment of biliary differentiation potential. 
!
4.2.9. In vivo assessment of  engraftment and repopulation potential of freshly isolated 
Sca1+ cells. 1x105 freshly isolated Sca1+ cells were suspended in saline and injected directly 
into the tail vein of a single male FAH-/- RAG2-/- IL2RG-/- (FRG) triple knockout transgenic 
mouse (treated). Normal saline was injected into the tail vein of a single male littermate as a 
control (untreated). Mice were weighed daily and a weight loss of greater than 10% from 
initial weight was used as the end-point, where mice would be killed and the experiment 
ended. NTBC was gradually reduced once immediately after infusion (4mg/L for 2 days, 
2mg/L for 2 days and 1mg/L for 2 days). Mice were put back onto 16mg/ml (100%) NTBC at 
day 18 following rapid weight loss and NTBC was again gradually reduced as per first the 
protocol at day 21 up to day 27. The untreated mouse was found dead on day 46 and the 
treated mouse was found dead on day 52, both before weight loss was greater than 10% of 
initial weight. Recorded weights were similar until around day 40 when weights began to 
converge with the treated mouse demonstrating slower weight loss than some recovery from 
day 48 (Fig 4.18). No obvious fluid retention or ascites were found post-mortem on day 52. 
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Figure 4.18. Increased survival time in a single FRG mouse infused with freshly isolated 
Sca1+ cells versus saline only. Daily recorded weights of FRG mice after infusion of 1x105 
Sca1+ cells suspended in saline (blue line) versus saline only (black line). Drinking water was 
gradully reduced in two cycles beginning immediately after infusion and on day 21. NTBC 
levels in drinking water were: 16mg/ml on days 18-21; 4mg/ml on days 1, 2, 22 and 23; 2mg/
ml on days 3, 4, 24 and 25; 1mg/ml on days 5, 6, 26 and 27 and absent on all other days.. 
Survival of treated mouse versus untreated mouse = 46 versus 52 days, n=1 for each treatment !
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4.3. DISCUSSION 
Here, PDGFα+ Sca1+ (PαS) cells are shown to be present in adult murine liver and their 
prospective isolation using fluorescence-activated cell sorting (FACS) demonstrated. Detailed 
characterisation studies indicate PαS cells are a potent source of fibrogenic cells and may 
have the potential to give rise to epithelial stem/progenitor cells. Preliminary functional 
studies were conducted, however the contribution of PαS cells to: liver fibrogenesis in chronic 
disease; regeneration through production of daughter cells capable of differentiation into 
mature, functional hepatocytes and/or biliary epithelial cells; and injury resolution, where 
they may have value as a novel target for anti-fibrosis therapy; remains to be demonstrated. 
!
In this study cells expressing both PDGFα and Sca1, an expression profile used to define 
potent mesenchymal stem cells in previous studies in other organs, were detected by 
immunohistochemistry and reproducibly isolated by prospective FACS. Freshly isolated PαS 
cells could be cultured in vitro on plastic in alpha-minimal essential media plus 10% foetal 
calf serum, conditions developed for the culture and long-term maintenance of murine 
mesenchymal stem cells (MSCs) isolated from bone marrow. In contrast to bone marrow 
MSCs, which maintain their potency and characteristic stromal cell morphology for long 
periods (weeks and serial passages), freshly isolated PαS cells rapidly take on myofibroblastic 
characteristics when cultured in identical conditions with significantly increased initial rates 
of proliferation, more in-keeping with reports of stellate cells isolated by density 
centrifugation. Activation and proliferation of freshly isolated PαS cells was increased by 
culture on type I collagen, known to activate stellate cells, and could be strongly inhibited by 
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culture with 2-deoxyglucose, a potent inhibitor of glycolysis, previously shown to be required 
for appropriate activation and transdifferentiation of stellate cells. When cultured in 
conditions allowing the selection and long-term culture of freshly isolated murine hepatic 
stem/progenitor cells, both PαS and Sca1+ cells formed heterogenous cultures of both stromal 
and epithelial cells. In the first few days post-isolation, cells were predominantly stromal, 
however over time areas comprised of cells with epithelial characteristics appeared as clearly 
defined colonies of tightly aggregated cells and slowly outgrew surrounding stromal cells. 
Due to the fewer numbers of isolated PαS cells per liver and their use in experiments 
characterising their fibrogenic potential, in was not possible to examine the long term growth 
of PαS cells under these conditions or their potential to differentiate into functional hepatic 
cell types, hepatocytes and biliary epithelial cells. However, it was possible to select and 
culture epithelial cells derived from cultures of freshly isolated Sca1+ cells for more than 12 
weeks and 10 passages without apparent loss of proliferative capacity of changes in 
morphology. Selected cells had an antigenic profile highly suggestive of, but not definitively, 
hepatic stem/progenitor cells. Functional assays demonstrated rapid differentiation, or 
conversion back, to myofibroblastic cells after culture in MSC conditions. However, in 
conditions designed for the differentiation of murine hepatic stem/progenitor cells into 
hepatocytes and biliary epithelial cells, it was not possible to demonstrate the differentiation 
of these cells into functional mature cell types. A single in vivo experiment assessing the 
potential use of selected epithelial cells as a cellular therapy for liver failure was encouraging 
but inconclusive. Thus, while much work remains to fully characterise prospectively isolated 
PαS and Sca1+, these results demonstrate the presence of peri-vascular stromal cells resident 
in adult murine liver with high colony forming potential, the ability to differentiate into 
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myofibroblastic cells and form long-term cultures of highly proliferative epithelial cells with 
stem cell characteristics that, with further study, may be definitively demonstrated as hepatic 
stem/progenitor cells. 
!
The location of PαS in normal liver is in-keeping with previous studies demonstrating the 
presence of cells with MSC-like characteristics, currently best termed ‘vascular stem cells 
(VSC)’, in most, if not all, organs. Early reports often described the location of these cells as 
‘perivascular’, however more detailed examination has revealed the vascular wall itself as the 
VSC niche under normal conditions. Immunohistochemistry performed on sections of normal, 
uninjured mouse liver demonstrated a similar location for PαS cells within the liver as 
reported for other organs. Although further immunohistochemical analyses using whole-
mount samples of large intra-hepatic arteries would be required to conclusively demonstrate 
presence of PαS cells within the vascular wall itself, PDGFRα and Sca1 staining was 
observed in all portal vessels and directly adjacent parenchyma. Interestingly this location is 
also the site of early fibrogenesis seen in chronic hepatocytic diseases, where fibrosis is first 
predominantly observed in peri-portal regions, before progressing to ‘bridging’ fibrosis where 
fibrotic septa span the parenchyma between portal triads. This therefore raises the possibility 
of PαS cells contributing to fibrosis, either directly through the deposition of collagen and/or 
indirectly by proliferating and differentiating into fibrogenic myofibroblasts. The relative 
contribution, if any, of PαS to fibrogenesis has yet to be shown but would be best elucidated 
through the use of chronic hepatocellular injury in cell fate tracking models, particularly the 
inducible PDGFRα cre recombinase transgenic mouse, where the presence of myofibroblasts 
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derived from PDGFRα+ cells would demonstrate a role for PαS cells in fibrogenesis. 
This study demonstrates the prospective isolation of a homogeneous population of PαS that 
rapidly take on myofibroblast morphology and alpha-smooth muscle actin expression when 
cultured on plastic or collagen type I. The use of 2-deoxyglucose, a specific inhibitor of 
glycolysis, inhibited the proliferation and myofibroblastic differentiation of PαS cells, 
confirmed by the reduced proportion of cells expression αSMA after 7 days culture in the 
presence of 2-DG. Despite oil red O staining failing to demonstrate substantial intracellular 
lipid content in PαS cells, the inhibition of PαS cells by 2-DG is likely to be through a similar 
mechanism to that reported for freshly isolated hepatic stellate cells183.  
!
The isolation of PαS cells from liver required significant modification and adaptation from the 
original protocol for isolation of of PαS cells from bone marrow168. Firstly, the digestion 
method for liver was based upon previous reports of isolation of primary murine liver cells 
and my experience of isolating hepatic stem cells from explanted liver and extra-hepatic bile 
duct (chapter 6) whilst attempting to maintain as much similarity with the original bone 
marrow digestion protocol as possible. The major modifications were thus based upon the 
mechanical dissociation of liver tissue, use of mesh filters and gradient centrifugation while 
keeping the collagenase digestion approximately the same. A major issue with liver digestion 
was debris resulting from rapid death and disintegration of hepatocytes which occurs rapidly 
upon liver excision and is a well described problem in primary hepatocyte isolation resulting 
in the need for in situ liver digestion. Here it was preferable to remove hepatocytes and 
associated debris from the isolation as soon as possible to prevent technical problems and 
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minimise the effect of factors released by dying cells on the cells targeted for isolation. From 
experience and trial and error, it was found that this was best achieved by fine dissociation 
with scalpels followed by a rapid digestion step with a high concentration of collagenase 
under vigorous agitation then removal of debris by filtration through fine mesh and re-
digestion of remaining tissue. Whilst this increased the degree of tissue dissociation, it did not 
appear to reduce the yield of PαS cells, indeed increased digestion time appeared to increase 
PαS yield and viability whilst it is known to have the opposite effect on hepatocyte isolation. 
The addition of a gradient centrifugation step, routinely used in protocols for the isolation of 
epithelial stem/progenitor cells from both rodent and human tissues, allowed selection of a 
fraction containing the majority of cells of interest whilst excluding large amounts of debris 
and unwanted cells types in the supernatant. This allowed a further increase in yield of PαS 
cells and speeded up sorting times, known to be a factor influencing the viability of freshly 
isolated cells.  
!
The prospective isolation of hepatic stellate cells from adult rodent or human liver tissue has 
not been previously described. The current gold standard method for the isolation of stellate 
cells exploits their characteristic high lipid content and consequential low density allowing 
their selection through density centrifugation alone. This approach yields cultures that contain 
a significant proportion of contaminating cells, notably macrophages and fibroblasts and 
commonly used culture conditions (plastic and high serum media) leads to rapid activation 
and transdifferentiation of stellate cells into myofibroblasts.  
!
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This method of prospectively isolating cell based on PDGFα and Sca1 expression may have 
utility in isolating hepatic epithelial stem/progenitor cell populations. Currently used methods 
for the isolation of hepatic stem/progenitor cells from murine liver rely on injury to facilitate 
proliferation of hepatic stem/progenitor populations allowing a significant yield. Further, 
protocols yielding the purest populations with greatest differentiation potential have relied on 
intracellular markers, preventing the use of prospective isolation with FACS, instead relying 
on labelling with inducible transgenic mouse models. Sca1 alone has previously used to 
prospectively isolate progenitor cells from adult murine liver178 and was shown to yield 
highly heterogeneous cultures of cells with stromal, endothelial, hepatocytic and biliary 
morphology and expression profiles. The use of selective culture conditions was not utilised 
in the study by Clayton at el. and thus at the point of isolation, the Sca1 population reported 
here may be highly similar with the differences in morphology and growth potential conferred 
by culture conditions only. However, this study demonstrated significantly higher colony 
formation of PαS compared to Sca1+ cells and that PαS cells were also capable of forming 
large epithelial colonies when cultured in OC+ conditions, indicating PαS cells likely 
represent a more enriched population of stem/progenitor cells than Sca1 alone. Further work 
utilising this isolation method may ultimately demonstrate it as a novel and superior method 
for the isolation of hepatic stem/progenitor cells without the need for liver injury, which 
almost certainly alters the phenotype and behaviour of stem/progenitor cells prior to isolation, 
and transgenic labelling models. However there are many of the challenges encountered in 
this study and limitations that remain to be resolved.  
!
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Firstly, the use of selective media was necessary for long-term growth and passaging of 
epithelial stem/progenitor cells. This study highlights the rarity of true epithelial stem/
progenitor cells in uninjured adult liver, and heterogeneity and plasticity of resulting in vitro 
cultures. Although the use of selective media is routine in both rodent and human, this 
approach may cause changes to cultured cells that do not accurately represent what occurs in 
vivo and artificially produce cells with stem/progenitor properties. In conditions designed for 
culture of MSCs only freshly isolated PαS were found to be viable, where they rapidly formed 
confluent highly homogeneous cultures of myofibroblastic cells, but Sca1+ cells failed to 
grow in these conditions. Both populations could be cultured in conditions for selection of 
epithelial stem/progenitor cells but gave rise to both stromal and epithelial cell types during 
the first few days before outgrowth of epithelial colonies. These results would suggest freshly 
isolated PαS cells are more potent and have the capacity to give rise to a greater range of cell 
types. Thus, despite epithelial cultures from PαS cells not being characterised, it would appear 
PαS cells represent a more primitive cell type than Sca1+ within the same lineage. 
Interestingly, although freshly isolated Sca1 cells fail to form myofibroblastic cells, stromal 
cells were observed in Sca1 cultures in OC+ and selected epithelial stem/progenitor cells from 
Sca1 cultures were capable of rapid differentiation into myofibroblasts.  
!
Further work is needed to demonstrate robust differentiation of selected epithelial stem/
progenitor cells into hepatocytes and biliary epithelial cells, the mature cell types of the liver. 
Although attempted several times, it was not possible to culture these cells in 3D collagen 
gels, conditions necessary for terminal differentiation of hepatic stem cells into biliary 
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epithelial cells and thus their capacity to form biliary epithelium could not be assessed. 
Attempts to demonstrate hepatocytic differentiation were also largely unsuccessful. One of 
the major technical issues was the continued high rate of proliferation even with addition of 
oncostatin-M, previously demonstrated to effectively halt proliferation of hepatic stem cells 
and induce differentiation. Although culture in hepatocyte differentiation media for 7 days did 
result in slight morphological change (cells appeared larger) this may have been largely due to 
decreased proliferation rate as there was no change in antigenic profile (negative for albumin, 
low level, patchy AFP expression). Further optimisation of this protocol may have resulted in 
more robust differentiation. This work is essential in definitively demonstrating PαS do have 
the capacity to form hepatic epithelial stem/progenitor cells. If selected epithelial colonies 
from PαS cells are shown to be unable to differentiate into functional hepatocytes, despite 
their characteristic morphology and expression of pan-CK and AFP, it is possible these cells 
represent fibroblastic cells that are closely associated with activated and proliferation hepatic 
stem/progenitor cells in the ductular reaction and are thought to express pan-CK and vimentin 
along with other stromal markers such as CD56 (NCAM). 
!
Lastly, the single experiment to assess the ability of selected epithelial stem/progenitor cells to 
engraft into, and reconstitute, chronically injured liver in vivo  was inconclusive. Hepatic stem 
cells isolated based on Lgr5 expression have been shown to have this capacity using the FRG 
model115 and this experiment is similarly important to hepatocyte differentiation assays in 
demonstrating the epithelial colonies observed in PαS cell cultures do represent hepatic stem 
cell colonies. Further replicates of this experiment are required, along with sectioning of 
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livers to demonstrate engraftment of infused cells. As hepatocytes of FRG mice are deficient 
in FAH expression, and isolated cells were from wild type mice, FAH immunohistochemistry 
can be used to identify transplanted cells and assess the degree of engraftment, proliferation 
and in vivo differentiation. 
Other future work on this project will investigate the fibrogenic potential of PαS cells by 
assessing matrix deposition, specifically collagens, and utilise wound healing (scratch) assays 
to quantify the speed at which cells can proliferate and resolve injury. A direct comparison 
between PαS cells and stellate cells isolated by density centrifugation would be particularly 
useful. Fibrogenic liver injury models, particularly acute and chronic carbon tetrachloride 
administration, could be used to investigate the contribution of PαS cells to fibrogenesis by 
immunohistochemical analysis to locate and quantify PαS after injury, and isolation to 
characterise the effect of injury on PαS cells. Cell fate tracing experiments using PDGFRα or 
Sca1 labelled mice, particularly in injury models, would further elucidate the role of PαS cells 
in hepatic fibrogenesis. 
!
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CHAPTER 5 
ACTIVATION OF HEPATIC STEM CELLS IN CHRONIC LIVER DISEASE AND 
ASSOCIATION WITH RISK OF HEPATOCELLULAR CARCINOMA 
!
!
!
!
!
!
!
!
!
!
!
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5.1. RATIONALE FOR STUDY 
Increased understanding of the maturation lineage and antigenic profiles of hepatic stem 
cells from in vitro studies has not been fully applied to histological studies. Recent studies 
have demonstrated the isolation and long-term in vitro culture of adult hepatic stem cells from 
both rodent75, 115 and human1. These studies, describing as many as 8 distinct stages of the 
hepatic stem cell maturational lineage3, have provided detailed characterisation and 
expression profiles of cells at each stage of differentiation. The use of markers specifically 
identifying hepatic stem/progenitor cells has not been reported in histological studies until 
recently. In mouse, markers that also detect mature biliary epithelium, panCK and EpCAM, 
were commonly used to assess hepatic stem cell activation. In human studies and clinical 
practice, CK19 and CK7 are used routinely to assess ductular reaction, the histological 
phenomena mostly closely associated with hepatic stem cell activation.  
!
There is a need for objective methods to objectively quantify hepatic stem cell activation 
and associated histological phenomena. The lack of specific markers of hepatic stem cells 
continues to prevent their direct assessment, and validated objective scoring systems that 
quantify and give clinical relevance to hepatic stem cell activation are still lacking. Currently 
used methods for quantifying other histological phenomena in liver disease rely on expert 
liver histopathologist opinion and semi-quantitative scoring systems44, 184. Recently there has 
been progress in the use of objective, fully quantitative assessment methods, particularly for 
fibrosis through measurement of collagen percentage area92. However this approach has yet to 
be applied to the measurement of hepatic stem activation. 
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The contribution of hepatic stem cell activation to homeostasis and carcinogenesis in 
chronic liver disease is incompletely understood. The activation the hepatic stem cell niche 
is tightly regulated and normally resolves quickly when the insult to the liver is removed19, 26, 
27. However, in chronic liver diseases, ie. viral, alcoholic and biliary cirrhosis, activation of 
the hepatic stem cell niche can be maintained over years in an attempt to maintain normal cell 
number and function. In this scenario, the consequences of rapid cell turnover and continuous 
supply from the hepatic stem cell niche, and the proportion of functional parenchymal cells 
derived from stem cells, are unknown. Further, the risk of primary liver cancer is known to be 
greatly increased in cirrhosis with experimental studies indicating hepatic stem cells may be 
involved in carcinogenesis46, 88, 89, 94. Any association between activation of the hepatic stem 
cell niche and risk of primary liver cancer, particularly hepatocellular carcinoma, is currently 
unknown. 
!
Therefore, immunohistochemical techniques allowing visualisation of histological phenomena 
related to hepatic stem cell activation (ductular reaction, CK19; intermediate hepatobiliary 
cells, CK7; hepatocytes newly derived from hepatic stem/progenitor cells, EpCAM; and 
hepatic stem/progenitor cells, Sox9) were assessed and methods for the objective 
quantification of each were developed. The association of each of these phenomena with risk 
of HCC development was assessed in two retrospectively identified cohorts of NASH and 
HCV cirrhotic patients that had undergone fine-needle liver biopsy and had greater than 3 
years follow up at the Queen Elizabeth Hospital Birmingham.  
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5.2. RESULTS 
5.2.1 Objective quantification of ductular reaction using Cytokeratin 19 (CK19) 
immunohistochemistry. Immunohistochemical staining for CK19 was observed on biliary 
epithelium (Fig 5.1. arrowheads) in normal, uninjured, adult liver with very occasional 
small, isolated, single cells (Fig 5.1. arrows) observed in peri-portal parenchyma. All CK19+ 
cells have characteristic biliary morphology, being largely cuboidal (cells of the larger bile 
ducts may be columnar), smaller than hepatocytes (approximately 8µm vs 20µm), located 
within the limiting plate arranged in lumen (Fig 5.1).  
In chronically diseased liver, CK19 marks biliary epithelium and ductular reactive cells, 
observed as partially formed lumen or strings of cells infiltrating into peri-portal parenchyma 
in close proximity to inflammatory infiltrates and fibrous septa. CK19+ cells are rarely 
observed in parenchyma distant from peri-portal or peri-septal regions (Fig 5.2A). CK19 
immunohistochemistry occasionally detects isolated hepatocytic cells potentially representing 
intermediate hepatobiliary cells or hepatocytes newly derived from hepatic stem cells. 
Stromal, immune and endothelial cells are invariably negative for CK19. 
High quality chromogenic CK19 staining, with intense staining and low background results in 
a high contrast image that can be analysed by the ‘Color Threshold’ function of ImageJ(39) 
The production of a binary image by ImageJ (Fig 5.2B) allows the quantification of ‘positive’ 
pixels and percentage area stained,  a value that can be used to closely approximate the degree 
of ductular reaction. 
!
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Figure 5.1. CK19 immunohistochemistry on normal liver specifically marks biliary 
epithelium. Representative image (100x) of CK19 immunohistochemistry on normal, 
uninjured, adult liver demonstrating specific staining of biliary epithelium (arrowheads) !
!
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Figure 5.2. CK19 immunohistochemistry can be quantified using ImageJ to measure 
ductular reaction. A, Representative image of cytokeratin 19 immunohistochemistry on 
explanted HCV cirrhotic liver (arrowheads, normal epithelium; arrows, ductular reaction; 
100x). B, Binary image produced from the same image by colour threshold function of 
ImageJ allowing quantification of CK19 staining and approximation of ductular reaction 
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5.2.2. Quantification of intermediate hepatobiliary cells using cytokeratin 7 (CK7) 
immunohistochemistry. Cytokeratin 7 (CK7) immunohistochemistry on normal, uninjured 
liver sections is similar to that observed for CK19 immunohistochemistry with only the 
biliary epithelium stained. However, in chronically diseased liver a number of cell types 
display cytoplasmic CK7 staining. Normal biliary epithelial cells are observed forming 
distinct lumen with ductular reactive cells seen as strings, or aggregates, of cells that do not 
form functional lumen. In addition, CK7 marks two other cell types. Occasional cells with 
distinct biliary morphology  and intense cytoplasmic CK7 staining are observed in isolation or 
small clusters within the liver parenchyma and distant from peri-portal or peri-septal regions 
(Fig 5.3. red arrows). These cells are commonly referred to as isolated cholangiocytes and 
are considered to be distinct from the ductular reaction with suggestion these cells represent 
terminal branches of the biliary tree known as the Canals of Hering or possibly hepatic stem/
progenitor cells. If these cells are hepatic stem/progenitor cells distinct from biliary 
epithelium and ductular reaction, their ancestry, fate and function have yet to be fully 
elucidated. Larger cells with hepatocytic morphology and less intense cytoplasmic CK7 
staining (Fig 5.3. green arrows) are also observed throughout the parenchyma, usually as 
clusters of cells (Fig 5.3. highlighted in green boxes), and are commonly referred to as 
‘intermediate hepatobiliary cells’ (IHCs). With high stringency chromogenic CK7 
immunohistochemistry, IHCs can be distinguished from biliary epithelium based on size and 
location, and from isolated cholangiocytes through size, morphology and CK7 staining 
intensity. 
!
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Figure 5.3. CK7 immunohistochemistry detects intermediate hepatobiliary cells in 
NASH cirrhotic explanted liver. Representative image (100x) of cytokeratin 7 
immunohistochemistry of NASH cirrhotic explanted liver. Red arrows highlight isolated 
mature cholangiocytes (possibly Canals of Hering). Green arrows and boxes highlight 
intermediate hepatobiliary cells !!!
!
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5.2.3. Quantification of hepatocytes newly derived from hepatic stem cells using 
epithelial cell adhesion molecule (EpCAM) immunohistochemistry. In normal liver 
epithelial cell adhesion molecule (EpCAM) is exclusively expressed by mature biliary 
epithelium, seen as intense cytoplasmic staining (Fig 5.4A, arrowheads), and occasional 
isolated cholangiocytes that are also identified with CK7 and CK19 immunohistochemistry 
(Fig 5.4A, arrows). Polygonal hepatocytic cells invariably have a membranous pattern of 
EpCAM expression in contrast to cholangiocytes that maintain a cytoplasmic distribution in 
injured liver. In NASH cirrhosis, EpCAM expression was always membranous and positive 
hepatocytes were in small foci in peri-portal or peri-septal areas, often in close proximity to 
ductular reaction (Fig 5.4B, arrows).  
In cases of HCV cirrhosis large numbers of hepatocytes displaying membranous EpCAM 
expression are commonly observed, particularly in peri-portal or peri-septal regions (Fig 5C-
F). Distinct regions of EpCAM+ parenchyma (Fig 5.4C, arrow) potentially identify active 
regeneration from hepatic stem/progenitor cells. Interestingly, EpCAM+ hepatocytes are most 
commonly observed in regenerating nodules of cirrhotic livers (Fig 5.4D), perhaps supporting 
previous evidence that these nodules are derived from proliferation of adjacent hepatic stem 
cells74. In some cases of HCV cirrhosis almost all hepatocytes were seen to be EpCAM+ (Fig 
5.4E). Intensity of EpCAM staining appears to decrease gradually from highest in peri-portal 
and peri-septal areas to weak or no expression on centri-lobular hepatocytes. Smaller cells 
with more intense membranous expression of EpCAM are observed directly adjacent to 
fibrotic septa (Fig5.3F, arrowheads) with larger, more distal cells seen to have less intense 
membranous EpCAM expression and were occasionally binucleate (Fig5.3F, arrows) 
characteristic of mature hepatocytes. 
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Figure 5.4. EpCAM immunohistochemistry allows identification of hepatocytes newly 
derived from hepatic stem/progenitor cells. Representative images of EpCAM 
immunohistochemistry on A, normal, uninjured adult liver (arrowheads, normal epithelium; 
arrows, isolated cholangiocytes; 100x) B, NASH cirrhotic explanted liver (arrowheads, 
normal epithelium; arrows, peri-septal EpCAM+ ductular reaction; 100x), C, HCV cirrhotic 
explanted liver with a distinct region of EpCAM+ parenchyma (arrow) adjacent to an area of 
EpCAM- parenchyma (arrowheads, normal epithelium; 100x), D, NASH cirrhotic biopsy 
tissue with EpCAM+ regenerative nodule (demarcated in red, 200x), E, HCV cirrhotic liver 
with a high proportion of EpCAM+ hepatocytes. F, high magnification (400x) view 
demonstrating small hepatocytes (arrowheads) and binuclear hepatocytes (arrowheads) of 
peri-septal region from panel E  
B.
C. D.
A.
E. F.
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As foci of parenchyma expressing EpCAM were reasonably clearly demarcated (Fig 5.5), 
ImageJ can be used to the quantify these areas after delineated by the user and produce a 
value for the proportion of parenchyma with cytoplasmic EpCAM expression. Thus, by also 
measuring the total parenchymal area using ImageJ, an approximation of the proportion of 
EpCAM+ hepatocytes can be calculated (area of EpCAM+ parenchyma divided by total area 
of parenchyma). 
!
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Figure 5.5. Presence of hepatocytes with membranous EpCAM expression in NASH 
cirrhosis. Representative image (100x) of EpCAM immunohistochemistry demonstrates 
cytoplasmic EpCAM staining of mature bile ductules (arrowheads) and membranous EpCAM 
staining of mature hepatocytes (demarcated in red) !
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5.2.4. Quantification of hepatic stem/progenitor cells using Sox9 immunohistochemistry. 
Sox9 has been reported as a specific marker of hepatic stem cells in both rodent and human 
adult liver. In normal liver, expression of Sox9 is infrequent and restricted to a small 
proportion of biliary epithelial cells only. In diseased liver, nuclear expression of Sox9 is 
observed on most biliary epithelial cells of normal lumen (Fig 5.6, arrowheads) and ductular 
reaction. Sox9 expression is predominantly observed in peri-portal regions and with the 
presence of Sox9+ becoming less frequent in centri-lobular regions. In cases of severe injury, 
particularly HCV cirrhosis, parenchymal regions are observed where almost all parenchymal 
cells display nuclear Sox9 expression (Fig 5.6, arrows). By morphology alone it is not 
possible to definitively assess the cell types expressing Sox9 but the close proximity of Sox9+ 
nuclei suggest Sox9 expressing cells are unlikely to be hepatocytes and most likely hepatic 
stem/progenitor cells, hepatoblasts or activated stellate cells. Sox9 expression has not been 
reported for any immune cell types. Although more recent studies have reported Sox9 
expression on activated stellate cells, detailed fate tracing studies have demonstrated the 
utility of Sox9 in identifying hepatic stem cells and failed to demonstrate stromal progeny 
from Sox9+ cells. Thus, for the purpose of this study the number of Sox9+ nuclei were 
counted as a measure of the number of hepatic stem cells and degree of hepatic stem 
activation. 
!
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Figure 5.6. Activation of the hepatic stem cell niche in HCV cirrhosis visualised by Sox9 
immunohistochemistry. Representative image (200x) of Sox9 immunohistochemistry on 
HCV cirrhotic explanted liver. Nuclear Sox9 staining is observed on normal biliary 
epithelium (arrowheads) and on peri-portal parenchymal cells (arrows) !
!
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5.2.5. Hepatic stem cell activation occurs in all major aetiologies of chronic liver disease. 
To assess hepatic stem cell activation in chronic liver disease, 5 samples of cirrhotic explanted 
liver tissue for each of the chronic liver diseases PBC, HCV, NASH and ALD were selected 
from the Centre for Liver Research tissue bank and stained with CK19, CK7, EpCAM and 
Sox9. 
!
Primary cirrhosis (PBC) 
In primary biliary cirrhosis (PBC), cytokeratin 19 (CK19) staining marks large bile ducts, 
remnant small ducts and peri-septal ductular reactive cells. Cytokeratin 7 (CK7) staining 
appears to mark the same population of cells as those marked by CK19 along with an 
expanded population of ductular reactive cells. Foci of CK7+ intermediate hepatobiliary cells 
are occasionally observed in cases of PBC. Through the use of sequential sections, IHCs 
appear to be negative for CK19, EpCAM and Sox9 and are often observed in centri-lobular 
locations distinct from ductular reactive cells detected with CK7 or EpCAM. EpCAM and 
Sox9 immunohistochemistry appears to mark all biliary epithelial and ductular reactive cells. 
Interestingly, cytoplasmic expression of Sox9 appears to be present in hepatocytic cells 
directly adjacent to peri-portal fibrotic septa, however EpCAM expression by hepatocytes is 
not observed in PBC. This observation has not previously been reported in PBC cirrhosis.  
!
!
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Figure 5.7. Characterisation of hepatic stem cell populations in PBC cirrhosis. 
Representative images (100x) of immunohistochemical staining for AB, CK19; CD, CK7; 
EF, EpCAM; and GH, Sox9 in serial sections from two cases (A,C,E,G and B,D,F,H) of 
PBC cirrhosis !
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Hepatitis C virus (HCV) cirrhosis 
Expression of CK19 in HCV cirrhosis is restricted to the biliary tree and a small proportion of 
ductular reactive cells. As observed in PBC, CK7 and EpCAM detect all biliary epithelial and 
ductular reactive cells. Sox9 expression is exclusively observed as nuclear staining of biliary 
epithelial and ductular reactive cells. The presence of EpCAM+ hepatocytes is frequently 
observed in HCV cirrhosis. EpCAM expression in hepatocytes is typically membranous, in 
contrast with the cytoplasmic pattern observed in biliary epithelium and ductular reactive 
cells. EpCAM+ cells are most frequently observed in peri-portal and peri-septal regions but 
may extend to throughout the lobule. Regenerative nodules are commonly entirely composed 
of EpCAM+ hepatocytes that may indicate stem cell mediated regeneration, particularly as 
previous studies have suggested these nodules may have clonal origins from hepatic stem 
cells. The proportion of hepatocytes expressing EpCAM is cirrhosis appears to be quite 
variable, ranging from small numbers of peri-portal hepatocytes to the majority of 
hepatocytes with membranous EpCAM expression extending throughout the liver 
parenchyma. 
!
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Figure 5.8. Characterisation of hepatic stem cell populations in HCV cirrhosis. 
Representative images (100x) of immunohistochemical staining for AB, CK19; CD, CK7; 
EF, EpCAM; and GH, Sox9 in serial sections from two cases (A,C,E,G and B,D,F,H) of 
HCV cirrhosis !
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Non-alcoholic steatohepatitis (NASH) cirrhosis 
CK7, EpCAM and Sox9 immunohistochemical analysis of NASH cirrhotic sections labelled 
all biliary epithelial cells and ductular reactive cells, with CK19 expression observed in a 
small proportion of ductular reactive cells similar to other other chronic diseases described 
above. Ductular reactive is commonly extensive in NASH cirrhosis and is closely associated 
spatially with fibrotic septa. The presence of EpCAM+ hepatocytes is rarely observed in 
NASH cirrhosis, being significantly more infrequent than commonly seen in HCV cirrhosis.  
!
Alcoholic liver disease (ALD) cirrhosis 
ALD is histologically similar to NASH with concurrent inflammation, fibrosis, ductular 
reaction and hepatic stem cell activation. Observations with CK19, CK7, EpCAM and Sox9 
on ALD cirrhotic samples (not shown) were not substantially different to those observed for 
NASH. 
!
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Figure 5.9. Characterisation of hepatic stem cell populations in NASH cirrhosis. 
Representative images (100x) of immunohistochemical staining for AB, CK19; CD, CK7; 
EF, EpCAM; and GH, Sox9 in serial sections from two cases (A,C,E,G and B,D,F,H) of 
NASH cirrhosis 
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5.2.6. Quantification of histological phenomena and association with subsequent 
development of HCC in NASH cirrhosis. NASH cirrhotic biopsies were retrospectively 
identified from patients with greater than 3 years follow up at the Queen Elizabeth Hospital 
Birmingham allowing any subsequent development of HCC after time of biopsy to be 
identified. A total of 18 biopsies were identified that had a definitive diagnosis of NASH 
without overlapping aetiologies or previous history of cancer. Clinical data was retrieved by 
Dr. Matthew Armstrong for each patient at the time of biopsy used. Not all data for each risk 
factor were available: gender data were available for all patients; hypertension for 13 of 18; 
obesity for 8 of 18; hyperlipidaemia for 7 of 18; and diabetes for 14 of 18 (Fig 5.10A). No 
significant differences in the incidence of hypertension, obesity, hyperlipidaemia, or diabetes, 
risk factors for NASH, were found between patients that did, and patients that did not, 
subsequently develop HCC (Fig 5.10B). Of the 18 patients, 6 were found to have 
subsequently developed HCC. All patients that developed HCC were male. Of those that did 
not 6 were male and 4 were female, in-keeping with the previously reported increased risk of 
HCC in male patients132.  
Ductular reaction was quantified by calculating the percentage area of the entire biopsy 
covered by CK19 immunohistochemistry. The presence of intermediate hepatobiliary cells 
using CK7 immunohistochemistry was defined as per Ziol et. al: “the observation of at least 2 
foci of more than 5 polygonal-shaped hepatocytes, measuring from 6 to 40 µm large, with 
cytoplasmic positivity”94. The presence and proportion of EpCAM+ hepatocytes was 
extremely low in this cohort of NASH cirrhotic biopsies and so was not suitable for further 
assessment. At the time of this analysis Sox9 immunohistochemistry had not been optimised 
and due to the clinical nature and scarcity of biopsy material, it was felt to be inappropriate to 
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re-section blocks for the purpose of analysing Sox9 expression for this study alone. Sox9 
immunohistochemistry was performed on the HCV cohort identified as a result of this 
preliminary study in NASH cirrhotics (described in 5.2.7). 
Quantification of CK19 immunohistochemistry revealed trend towards greater severity of 
ductular reaction in biopsies from those patients that subsequently developed HCC (Fig 
5.11A, p=ns). Due to the lower number of patients included in this study it is possible that this 
association would reach significance in a larger study with greater statistical power. 
Ten biopsies were found to have presence of CK7+ IHCs with IHCs absent in the remaining 8. 
4 out of the 10 (40%) biopsies with presence of IHCs and 2 out of the 8 (25%) biopsies with 
absence of IHCs subsequently developed HCC (Fig 5.11B). As some patients had a greater 
period of follow-up incidence per year was calculated and patients with presence or absence 
of IHCs on biopsy were compared. Patients with presence of IHCs were found to have an 
annual incidence of HCC of 7.8% whilst patients with absence of IHCs were found to have an 
annual incidence of 4.9%. The incidence rates, 8.14% and 3.12% respectively, were similar to 
those previously reported by Ziol et. al94 (Table 5.1) in a cohort of HCV cirrhotic patients, 
however the difference was non-significant in our cohort possibly due to low numbers of 
patients included and consequent lack of statistical power. Due to the size of this cohort it was 
not possible to perform multivariate analysis to determine the contribution of known risk 
factors for HCC including male gender, age, ethnicity, obesity, and type 2 diabetes. Without 
this analysis it is not possible to fully assess the association between ductular reaction and 
presence of CK7+ intermediate hepatobiliary cells and risk of HCC development in this cohort 
of NASH cirrhotic patients. 
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Figure 5.10. Available data on risk factors for NASH reveal no significant associations 
with development of HCC. Bar charts representing A, the total number of patients with 
presence (black bars) and absence (white bars) and B, prevalence of clinical measures: male 
gender; hypertension; obesity; hyperlipiaemia; and diabetes in the 18 patients used for the 
NASH cirrhotic biopsy cohort. The number of patients where no data were available for each 
clinical measure is shown (grey bars) 
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Figure 5.11. Quantification of histological phenomena in NASH cirrhotic biopsies 
reveals an association with subsequent development of HCC. A, Comparison of 
percentage area covered by ductular reaction in NASH cirrhotic biopsies in patients that did 
and did not develop HCC subsequently (p=ns, 0.055, error bars represent S.E.M.). B, Number 
of patients with presence or absence of IHCs that subsequently did or did not develop HCC 
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Table 5.1. The subsequent incidence of HCC in NASH cirrhotic patients with and 
without presence of intermediate hepatobiliary cells in liver biopsy. !
!!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
Intermediate hepatobiliary cells Present Absent
Number of biopsies 10 8
Overall incidence of HCC 40% 25%
Average follow-up time (years) 5.1 5.1
Incidence per year 7.8% 4.9%
Incidence per year reported by Ziol et al. 8.14% 3.12%
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5.2.7. Retrospective identification and characterisation of a large cohort of HCV 
cirrhotic patients. Due to the low power and inability to detect significant associations using 
a small number of NASH cirrhotic biopsies, a larger cohort of patients that allowed 
assessment the association of quantified histological phenomena related to hepatic stem cell 
activation and risk of HCC development was identified. Liver biopsies from the original 
diagnosis of HCV cirrhosis were retrospectively identified where patients had at least 3 years 
follow-up at the Queen Elizabeth Hospital Birmingham allowing subsequent development of 
HCC to be assessed. All patients with overlapping aetiologies or previous history of cancer 
were excluded. Unlike with NASH, the diagnosis of HCV is definitive with the most common 
overlapping aetiologies, co-infection with HIV and/or HBV, being similarly simple to 
determine. This allowed the identification of a larger cohort of 74 HCV cirrhotic patients, 
characterised in Table 5.2. As with the NASH cohort there was a greater proportion of male 
patients (54 of 74, 73%). The mean age at biopsy was 51 years. 2 patients were lost to follow-
up, of those with data, the mean follow up time was 9 years to February 2014, at which point 
development of HCC was identified in 16 patients (22%). Ishak scores were recorded from 
biopsy reports. All biopsies had an Ishak fibrosis score of 5 or 6 out of 6 (cirrhotic) and a 
median necroinflammation score of 5. Portal inflammation and interface hepatitis were the 
most reported individual components of the Ishak score (median = 2). All biopsies were 
stained for CK19, CK7, EpCAM and Sox9. Due to blinding, analysis is ongoing and cannot 
be completed until all sections have been fully quantified. Final analysis will include 
correction for all relevant clinical and histological data to assess independent associations 
between quantified histological phenomena and risk of HCC development. 
!
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Table 5.2. Clinical data on retrospectively identified HCV cirrhotic patients. !
!!
Number of male patients (%) 54 (73)
Mean age at biopsy in years (standard deviation) 50.7 (8.9)
Median periportal/septal interface hepatitis score (/4) 2
Median confluent necrosis score (/6) 0
Median focal lytic necrosis score (/4) 1
Median portal inflammation score (/4) 2
Median Ishak necroinflammation score (/18) 5
Median Ishak fibrosis score (/6) 6
Mean years of follow up February 2014 (standard deviation) 9.0 (2.0)
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5.3. DISCUSSION 
Each of the markers used in this study, CK19, CK7, EpCAM and Sox9, identified cells at 
different stages of the hepatic stem maturational lineage allowing the quantification of 
ductular reaction, intermediate hepatobiliary cells, hepatocytes newly derived from hepatic 
stem cells and hepatic stem cells specifically. 
!
Cytokeratin 19 (CK19) is routinely used histologically to specifically stain biliary epithelial 
cells and has utility in assessing biliary pathologies and characterising tumour phenotype101. 
CK19 was restricted to the biliary epithelium marking only mature biliary epithelial and 
ductular reactive cells in all aetiologies assessed in this study. 
!
Cytokeratin 7 (CK7) was found to mark the same population of biliary and ductular reactive 
cells as observed with CK19 immunohistochemistry. CK7 also identifies a population of 
parenchymal cells that extended throughout the lobule with hepatocytic morphology that have 
previously been described as ‘intermediate hepatobiliary cells’94 perhaps representing 
hepatoblasts. There is currently controversy around the placement of IHCs within the 
maturational lineage of hepatic stem cells, with the possibility that IHCs are hepatocytes 
expressing CK7 de novo in response to injury. IHCs were found to be particularly common in 
HCV cirrhosis, were occasionally observed in ALD and NASH cirrhosis and rarely in PBC. 
!
Epithelial cell adhesion molecule (EpCAM) is routinely used to prospectively isolate hepatic 
stem cells from foetal and normal adult liver through the use of magnetic immunoselection 
and selective culture conditions1. However the cell types expressing EpCAM were only 
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recently reported in chronic liver injury74. These immunohistochemical studies demonstrate 
EpCAM expression to be restricted to the biliary epithelium in normal adult liver as 
previously reported87. In injured liver EpCAM is found on all cells of the biliary epithelium, 
ductular reactive cells and hepatocytes. Whilst biliary and ductular cells have a cytoplasmic 
distribution of EpCAM, in hepatocytes EpCAM expression was invariably restricted to the 
cell membrane. EpCAM+ hepatocytes are commonly observed adjacent to portal triads and 
fibrous septa potentially indicating a relationship with the hepatic stem cell niche or ductular 
reactive cells respectively. Following this study, increased telomere length in EpCAM+ 
hepatocytes was reported74 indicating fewer replications and therefore more recent genesis of 
EpCAM+ hepatocytes supporting the hypothesis that these cells are newly derived from 
proliferating hepatic stem cells. The large proportion of EpCAM+ hepatocytes possibly 
indicates rapid proliferation and differentiation of hepatic stem/progenitors contributing to 
parenchymal regeneration that mature hepatocytes may no longer provide. In these cases 
regenerative nodules are invariably constituted entirely of EpCAM+ hepatocytes 
corroborating this hypothesis. 
!
Immunohistochemical studies of Sox9 in chronic liver diseases have not previously been 
reported. This study demonstrated the presence of Sox9+ cells in explanted diseased adult 
liver. Sox9 expression was observed on all cells of the biliary epithelium and was frequently 
observed on parenchymal cells adjacent to fibrotic septa or within regenerating nodules. Sox9 
is a nuclear transcription factor and as such is most commonly observed in the nuclei of 
cells165. Interestingly, in PBC livers we observed the presence of hepatocytic cells with 
cytoplasmic Sox9 expression directly adjacent to fibrous septa. This observation was not seen 
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in any of the ALD, NASH or HCV livers examined (n=5 for each group) and has not been 
previously reported. Whether this observation reflects aberrant differentiation of Sox9+ 
(hepatic stem/progenitor) cells in PBC, where presumably these cells should be restricted to 
the biliary lineage, is unknown. Previous studies have however described the presence of 
cytoplasmic Sox9 as conferring abrogation of proliferation in breast cancer cell lines185, 
increased proliferation of breast cancer cells and poor prognosis186. Further study of 
hepatocytic cells with cytoplasmic expression of Sox9 should determine the clinical relevance 
and pathophysiological role of these cells. 
!
Once techniques had been optimised for the quantification of histological phenomena using 
markers associated with hepatic stem/progenitor cells: ductular reaction (CK19), intermediate 
hepatobiliary cells (CK7); and hepatocytes newly derived from hepatic stem/progenitor cells, 
a cohort of 19 NASH cirrhotic biopsies were identified. Biopsies were included if they were 
the first biopsy diagnostic of cirrhosis, from at least 3 years ago and from patients with no 
previous history of cancer or overlapping liver disease. This allowed the association between 
the numbers of each cell type and subsequent risk of developing HCC to be assessed. 
!
In this small cohort, no association was detected between the severity of ductular reaction and 
subsequent risk of developing HCC in NASH cirrhosis. Ductular reaction is currently 
regarded as the abnormal proliferation of mature cholangiocytes and is seen in almost all 
aetiologies of chronic liver disease66, 187. It is known that activation of the hepatic stem cell 
niche also occurs in these situations and it is possible that the ductular reaction is driven, at 
least partly, by the proliferation of hepatic stem cells and their differentiating progeny, 
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although this hypothesis is currently untested in humans due to the nature of histological 
sampling. In murine models the ductular reaction is less well described, but the accumulation 
of hepatic stem cells, has been demonstrated in a number of injury models69, 161 and fate 
tracing experiments have shown the accumulation, or increased numbers, of hepatic stem cells 
based upon marker expression and lineage tracing studies9, 115. A larger cohort would have 
allowed greater statistical power and may have detected a significant association between 
severity of ductular reaction and risk of HCC. Further, larger cohorts would allow clinical 
factors influencing severity of ductular reaction to be identified, quantified and adjusted for 
which would then allow associations between severity of ductular reaction and other 
quantified populations to be assessed. This provide information on the relationship between 
ductular reaction and the activation of the hepatic stem cell niche. 
!
The presence of intermediate hepatobiliary cells has recently been reported to be 
independently associated with increased risk of hepatocellular carcinoma development in a 
prospectively identified cohort of patients with hepatic C virus cirrhosis94. Intermediate 
hepatobiliary cells were infrequent in NASH cirrhosis biopsies by cytokeratin 7 
immunohistochemistry making the quantification of absolute numbers of these cells 
uninformative. Instead the definition used for assessing the presence or absence of 
intermediate hepatobiliary cells used in the study by Ziol et al. was used. This cohort of 18 
NASH cirrhotic patients demonstrated similar incidence of HCC per year for those patients 
with presence of IHC (7.8% vs. 8.14% per year) and patients with an absence (4.9%. vs. 
3.12% per year) in liver biopsies. As with assessing the association between ductular reaction 
and risk of HCC, a larger cohort of NASH cirrhotic patients is necessary for the potential 
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association to be fully assessed and a comparison of the association described in HCV 
cirrhotic patients to be made in patients with NASH cirrhosis. 
!
Although the presence and potential relevance of EpCAM+ hepatocytes could not be assessed 
in this cohort of biopsies due to the small numbers and scarcity of this cell type in NASH 
cirrhosis, the use of EpCAM is of great interest in the light of work suggesting these cells are 
hepatocytes recently derived from liver progenitor cells74 and the association of EpCAM with 
a number of cancer related processes and cell types83, 84, 86, 88, 89.  
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The prevalence of HCC in NASH patients is increasing46, and not only in those patients with 
cirrhosis but also in non-cirrhotic patients with other components of the metabolic 
syndrome48, 162. As HCC therapy and survival rates are currently unsatisfactory, largely due to 
late diagnosis and consequent diminishing of choice and efficacy of treatment options, this 
approach could assist in identifying patients most at risk, possibly allowing the use of more 
powerful and effective imaging techniques (CT or MRI vs US) that are currently too 
expensive for surveillance of all cirrhotic patients. However, it is important that the potential 
benefits of this approach outweigh the risks associated with liver biopsy188. 
!
!
The results obtained from the preliminary work possible with the small cohort of NASH 
cirrhotic patients identified at the Queen Elizabeth Hospital, Birmingham (QEHB) are 
encouraging and represent the first work attempting to identify patients that are at increased 
risk of developing HCC based on the original biopsy from which a diagnosis of NASH 
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cirrhosis was made following on from demonstration of the utility in HCV cirrhotic 
biopsies94. Obtaining clinically important information about a patients risk of HCC from 
immunohistochemical analyses, quick and inexpensive technique, using a resource that is 
already routinely obtained (liver biopsy) has the potential to change the current surveillance 
and followup strategies employed in this patient cohort. 
!
Due to the limited number of patients with a definitive, non-overlapping diagnosis of NASH, 
this study was extended through the identification of a larger cohort of patients with hepatitis 
C virus cirrhosis. HCV was chosen due to the greater number of HCV cirrhotic biopsies 
available due to the less problematic diagnosis and retrospective identification of HCV 
cirrhosis. This larger cohort will allow a more powerful analysis of  the association between 
the histological phenomena related to hepatic stem cell activation and subsequent risk of 
HCC. As IHCs and EpCAM+ hepatocytes were also found to be more common in HCV, this 
cohort will allow the absolute quantification of IHCs rather than a simple score for presence 
or absence, the proportion of hepatocytes newly derived from the hepatic stem cell niche and 
the total number of Sox9+ hepatic stem cells to be including in the final analysis. 
!
!
!
!
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CHAPTER 6 
ISOLATION OF HUMAN ADULT BILIARY TREE AND HEPATIC STEM CELLS 
FROM COMMON BILE DUCT AND EXPLANTED CIRRHOTIC LIVER 
!
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6.1. RATIONALE FOR STUDY 
The isolation of human hepatic stem cells currently relies on foetal and donor liver 
tissue. Currently used tissues for the isolation of human hepatic stem cells are foetal 
cadaveric tissue and livers donated to transplant programs that are unused1, usually due to 
long ischaemia times or high fat content. Not only are these tissues scarce, but their use in 
basic research, and potentially in future clinical trials and therapies, makes them highly 
controversial. Donor livers deemed unsuitable for transplantation are also unlikely to yield 
high quality cultures of hepatic stem cells. Consequently methods for the isolation and 
propagation of human hepatic stem cells from other tissue sources are appealing. 
!
The isolation of adult hepatic stem cells from explanted cirrhotic liver tissue has not 
previously been demonstrated. The number of liver transplants being performed in the UK 
and worldwide is increasing. Explanted diseased liver tissue is currently used for research 
(with patients’ consent) or discarded. Robust methods exist for the isolation of hepatic stem 
cells from foetal and donor liver, currently the main method used to obtain and study hepatic 
stem cells, however there is a lack of research demonstrating the isolation of significant 
numbers of potent hepatic stem cells from explanted cirrhotic livers189. If the isolation of 
hepatic stem cells with preserved proliferative and differentiation capacity can be 
demonstrated, explanted liver tissue could become a major source of hepatic stem cells, 
potentially negating the need for foetal and donor tissue and increasing the availability of 
hepatic stem cells for research and therapeutic uses. 
!
!
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Hepatic stem cells isolated from diseased liver are likely to further our understanding of 
the reciprocal impact of hepatic stem cell niche dysfunction and end stage liver failure. 
The use of diseased explanted liver also provides a valuable opportunity to study the functions 
and characteristics of hepatic stem cells that have been exposed to long-term liver injury and 
regeneration. Currently the relative contribution of the hepatic stem cell niche to long term 
liver regeneration and tissue homeostasis is unknown, particularly in clinical disease. 
Furthermore, chronic liver disease may fundamentally alter or damage the hepatic stem cell 
niche contributing to liver failure or potentiating carcinogenesis. Thus, the development of 
robust methods for the isolation of hepatic stem cells from explanted liver has the potential to 
greatly increase our understanding of the impact of chronic disease on the hepatic stem cell 
niche and how these changes, or defects, in the hepatic stem cell niche worsen or expedite end 
stage liver disease and liver failure.  
!
!
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6.2. RESULTS 
6.2.1. Hepatic stem cells can be isolated from explanted cirrhotic liver can by immuno-
selection and selective media conditions. Biliary epithelial cells (BEC) can be routinely 
isolated from explanted cirrhotic liver tissue through the use of immuno-selection of cells 
based on expression of EpCAM. Recent work has demonstrated the use of EpCAM immuno-
selection for the isolation of hepatic stem cells from foetal and donor liver. This method 
selects hepatic stem cells through the use of media with very few growth factors (modified 
Kubota’s media (MKM), detailed in methods). The proliferation and morphology of BEC that 
had previously been passaged three times was assessed when cultured in normal conditions 
for the culture of BEC or in conditions described for the selection of hepatic stem cells. The 
number of BEC was found to increase by roughly 200% after 3 days when cultured in BEC 
media on collagen type I, normal conditions for the culture of BEC. Cell number increased by 
approximately 500% after 3 days when BEC were plated on low-growth factor Matrigel, 
matrix designed for the culture of stem cell populations, in BEC media. Cell number 
decreased by roughly 70% after 3 days when BEC were cultured on Matrigel in MKM (Fig 
6.1A). BEC cultured under normal conditions retained elongated morphology (Fig 6.1B) with 
similar morphology observed with increased cell density after culture on Matrigel in normal 
BEC media (Fig 6.1C). Fewer cells were observed after culture in MKM on Matrigel for 3 
days. Remaining cells were generally more ovoid and smaller than normal BEC cultures, 
however no obvious hepatic stem cell colonies were observed (Fig 6.1D). Direct plating of 
EpCAM+ immunoselected cells from cirrhotic explanted liver in MKM on Matrigel resulted 
in appearance of small clusters of densely packed ovoid cells with high nuclear to cytoplasmic 
ratios characteristic of hepatic stem cell colonies (Fig 6.1E). 
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Figure 6.1. Modified Kubota’s medium (MKM) allows selection of hepatic stem cells 
from explanted diseased liver. A, Bar graph representing the change in cell numbers 
observed in 3 random 200x magnification fields before and after 3 days culture of passage 3 
biliary epithelial cells in normal BEC culture conditions, on Matrigel, and in MKM. 
Representative light microscopy images (200x magnification) of passage 3 biliary epithelial 
cells from ALD liver after 3 days culture in B, BEC media on collagen type I, C, BEC media 
on Matrigel, and D, modified Kubota’s medium on Matrigel. E, Representative light 
microscopy image of a single hepatic stem cell colony derived from directly plated immuno-
selected EpCAM+ cells after culture for one day in modified Kubota’s medium on Matrigel 
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Foetal calf serum (FCS), used in many, including BEC, media, and containing a myriad of 
growth factors, was found to slow proliferation of hepatic stem colonies and eventually lead 
to loss of colonies after approximately 3 days culture (Fig 6.2). Colonies continue to grow for 
the first 2 days when cultured in MKM plus 10% FCS then begin to decrease in overall size. 
The appearance of projections was also noted (Fig 6.2CD, arrows). It was difficult to assess 
whether these processes were the remnants of cells that had died within the colony or 
represented eruptions of differentiating cells that became unviable in MKM during 
differentiation towards mature parenchymal cell types. Interestingly, similar observations 
were occasionally observed spontaneously in cultures of hepatic stem cell colonies in MKM 
alone after around 4 days culture, particularly in cultures from livers with hepatocytic disease. 
Decreased growth and eventually loss of all colonies, similar to observations of culture with 
FCS, occurred in all hepatic stem cell colonies from these livers. It was not possible to 
ascertain the cause, or underlying processes, responsible for the spontaneous loss of cultured 
colonies from certain livers. 
!
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Figure 6.2. Foetal calf serum reduces proliferation and reduces viability of hepatic stem 
colonies. Light microscopy of a single representative hepatic stem cell colony cultured for 5 
days in MKM on Matrigel then in MKM +10% foetal calf serum A, immediately after media 
change  and after B, 1 day, C, 2 days, and D, 3 days culture. Arrows highlight projections 
from dying colonies likely representing remnant dying hepatic stem cells  !
!
!
!
!
!
!
!
!
A. B.
C. D.
!188
6.2.2. Hepatic stem cells isolated from explanted cirrhotic liver have similar expression 
profiles to that reported for hepatic stem cells isolated from foetal and donor liver. 
Immunofluorescent analysis of hepatic stem cell colonies from ALD cirrhotic explanted liver 
cultured for 5 days in MKM on Matrigel demonstrated expression of markers previously 
described for hepatic stem cells isolated from foetal and donor liver tissue. Hepatic stem cell 
colonies from individual livers were found to have highly homogeneous antigenic profiles. 
Hepatic stem cells co-expressed NCAM and EpCAM (Fig 6.3A), a combination described as 
specific for hepatic stem cells, with a small proportion of cells at the periphery of colonies 
expressing NCAM in the absence of EpCAM (stained red). These cells also appeared slightly 
larger than cells at the centre of colonies and were also slightly more elongated with 
occasional cytoplasmic processes. Hepatic stem cells were positive for Sox9 (nuclear staining 
may be obscured by DAPI counterstain), demonstrating nuclear staining and occasional 
clusters of cells with cytoplasmic staining (Fig 6.3B). All hepatic stem cell colonies were 
found to express cytokeratin 7 (Fig 6.3C), a marker of biliary epithelial cells, and cytokeratin 
18 (Fig 6.3D), a marker of hepatocytes. Staining of CK7 and CK18 was diffuse and 
cytoplasmic and observed on all hepatic stem cells. 
!
!
!
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Figure 6.3. Hepatic stem cell colonies from explanted ALD cirrhotic liver express stem 
cell, biliary and hepatocytic markers. Immunofluorescent staining of representative hepatic 
stem cell colonies from explanted alcoholic liver disease cirrhotic liver after 5 days culture in 
modified Kubota’s medium on Matrigel type I for A, neural cell adhesion molecule (red) and 
epithelial cell adhesion molecule (green) B, Sox9, C, cytokeratin 7, and D, CK18. All 
colonies were counterstained with DAPI to visualise cell nuclei (blue) !
!
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Hepatic stem cells isolated from explanted primary biliary cirrhosis (PBC) tissue were plated 
on Matrigel-coated plastic in modified Kubota’s medium. Approximately 200 colonies were 
observed within 24 hours (Fig 6.4A) and grew to almost complete confluence within 5 days in 
single 10cm2  well. A conservative estimate of the total number of liver stem/progenitor cells 
at day 5 would be in  excess of 1,000,000 cells with an approximate doubling time of around 
12 hours. Hepatic stem cell colonies observed at day 1 generally consisted of uniformly small, 
densely packed cells. At day 5, regions with typical morphology were still observed (Fig 
6.4B, arrows) surrounded by larger cells with much more elongated morphology and a much 
smaller nuclear to cytoplasmic ratio, morphology similar to mature BEC. Throughout the 
confluent colony, stem cell-like regions and areas of larger, biliary cells were clearly distinct 
from each other suggesting the sudden increase of larger, apparently more differentiated cells 
resulted from spontaneous, rapid proliferation and differentiation of hepatic stem cells 
isolated from this particular explanted PBC liver. 
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Figure 6.4. Hepatic stem cells isolated from explanted liver with chronic biliary disease 
form rapidly proliferating heterogeneous cultures. Representative light microscopy images 
of hepatic stem cells isolated from primary biliary cirrhosis explanted liver after culture in 
MKM on Matrigel type I for A, 1 day and B, 5 days. Arrows highlight dense clusters of cells 
with hepatic stem cell morphology surrounded by larger cells with biliary morphology 
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6.2.3. Characterisation of the effects of culture conditions on the proliferation and 
morphology of hepatic stem cells from explanted cirrhotic liver. Hepatic stem cells 
isolated from an ALD cirrhotic explanted liver were plated on 12 Matrigel-coated wells in 
MKM for 5 days. Media was changed to give four equal groups of three cultures in: MKM, 
MKM-C (designed for differentiation to biliary epithelial cells), MKM-H (designed for 
differentiation to hepatocytes), and MKM co-cultured with CD14+CD16+ peripheral blood 
mononuclear cells for 3 days. Hepatic stem cell colonies cultured in MKM on Matrigel 
proliferated rapidly with an approximate doubling time of 2 days (Fig 6.5). Over time, cells 
formed a ‘swirling’ pattern characteristic of biliary tree stem cell cultures previously 
described by Cardinale et al. as “small (7-9um), densely packed, uniform with high nucleus to 
cytoplasmic ratios” with NCAM and EpCAM duel positivity throughout the colony11. 
Immunofluorescent staining of the colony visualised in Fig 6.5 demonstrated the presence of 
a significant proportion of NCAM+ EpCAM+ dual-positive cells (stained yellow) throughout 
the colony after 10 days culture. Dual positive cells often constituted the swirling patterns 
observed towards the centre of colonies (Fig 6.6, black arrows). Regions of single positive 
EpCAM+ cells (stained green) with cytoplasmic staining were observed in regions of the 
colony without the swirling pattern (Fig 6.6. white arrows) and may represent cells 
beginning to differentiate towards a mature biliary phenotype. NCAM+ EpCAM- cells (stained 
red) appeared slightly larger than cells at the centre of colonies with elongated morphology 
and were most commonly observed at the peripheries (Fig 6.6, black arrowheads) 
potentially representing transitional cells in the maturational lineage of hepatic stem cells72 or 
similarity with peri-vascular stromal cells/angioblasts190 that have previously been reported to 
have close associations with hepatic stem cells both in vivo and in vitro culture17.  
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Figure 6.5. Hepatic stem cell colonies proliferate rapidly and maintain morphology in 
modified Kubota’s medium on Matrigel. Light microscopy images (100x magnification) of 
a single hepatic stem cell colony isolated from explanted ALD cirrhotic liver cultured in 
modified Kubota’s medium on Matrigel after A, 6 days, B, 7 days, C, 8 days, D, 9 days, and 
E, 10 days culture 
A.
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Figure 6.6. NCAM and EpCAM immunofluorescence reveals antigenic heterogeneity 
within hepatic stem cell colonies. Fluorescent microscopy (100x magnification) for A, 
NCAM B, EpCAM C, DAPI and D, merged image of NCAM (red), EpCAM (green and 
DAPI (blue) of a large hepatic stem cell colony (imaged in Fig 6.4.) from explanted alcoholic 
liver disease cirrhotic liver after 10 days culture in modified Kubota’s medium on Matrigel 
type I. Dual NCAM and EpCAM staining demonstrates the presence of small, dual positive 
cells densely arranged in swirling patterns (stained yellow, highlighted by black arrows), 
larger, elongated cells positive for NCAM only (stained red, highlighted by black arrowheads) 
and regions of cells positive for EpCAM only (stained green, highlighted by white arrows) !
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The growth of hepatic stem cell colonies appeared to slow almost immediately after 
incubation with MKM-C (Fig 6.7). After 2 days the borders of hepatic stem cell colonies 
began to become irregular, with larger more elongated cells observed in the centre of the 
colony (Fig 6.7C). After 5 days culture in MKM-C, the borders of hepatic stem cell colonies 
appeared highly irregular, with many cells within the colony now displaying more elongated 
morphology more closely resembling that of primary BEC (Fig 6.7E). Growth relative to 
colonies cultured in MKM was reduced. It was not possible to ascertain whether the reduced 
growth was due to reduced proliferation of hepatic stem cells in MKM-C, or due to 
substantial loss of differentiating cells, particularly at the borders of colonies where cells were 
more irregularly shaped, perhaps undergoing cell death and sloughing. 
!
Hepatic stem cells cultured in MKM-H rapidly stopped proliferating within 24 hours before 
being lost in a similar manner to that described for hepatic stem cell colonies cultured with 
foetal calf serum (Fig 6.2). Attempts to differentiate hepatic stem cell colonies subsequently 
isolated from explanted cirrhotic livers resulted in the same outcome.  
!
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Figure 6.7. Culture of hepatic stem cells in conditions designed for biliary differentiation 
maintains proliferation and induces limited morphological change. Light microscopy 
images (100x magnification) of a single representative hepatic stem cell colony cultured for 5 
days in MKM on Matrigel type I then in biliary differentiation media (MKM-C) A, 
immediately after media change and after B, 1 day, C, 2 days, E, 3 days, and E, 4 days culture !
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Figure 6.8. Hepatic stem cells cultured in MKM-C for 3 days retain expression of 
EpCAM and NCAM. Fluorescence immunohistochemistry (400x magnification) for NCAM 
(red), EpCAM (green) and DAPI (blue) of a single representative hepatic stem cell colony 
after 3 days culture in MKM-C !
!
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CD14+CD16+ PBMCs are recruited by LSEC into the liver parenchyma during liver 
inflammation and are the monocyte subset most likely to differentiate into macrophages. 
Macrophages have been to shown to have potent effects on hepatic stem cell proliferation and 
have critical function in patterning hepatocytic differentiation26. The growth of hepatic stem 
cell colonies co-cultured with CD14+CD16+ PBMCs in modified Kubota’s medium was 
immediately inhibited, with no growth observed for the duration of the experiment. Cells 
retained typical hepatic stem cell morphology, being relatively small, with high cytoplasmic 
to nuclear ratio, and were observed in a compact, uniform colonies with smooth borders, in 
contrast to the stem cell colonies cultured in MKM-C (Fig 6.8). Immunofluorescent staining 
with NCAM and EpCAM demonstrated that, although the growth of the liver stem cell colony 
was strongly inhibited by CD14+CD16+ PBMCs, hepatic stem cells retained expression of 
stem cells markers (Fig 6.9). EpCAM expression was observed on all hepatic stem cells 
throughout colonies and around half of hepatic stem cells co-expressed NCAM, results 
indicating hepatic stem cells were maintained in an undifferentiated state (Fig 6.10).  
!
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Figure 6.9. Co-culture with CD14+CD16+ peripheral blood mononuclear cells inhibits 
proliferation of hepatic stem cells. Light microscopy of a single representative hepatic stem 
cell colony cultured for 5 days in MKM on Matrigel type I then in the presence of 
CD14+CD16+ peripheral blood mononuclear cells A, immediately after addition of peripheral 
blood mononuclear cells and after B, 1 day, C, 2 days, and D, 3 days co-culture !
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Figure 6.10. Maintenance of EpCAM expression by hepatic stem cells after co-culture 
with CD14+CD16+ PBMCs. Fluorescent microscopy (200x magnification) for A, NCAM B, 
EpCAM C, DAPI and D, merged image of NCAM (red), EpCAM (green) and DAPI (blue) of 
a single hepatic stem cell colony after 3 days co-culture with CD14+ CD16+ peripheral blood 
mononuclear cells !
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6.2.4. Biliary tree stem cells can be isolated from common bile duct and have similar 
characteristics to hepatic stem cells from explanted liver. Peribiliary glands (PBGs) are 
acinar structures found throughout the biliary tree and are larger and more numerous in 
proximal regions (Fig 6.1AB, arrows). High proportions of epithelial cells of peribiliary 
glands express stem cell markers and have been hypothesised to be the precursors of all 
biliary epithelial cells and potentially all epithelial cells of the hepatopancreatic system11-13. 
Successful isolation of intact peribiliary glands from common bile duct samples could be 
achieved with brief collagenase digestion of bile duct tissue and washes with EDTA resulting 
in a suspension of intact PBGs (Fig 6.11CD). PBGs were cultured on plastic in MKM. In 
these conditions large numbers (typically over 100) of PBGs adhered to plastic over a few 
hours and formed colonies of cells with proliferation rates and morphology similar to hepatic 
stem cells (Fig 6.12A-D). PBGs were also found to co-express biliary (CK7, Fig 6.12E) and 
hepatocytic markers (CK18, Fig 6.12F). 
!
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Figure 6.11. Collagenase digestion and EDTA washes of common bile duct tissue allows 
isolation of intact peri-biliary glands. AB, Representative images (200x magnification) of 
haematoxylin and eosin staining of common bile duct wall sections demonstrating presence of 
peri-biliary glands (arrows). CD, Light microscopy of freshly isolated intact peri-biliary 
glands from explanted common bile duct by brief collagenase digestion and repeated washes 
in high concentration EDTA !
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Figure 6.12. Freshly isolated PBGs adhere to plastic in Modified Kubota’s Medium, 
form distinct, slow growing colonies colonies with biliary stem cell morphology and 
expression profile. Representative light microscopy images (200x magnification) of biliary 
tree stem cells isolated from explanted common bile duct and plated on plastic in modified 
Kubota’s medium A, immediately after isolation and after  B, 2 hours, C, 1 day and D, 3 days 
(100x magnification) culture. E, Cytokeratin 7 and B, cytokeratin 18 fluorescence 
immunohistochemistry of biliary tree stem cell  colonies after 5 days culture in Kubota’s 
modified media on plastic. Colonies were counterstained with DAPI !
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6.3. DISCUSSION 
This study demonstrates the isolation of human hepatic stem cells from adult, explanted 
cirrhotic liver and non-pathological common bile duct from Whipple’s procedures using 
techniques previously reported for the isolation of hepatic stem cells from foetal and 
uninjured liver1. The use of explanted liver tissue and common bile duct from Whipple’s 
procedures as a source of hepatic stem cells is attractive as these sources negate the use of 
foetal and donor liver tissues. However, the use of these sources is challenging due to the 
heterogeneity of samples, due to range of aetiologies and severity of liver disease among 
individual livers. Hepatic stem cells isolated from diseased livers are likely to be altered 
compared to those from normal liver due to sustained exposure to the milieu of factors 
secreted in response to chronic liver injury. Due to the heterogeneous nature of explanted liver 
tissue used the behaviour of isolated hepatic stem cells colonies frequently demonstrated 
substantial variation. Hepatic stem cell colonies were observed after 2 to 3 days for most 
isolations then either proliferated consistently for weeks forming distinct colonies or 
underwent slowing of proliferation and colony collapse with all cells typically lost by around 
day 7. In rare instances, large numbers of hepatic stem cell colonies would be observed soon 
after isolation (within 24 hours of plating) and proliferate to confluence over a few days. 
Large variability in the numbers, viability and behaviour of isolated hepatic stem cells from 
individual explanted livers were observed, making comparisons between isolations difficult. 
Consequently, much of the work in this study is descriptive and observational. 
!
Hepatic stem cells isolated from explanted liver have potential utility as a source of cells for 
basic research or for use as a cellular therapy. In both cases, understanding the differences 
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between cells isolated from normal and diseased tissues is important. This study revealed a 
number of differences between cells isolated from explanted tissue, and reports of hepatic 
stem cells isolated from normal, or foetal, tissues. Whilst the isolation of hepatic stem cells 
from normal and foetal tissues is relatively robust, with predictable numbers of colonies 
observed that are viable for weeks to months, there was a large degree of variability in 
isolations from explanted liver that were not accounted for by the amount of tissue used. Due 
to the nature of the isolation technique, the number of freshly isolated EpCAM+ cells is hard 
to quantify. As the majority of cells isolated by EpCAM immuno-selection are mature BEC 
that are non-viable in the selective media used, it is difficult to quantify the number of hepatic 
stem cells obtained from individual isolations. Further, immuno-selection with beads 
commonly results in the isolation of clumps of cells rather than single cell suspensions 
making quantification by cytometric analysis challenging. From experience it appears greater 
viability and yields and result from isolations where greater clumping of isolated cells is 
observed, in keeping with the results from common bile duct where viable cultures only 
resulted from techniques isolating intact peri-biliary glands. Structural integrity of the glands 
is known to be important for keeping supportive stromal cells in close proximity to the biliary 
stem cells, increasing viability and maintaining physiological patterning of the niche. 
Previous attempts to isolate stem cells from a variety of organs have demonstrated greatly 
decreased viability when somatic stem cells are fully dissociated11-13.  
!
Primary BEC cultures in normal conditions can be passaged and cells gradually take on 
stromal, or fibroblastic, characteristics, and lose expression of biliary markers, with culture 
duration. In these conditions BEC proliferate as mono-layers and display a degree of contact 
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inhibition, The use of modified Kubota’s media (MKM) is critical for the selection of hepatic 
stem cells. Culture of passage 3 BEC in MKM resulted in a decrease in cell number of 3 days, 
where in normal conditions cells proliferated rapidly to confluence. This experiment 
demonstrated mature BEC are not viable in MKM. Plating of freshly isolated immuno-
selected EpCAM+ cells however did result in the appearance of distinct colonies of tightly 
packed cells with typical hepatic stem cell morphology3, 12, 191. 
!
Culture of hepatic stem cell colonies in the presence of foetal calf serum (FCS) led to 
senescence and rapid loss of hepatic stem cell colonies over the course of 3 to 4 days. This 
observation either represents a stimulatory effect of FCS on hepatic stem cells leading to rapid 
initiation of hepatocytic differentiation and maturation, with mature hepatocytes lost due to 
lack of appropriate growth factors in MKM, or direct negative effects of FCS on hepatic stem 
cell colonies. The presence of NCAM+EpCAM- cells on the peripheries of colonies 
potentially represent stromal supportive cells, or angioblasts, however there is great 
uncertainty regarding the presence, and characteristics, of these cells in liver32, 192. These cells 
may be important for maintaining the viability of isolated hepatic stem cells in vitro and 
further work fully characterising their identity and expression profile may increase our 
understanding of the role of these cells in maintaining hepatic stem cell colonies. 
!
Experiments to assess the functional capacity of hepatic stem cells from explanted liver failed 
to definitively demonstrate differentiation into mature cell types. Subtle morphological 
changes with the use of media designed for the differentiation of adult human hepatic stem 
cells into mature biliary epithelial cells. After 4 days culture, hepatic stem cells demonstrated 
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a slightly elongated morphology more in keeping with mature biliary epithelial cells. 
However proliferation was greatly reduced by day 4 with some cells displaying changes 
suggestive of early apoptosis and cell death. The use of hepatocyte differentiation media 
invariably resulted in loss of hepatic stem cell colonies within 2 days. These findings again 
suggest that media with a greater number of growth factors and higher nutrient content may 
be required to support mature cell types derived from hepatic stem cell colonies.  
!
The lack of media conclusively shown to support mature hepatocytes may also have impacted 
on the result of co-culture experiments with hepatic stem cell colonies and CD14+CD16+ 
PBMCs. For these reasons, the results of the co-culture experiment are hard to interpret as any 
hepatic stem cells differentiating into mature cell types may have died rapidly, masking any 
effects PBMCs may have had on the differentiation of hepatic stem cell colonies. 
Nevertheless, it was clearly demonstrated that PBMCs had a potent inhibitory effect on 
hepatic stem cells without altering the expression of EpCAM and NCAM by hepatic stem 
cells after 4 days co-culture. 
!
Finally, the isolation of biliary tree/hepatic stem cells from common bile duct was 
demonstrated. Stem cell colonies obtained had very similar morphology and expression 
profiles to that of hepatic stem cells isolated from explanted liver and previous reports of 
hepatic stem cells from donor and foetal liver. The yields and growth characteristics of stem 
cells derived from common bile duct appeared to demonstrate less variability than cultures 
from explanted liver. Thus, common bile duct may provide a more robust source of biliary 
tree/hepatic stem cells as well as providing unaltered stem cell colonies allowing direct 
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comparison with those obtained from diseased explanted liver. Further work will attempt to 
optimise conditions for the long term maintenance and differentiation of biliary tree stem cells 
from Whipple’s procedures and then apply modified techniques to cultures from explanted to 
try and reduce the variability of results and more informative comparisons between cultures 
from the two sources. 
!
Ultimately, this study demonstrated the difficulty in using cirrhotic liver for the isolation of 
hepatic stem cells. Although hepatic stem cells could be isolated and their expression profile 
assessed, differentiation assays have to date failed to demonstrate production of functional 
parenchymal cell types, a key criteria needed to definitively prove cultured cells are adult 
hepatic stem cells. Further optimisation of culture conditions, possibly using 3D scaffolds or 
feeder/companion cells, are likely to be required if the isolation, long-term culture and 
maintenance of undifferentiated hepatic stem cells from explanted liver is to be demonstrated. 
!
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CHAPTER 7 
CONCLUSIONS AND FUTURE WORK 
!
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7.1. OVERVIEW 
There is increasing interest in hepatic stem cells as their role in tissue homeostasis, liver 
regeneration and carcinogenesis is further elucidated, potentially paving the way for targeted 
clinical interventions that may stimulate, or facilitate, more efficient activation and 
differentiation of the hepatic stem cell niche in situ, or development of hepatic stem cells as a 
efficacious cellular therapy. However there remain a number of unresolved questions, and 
apparent contradictions, concerning the function and behaviour of hepatic stem cells in vivo, 
particularly in the case of long-term chronic liver injury.  
!
!
Native mature hepatocytes are known to have substantial regenerative capacity, thus, at least 
in conditions where hepatocytes retain significant proliferative capacity, hepatic stem cells 
appear to be a redundant secondary mechanism of liver regeneration. Thus, the contribution 
of hepatic stem cells to tissue homeostasis, the maintenance of parenchymal cell numbers and 
function, in normal conditions and regeneration in response to liver injury remains to be 
conclusively determined. This will likely require the use of animal models, particularly 
lineage tracing models that specifically identify hepatic stem cells and their progeny and 
disease models that accurately replicate the pathophysiology of chronic metabolic liver 
diseases.  
!
Chapter 3 presents the characterisation of injury resulting from long-term administration of a 
previously reported dietary model of non-alcholic liver disease. This study demonstrated 
wild-type mice fed a diet containing high proportions of trans-fatty acids and fructose over 12 
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months developed the full spectrum of NAFLD, including significant fibrosis, and 
hepatocellular carcinoma. This result demonstrates for the first time that diet alone is 
sufficient to cause NASH and HCC. Activation of the hepatic stem cell niche was also 
demonstrated in the ALIOS model, establishing it as the most pathophysiological model for 
the study of hepatic stem cell activation as a result of chronic metabolic liver injury as it 
avoids the use of transgenic animals or toxic diets. Further, the demonstration of tumour cells 
expressing hepatic stem cell markers in ALIOS mice provided further evidence for a link 
between hepatic stem cell activation and the development of HCC. 
!
!
The relationship between epithelial and mesenchymal populations in adult human liver is 
currently poorly understood despite the close spatial and temporal association between 
ductular reaction and fibrosis. In other organs, particularly skin193 and intestine90, it is 
increasingly recognised that stromal populations within epithelial stem cell niches are 
important mediators of epithelial stem cell activation and patterning. In the liver, the ductular 
reaction and fibrosis may represent a common process facilitating the proliferation, migration 
and differentiation of hepatic stem cells into mature hepatocytes through niche remodeling, 
secretion of mitogenic factors and recruitment of other cell types, particularly macrophages. 
The association between stromal and epithelial components of the hepatic stem cell niche is 
further complicated by recent reports of hepatic stellate cells expressing hepatocytic and 
epithelial stem cell markers18, 194 and fate tracing experiments demonstrating hepatocytes 
derived from stromal populations in response to liver injury181.  
!
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Chapter 4 demonstrates the prospective isolation of a resident population of hepatic stromal 
cells with high colony forming potential and ability to undergo rapid differentiation into 
myofibroblastic cells, potentially identifying them as significant contributors to liver fibrosis. 
The isolation of these cells (PαS) was based on the expression of PDGFRα and Sca1, a 
combination previously reported for mesenchymal stem cells of the bone marrow and other 
visceral organs. PαS cells were shown to reside in close proximity to the walls of hepatic 
veins, hepatic arteries and portal veins. The peri-portal location of PαS cells makes it 
conceivable that PαS cells contribute to fibrogenesis, ductular reaction and/or hepatic stem 
cell activation, processes that all originate from peri-portal locations. Further, culture of PαS 
cells in conditions designed for the selection and growth of hepatic stem cells, resulted in the 
appearance and rapid growth of epithelial stem cell colonies that could be passaged and 
cultured long-term. This observation potentially demonstrates PαS as a potent source of both 
stromal and epithelial populations in adult liver. However, more work is needed to 
demonstrate PαS directly transdifferentiate into epithelial cells and exclude the possibility of 
these colonies being derived from contaminating epithelial cells. Further, it needs to be 
demonstrated that epithelial cells selected from PαS cultures are capable of differentiation into 
mature epithelial cell types to definitively prove these cells are indeed hepatic stem/progenitor 
cells. The study of PαS cells may provide important information on the relationship between 
stromal and epithelial stem cell populations in adult liver and aid in elucidating whether 
epithelial to mesenchymal transition (EMT), and the reverse process (MET), occur and have 
relevance in response to liver injury.  
!
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Patients with end-stage liver disease, cirrhosis, are at greatly increased risk of hepatocellular 
carcinoma (HCC). Many HCC tumours are found to express biliary or epithelial stem cell 
markers, suggesting hepatic stem cells, or transitional cells within the maturational lineage, 
may be the cell of origin in some cases of HCC. This would be in-keeping with the 
concomitant and ongoing activation of the hepatic stem cell niche and increased numbers of 
hepatic stem cells and their progeny in cirrhotic livers. Experimental studies in animal 
models, and recent clinical studies, have provided further evidence linking hepatic stem cells 
and HCC. 
!
Chapter 5 describes novel techniques for the objective quantification of hepatic stem cells and 
related histological phenomenon in liver biopsy tissue. These methods allow the ductular 
reaction, number of intermediate hepatobiliary cells, hepatic stem cells, and hepatocytes 
newly derived from hepatic stem cells to be fully quantified immunohistochemical analyses. 
This study identified a small cohort of NASH cirrhotic biopsies and demonstrated the ability 
to objectively quantify ductular reaction and identify intermediate hepatobiliary cells and 
hepatocytes newly derived from hepatic stem cells but, due to small numbers, the association 
between these cell types and patients’ risk of HCC development could not be assessed. 
However, the presence of intermediate hepatobiliary cells in liver biopsies was found to 
confer a similar increased risk of HCC in this small cohort of NASH cirrhotic patients to that 
reported for HCV cirrhotic patients in a previous study94, perhaps indicating the association is 
preserved across all chronic liver disease aetiologies. Therefore a much larger, 72 patient 
cohort of HCV cirrhotic patients’ with liver biopsy material and follow-up at the Queen 
Elizabeth Hospital, Birmingham, was identified. Each of the quantification techniques have 
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been applied to this cohort allowing full quantification of each cell type and, along with 
clinical data, will allow the association to be fully assessed. Although much of this work is 
complete, due to blinding it has not been possible to make any preliminary observations or 
conclusions from this larger study. 
!
There is currently a lack of suitable sources of human hepatic stem cells due to the scarcity of 
currently used tissues, foetal cadaveric livers and donor livers unused for transplant. This has 
inhibited in vitro research on human adult hepatic stem cells and is a major obstacle to their 
use as a clinical therapy.  
!
In this study, the isolation of hepatic stem cells with typical morphology and expression 
profiles was demonstrated from explanted cirrhotic liver and common bile duct from 
Whipple’s procedures. Although significant variability was observed between isolations, 
particularly from explanted liver, some cultures could be maintained long-term without loss of 
proliferation or alteration in expression profiles. However, this study failed to demonstrate 
differentiation of human hepatic stem cells from these sources in to functional parenchymal 
cell types. The production of hepatocytes from isolated hepatic stem cells is a critical step, not 
only in confirming isolated cells as hepatic stem cells, but in demonstrating their potential 
utility as a meaningful source of cells for research and cellular therapy applications.  
!
!
!
!
!215
7.2. FUTURE WORK 
7.2.1. Hepatic stem cell activation and hepatocellular carcinoma in a mouse model of 
non-alcoholic steatohepatitis 
• Further investigate the mechanisms mediating the effects of the ALIOS diet through 
the use of pharmacological interventions or transgenic models to rescue or attenuate liver 
injury and HCC development 
• Use the ALIOS model with cell fate tracing models that specifically mark murine 
hepatic stem cells (Lgr5, Foxl1, Sox9) to assess the contribution of hepatic stem cells to 
regeneration and determine whether hepatic stem cells are the cell of origin for HCC as a 
result of ALIOS 
!
!
7.2.2. Prospective isolation of stem/progenitor cells from adult murine liver 
• Continue to optimise conditions for the selection of epithelial stem cells from PαS 
cells and their differentiation into mature parenchymal cell types to conclusively demonstrate 
them as hepatic stem cells 
• Conduct gene expression fingerprinting analysis on freshly isolated PαS to further 
elucidate their identity and cell lineage 
• Co-stain for PDGRα and Sca1 in sections from a range of liver injury models to assess 
the proliferation and fibrogenic potential of PαS in response to liver injury 
• Use cell fate tracing models (PDGRα) to definitively determine the contribution of 
PαS to fibrogenic and epithelial cell types in response to liver injury 
!
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7.2.3. Activation of hepatic stem cells in chronic liver disease and association with risk of 
hepatocellular carcinoma 
• Complete immunohistochemical analyses and quantification in HCV cirrhotic cohort 
and determine association with risk of HCC after adjusting for clinical risk factors 
• Use confocal microscopy to stain for all markers simultaneously to further define the 
relationship between studied cellular populations and their place in the maturational lineage of 
hepatic stem cells 
• Investigate the utility of more recently described markers of hepatic stem cells (Lgr5) 
in quantifying hepatic stem cells 
!
7.2.4. Isolation of human adult hepatic stem cell from explanted liver and common bile 
duct 
• Develop more robust isolation methods using hepatic stem cells from common bile 
duct to decrease variability observed in cultures from explanted cirrhotic liver 
• Develop differentiation assays for the production of functional hepatocytes and biliary 
epithelial cells from isolated hepatic stem cell colonies to aid in assessing the potential and 
function of hepatic stem cells isolated from diseases liver 
• Further optimise culture conditions allowing higher yields and viablity of hepatic stem 
cell colonies from explanted cirrhotic liver, most likely through the use of 3D culture systems, 
companion/feeder cells and hormonally defined media more representative of the hepatic 
stem cell niche 
!
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